I4V-MC-KHAA Protocol (e)  
 
Randomized, Double -Blind, Placebo -Controlled, Parallel- Group Phase 3 Study of Baricitinib in Patients with 
COVID- 19 Infection  
 
[STUDY_ID_REMOVED]  
 
Approval Date: 25- Nov-2020  
 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clin ical 
investigation of baricitinib ( LY3009104) , unless such persons are bound by a confidentiality agreement with 
Eli Lilly and Company or its subsidiaries .
Note to Regulatory Authorities: This document may contain protected personal data and/or commercia lly confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.
Protocol Title: A Rando mized, Double -Blind, Pl acebo -Controlled, Parallel -Group Phase 3 
Study  of Barici tinibin Pat ients with COVID-19Infect ion
Protocol Number: I4V-MC-KHAA
Protocol Amendment Number:   E
Compound :baricitinib(LY3009104)
Study Phase: 3
Acronym :COV -BARRIER
Sponsor Name: Eli Lilly  and Com pany
Legal Registered Address: Indianapo lis, Indiana USA 46285
Regulatory Agency Identifier Numbers
IND: 149279
EudraCT: 2020 -001517-21
Approval Date: Protocol Amendment ( e) Electronically Signed and Approved by Lilly ondate 
provi ded below.
Approval Date: 25-Nov-2020 GMT
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
2Medical monitor name and contact information will be provided separately .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Original Protocol 18 May  2020
Amendment A 27 May  2020
Amendment B 03Jun2020
Amendment C 12 Aug 2020
Amendment D 20 Oct 2020
Amendment E
This amendment i s consi dered substant ialbased on the cri teria set forth in Art icle 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
This protocol amendment addresses thesample size re -estimation and the addi tion of  a 
subpopulati onfor the primary endpo int.  
Section s# and Name Description of Change Brief Rationale
1.1 Synopsis Updated primary endpoint to match 
Section 3.0.To provide additional data for the 
treatment of COVID -19
1.1 Synopsis Changed sample size to 
approximately 1400 patients To evaluate disease progression in 
additional subpopulation of patients . 
3.0 Objectives and Endpoints Added subpopulation for the primary 
endpoint to evaluate disease 
progression in all randomized 
patients or patients who, at baseline, 
requir eoxygen supplementation and 
arenot receiv ingdexamethasone or 
other systemic corticosteroids for the 
primary  study  conditio n.Toprovide additional data for the 
treatment of COVID -19.
4.1 Overall Design Updat ed description to include the
twopopulations for the primary 
endpointTo provide clarification of 
populatio ns being evaluated.
4.2 Scientific Rationale Added rationale for inclusion of 
additional subpopulation in the 
primary  endpointTo evaluate disease progression in 
patients requiring oxygen 
supplementation without use of 
dexamethasone or systemic 
corticosteroids at baseline . 
5.2 Exclusion Criteria Added exclusion criteria for 
neutralizing antibodiesBased on recent Emergency Use 
Authorizatio n approvals in the 
United States and potential to 
confound assessment of baricitinib’s 
antiviral activity.
9.1 Statistical Hypotheses Added primary  endpoint population
andhypotheses , and testing scheme .Toupdate statistical methods
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
4Section s# and Name Description of Change Brief Rationale
9.2 Sample Size Determination Provided new assumptions for 
amendment ETo update the assumptions used to 
calculate the new sample size based 
on scenarios with two primary 
endpoints and differing assumptions 
about the effect of 
dexamethasone /corticosteroids on 
the treatment effect.
9.4.2 Primary Endpoint Added statement about populations 
assessedTo reflect the inclusion of two 
populatio ns for the primary 
endpoint.
Throughout the protocol Minor editorial and formatting 
changesMinor, therefore not described
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
5Table of Contents
1. Protocol Summary ...................................................................................................... 8
1.1. Synopsis ....................................................................................................................... 8
1.2. Schema ....................................................................................................................... 11
1.3. Schedule of Act ivities (SoA) ...................................................................................... 12
2. Introduction .............................................................................................................. 22
2.1. Study  Rati onale .......................................................................................................... 22
2.2. Background ................................................................................................................ 23
2.3. Benefit/Risk Assessment ............................................................................................ 24
3. Objectives and Endpoints ......................................................................................... 27
4. Study Design ............................................................................................................. 29
4.1. Overall Design ............................................................................................................ 29
4.2. Scientific Rationale for Study  Design ......................................................................... 30
4.3. Justification for Dose .................................................................................................. 31
4.4. End-of-Study  Definit ion............................................................................................. 32
5. Study Population ...................................................................................................... 33
5.1. Inclusio nCriteria........................................................................................................ 33
5.2. Exclusio n Cri teria....................................................................................................... 34
5.3. Lifest yle Considerat ions............................................................................................. 36
5.4. Screen Failures ........................................................................................................... 36
5.4.1. Allowed Retest ing of Screening Invest igations........................................................... 36
5.4.2. Rescreening of Individuals Who Failed Screening ...................................................... 36
6. Study Intervention .................................................................................................... 37
6.1. Study  Intervent ions Administered ............................................................................... 37
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 37
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 38
6.4. Study  Intervent ion Compliance ................................................................................... 39
6.5. Concomitant Therapy .................................................................................................39
6.5.1. Prior Medi cations....................................................................................................... 40
6.5.2. R equired and Permi tted Concomi tant Therapy ............................................................ 40
6.5.3. Prohibited Conco mitant Therapy ................................................................................ 40
6.6. Dose Modificat ion...................................................................................................... 41
6.7. Intervention after the En d of the Study ........................................................................ 41
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 42
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 42
7.1.1. Criteria for Perm anent Discon tinuation of Study  Drug ................................................ 42
7.1.2. Criteria for Tem porary  Interrupti on (Wi thhol ding) of Study  Drug ............................... 44
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 44
7.2.1. Discontinuati on of  Inadvertent ly Enrolled Participants ............................................... 45
7.3. Lost to Follow -up....................................................................................................... 45
8. Study Assessments and Procedures ......................................................................... 46
8.1. Efficacy Assessments .................................................................................................46
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
68.1.1. COVID -19 Clinical Status Assessment ....................................................................... 46
8.1.2. Ordinal Scale .............................................................................................................. 46
8.1.3. Other Efficacy  Assessments ........................................................................................ 47
8.2. Safety Assessments .................................................................................................... 49
8.2.1. Vital Signs.................................................................................................................. 50
8.2.2. Physical Examinat ions................................................................................................ 50
8.2.3. Electrocardiograms ..................................................................................................... 51
8.2.4. Chest Im aging Studi es................................................................................................ 51
8.2.5. Laboratory  Tests ......................................................................................................... 51
8.2.6. Hepati c Safet y Moni toring .......................................................................................... 52
8.3. Adverse Events and Serious Adverse Events .............................................................. 52
8.3.1. Time Period and Frequency  for Collect ing Adverse Event and 
Serious Adverse Event Information ............................................................................ 53
8.3.2. Method of Detecting Adverse Events and Serious Adverse 
Events ......................................................................................................................... 53
8.3.3. Follow-up of  Adverse Events and Serious Adverse Events ......................................... 53
8.3.4. Regulatory  Reporting Requirements for Serious Adverse Events ................................ 54
8.3.5. Pregnancy ................................................................................................................... 54
8.3.6. Speci al Assessments of Infect ions and Venous Thromboembo lic 
Events ......................................................................................................................... 54
8.3.7. Com plaint Handling ................................................................................................... 54
8.4. Treatment of Overdose ............................................................................................... 55
8.5. Pharmacokinet ics........................................................................................................ 55
8.6. Pharmacodynamics ..................................................................................................... 56
8.7. Genet ics..................................................................................................................... 56
8.8. Biomarkers ................................................................................................................. 56
8.9. Immunogenicit y Assessments ..................................................................................... 57
8.10. Medical Resource Utilizat ion and Healt h Economics .................................................. 57
9. Statistical Considerations ......................................................................................... 58
9.1. Statistical Hypotheses .................................................................................................58
9.2. Sample Si ze Determinat ion......................................................................................... 59
9.3. Popul ations for Analyses ............................................................................................ 60
9.4. Statistical Analyses ..................................................................................................... 60
9.4.1. G eneral Considerations ............................................................................................... 60
9.4.2. Primary Endpo int........................................................................................................ 63
9.4.3. Secondary  Endpo ints.................................................................................................. 63
9.4.4. Safety Analyses .......................................................................................................... 63
9.4.5. Pharmacokinet ic Analysis ........................................................................................... 64
9.5. Interim Analyses ......................................................................................................... 64
9.6. Data Monitoring Committee (DMC) ........................................................................... 65
10. Supporting Documentation and Operational Considerations ................................ 66
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 66
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 66
10.1.2. Financial Disclo sure................................................................................................... 66
10.1.3. Inform ed Consent Process .......................................................................................... 67
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
710.1.4. Data Protection ........................................................................................................... 67
10.1.5. Committee Structure ................................................................................................... 68
10.1.6 .Disseminat ion of Clinical Study  Data ......................................................................... 68
10.1.7. Data Qualit y Assurance .............................................................................................. 68
10.1.8. Source Documents ...................................................................................................... 70
10.1.9. Study  and Si te Start and Cl osure................................................................................. 70
10.1.10. Publicat ion Policy ....................................................................................................... 71
10.1.1 1.Invest igator Informat ion............................................................................................. 71
10.1.12. Long -Term  Sample Retent ion..................................................................................... 71
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 72
10.2.1. Clinical Laborator y Tests ............................................................................................ 72
10.2.2. Clinical Laboratory  Calculat ions................................................................................. 74
10.3. Appendix 3: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting ....................................................... 75
10.3.1. Definit ion of AE......................................................................................................... 75
10.3.2. Definit ion of SAE....................................................................................................... 76
10.3.3. Recording and Fo llow
-Up of AE and/or SAE ............................................................. 77
10.3.4. Reporting of SAEs ...................................................................................................... 78
10.4. Appendix 4: Contraceptive Guidance and Co llection of 
Pregnancy Information ............................................................................................... 79
10.4.1. Definit ions.................................................................................................................. 79
10.4.2. Contraception ............................................................................................................. 79
10.4.3. Collect ion of Pregnancy  Information.......................................................................... 80
10.5. Appendix 5: Abbreviat ions......................................................................................... 82
10.6. Appendix 6: Protocol Amendment History .................................................................86
11. References ................................................................................................................. 96
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
81. Protocol Summary
1.1. Synopsis
Protocol Title: A Rando mized, Double -Blind, Placebo -Controlled, Parallel -Group Phase 3 
Study  of Barici tinibin Pat ients with COVID -19Infect ion
Rationale : 
Baricitinib, an approved therapy  for the treatm ent of m oderately to severely act ive rheumatoid 
arthri tis (RA) in adults, is being proposed as a potent ial therapy for patients wi th COVID -19
infect ion. The proposed m echanism of act ion in COVID- 19 infect ion includes reduc tion of
cytokine -mediated inflammat ion and the potential for ant iviral act ivity.
There are currently no approved therapies for the treatm ent of COVID- 19 infect ion. 
Management of COVID -19 is supportive, and respiratory  failure fro m acute respi ratory  distress 
syndro me (ARDS) is the leading cause of mortalit y. The cause of ARDS i sa hyperinflammatory  
state characterized by upregulat ion of multiple cy tokines. Bari citinib, an orally  administered 
inhibitor of JAK1 and JAK2, could be a therapeutic option for this condi tion because of the 
potenti al to inhibi t signaling from  multiple cy tokines that are implicated in COVID -19 ARDS
(McInnes et a l. 2019). In pati ents wi th RA, treatm ent wi th the 4-mg dose of baricit inibresul ted 
in a reducti on from baseline in serum IL -6 at Week 12 in a Phase 2, randomized, placebo -
controlled study  of baricit inib(Stebbing et al . 2020) . The potent anti -inflammatory effects of 
baricit inib have also been demo nstrated by  the reduction of serum levels of IFN -γ, IP-10, GM -
CSF and MCP -1 in pediatric pat ients with steroi d-dependent chronic inflammat ion, result ing in 
the abilit y to wean or taper steroids (Sanchez et al. 201 8).
In addit ionto the anti -cytokine effect , baricit inib has recent ly been hypothesized (Richardson et 
al. 2020) and shown ( Stebbing et al .
2020) to be a potent inhibitor of numb -associ ated kinases 
(NAKs), which include AAK1, GAK, and BIKE. These proteins play a cri tical role in the host 
epithelial cell  to facilitate propagation of viruses, including SARS
-CoV -2, that rely on the 
scaffo ld protein known as activator protein 2 (AP2). Inhibit ing the NAK proteins that activate 
the AP2 scaffo lding protein vital t o viral entry  and propagati on coul d be one therapeuti c 
approach to managing COVID -19 infect ion.
The rationale for study  treatm ent for up to 14 day s is based on the known onset of efficacy  in the 
RA popul ation, which is as early as 1 week ( Olumiant Summary of Product Characteri stics),and
on the expected duration of treatment needed for an acute infect ion such as COVID -19. 
Recent ly, data were published on a case series describing a 14-day treatm ent course of baricitinib 
in patients with mild to moderate COV ID-19 infection (Cant ini et al. 2020) .
Baricitinib is administered orally once a day . It has a short half -life ( approximately  
12hours in 
RA pat ients), so treatment can be interrupted or stopped if necessary. It has few drug -drug 
interact ions (due to low C YP inhibitory  activit y) so i t can be given concomitant ly wit h 
background therapies. Baricit inib has a well -established safety  profile, based on clinical trial data 
and postm arket ing data in patients with RA.
This profile, together with the observat ion that baricit inib is a potent AAK1/BIKE/GAK 
inhibitor withknown ant i
-cytokine profile , provi de the rati onale to study  baricitinib in the 
context of a randomized, controlled clinical trial in patients with COVID -19 infect ion.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
9Objectives and Endpoint s
Objectives Endpoints
Primary
To evaluate the effect of baricitinib 4 -mg once 
daily  (QD) compared to placebo on disease 
progression in patients with COVID -19 infectionProportio n of patients who die or requir enon-invasive 
ventilatio n/high-flow oxygen or invasive mechanical ventilation 
(including extracorporeal membrane oxygenation [ECMO]) by Day 
28in these 2 populations
Population 1 -all randomized patients 
Population 2 –patients who, at baseline, requir eoxygen 
supplementation and are not receiving dexamethasone or 
other systemic corticosteroids for the primary study 
conditio n.
Key Secondary
To evaluate the effect of baricitinib 4 -mg QD 
compared to placebo on clinical outcomes in 
patients with COVID -19 infectionProportio n of patients with at least 1 -point improvement on NIAID -
OS or live discharge from hospital at Day 4, Day 7, Day  10, Day  14
Number of ventilator -free days (Day  1 to Day  28)
Time to recover y (NIAID -OS) ( Day 1 to Day  28)
Overall improvement on the NIAID -OS evaluated at Day 4, Day 7, 
Day 10, Day  14
Duration of hospitalization ( Day 1 to Day  28)
Proportio n of patients w ith a change in oxygen saturation from 
<94% to ≥94% from baseline to Day 4, Day 7, Day 10, Day 14
All-cause mortality ( Day 1 to Day  28)
Overall Design
Study  I4V-MC-KHAA (KHAA) is Phase 3 , multicenter, randomized, doubl e-blind, 
placebo -controlled, parallel- group study  designed to evaluate the efficacy and safet y of 
baricit inib4-mggiven once daily (QD). The primary  endpo int is the proporti on of  patients who 
die or requir e non- invasive ventilat ion/high-flow oxygen or invasive mechanical vent ilation 
(including extracorporeal  membrane oxygenat ion [ECMO] ) by Day 2 8.
The study  durati on will be up to approximately  
60 days over 3 study  periods:
Screening: on Day 1 prior to dosing
Treatment period: treatment is administered for up to 14 days, or up to the day  of hospital 
discharge, whichever comes first, followed by treatment evaluat ions up to Day  28
Follow-up: Period starting after treatment eval uation, with a follow-up visit 
approximately  28 days after last dose of study  drug and another fo llow-up visit at
approximately Study  Day  60.
Disclosure Statement : 2-armparallel treatm ent period ,participant -blinded and 
investigator -blinded .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
10Number of Participants: Approximately 1 400patients are pl anned to be randomized, with the 
potenti alto increase the final sample size, if indicated, at an interim analysis to maintain a n 
adequately  powered study .
Intervention Groups :
At baseline, participants will be rando mized in a 1:1ratio to oneof twotreatm entsgroups :either 
baricit inib or placebo.
Both treatm ent group swill receive background therapy in keeping with local clinical pract ice for 
management of COVID -
19infect ion.
Data Monitoring Committee: Yes
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
111.2. Schema
Note: Dosing occurs from the day of randomization until Day 14, or until hospital discharge, whichever comes first.  
Placebo or baricitinib are given with background therapy in keeping with local clinical practice for management of COVID -19, as defined in the protocol.
Abbreviations: D = study day; QD = o nce daily .
Figure 1.Schema of Study I4V-MC-KHAA .

CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
121.3. Schedule of Activities (SoA)
Day 1 procedures m ay be conducted over more than 1 day,as long as all  activi tiesare com pleted wi thin the allow edinterval tolerance.
Activities at the first follow-up visit (28 day s after last dose) arerequired for all rando mized patients and can be conducted as a 
telephone visit.Activities at the second follow-up visit (on Study Day 60 ) are also required for all rando mized pat ients and can be 
conducted as a telephone visit. If a telephone visit is conducted after hospital discharge, assessments will include: conco mitant 
medicat ions,adverse events , COVID -19 clinical symptoms , and Clinical Status Assessment . Collect ion of laboratory  samples i s 
preferred at designated timepo ints, but it will not be a protocol deviat ion if, after hospi taldischar ge,phone visit sareconducted and
laboratory  samples are not collected because the visits are by telephone . See the Comment scolumn for details about daily  collecti on 
of clinical assessments and vital signs.
Study day 1 4 7 10 14 28Follow -up 
(28 Days 
after Last 
Dose)Follow -up 
Day 60ETVUnsched
uledComments
Interval tolerance (days) ≤3 — — — — — ±4 +7 — —If patient is discharged from hospital, the 
study  visit may include a visit interval 
tolerance (window) of ±2 at Study Day 4, 
Day 7,Day10, Day 14,and Day 28.
Site Visit X X X X XSite visit is preferred after discharge, but 
telephone visit is acceptable after discharge 
and should include collection of 
concomitant medications, adverse events, 
COVID -19 clinical symptoms, and Clinical 
Status Assessment. Failure to conduct 
activities that cannot be reasonably 
performed over the telephone will not be 
considered a protocol deviation.
Telephone Visit X X
Informed consent X
Inclusion and exclusion criteriaX
DemographicsX
Pre-existing conditions and 
medical history, including 
relevant surgical historyXObtained from interview or available 
information, for example, medical 
records.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
13Study day 1 4 7 10 14 28Follow -up 
(28 Days 
after Last 
Dose)Follow -up 
Day 60ETVUnsched
uledComments
Interval tolerance (days) ≤3 — — — — — ±4 +7 — —If patient is discharged from hospital, the 
study  visit may include a visit interval 
tolerance (window) of ±2 at Study Day 4, 
Day 7,Day10, Day 14,and Day 28.
Site Visit X X X X XSite visit is preferred after discharge, but 
telephone visit is acceptable after discharge 
and should include collection of 
concomitant medications, adverse events, 
COVID -19 clinical symptoms, and Clinical 
Status Assessment. Failure to conduct 
activities that cannot be reasonably 
performed over the telephone will not be 
considered a protocol deviation.
Telephone Visit X X
Prespecified medi cal histo ry: 
comorbiditiesXIncludes comorbidities such as, but not 
limited to, diabetes, hypertension, 
cardiovascular disease, underlying 
pulmo nary disease.
Prespecified medical history : 
COVID -19XIncludes COVID -19 diagnosis date and 
onset of COVID -19 sy mptoms.
Prior treatments of special 
interest within last 2 weeksXIncludes NSAIDs, antiviral s, 
antibiotic s, antimalarial s, 
corticosteroids , herpes zoster vaccine, 
immunosuppressive medications .
Substance use (tobacco use) X
Concomitant medications X X X X X X X X XAssess daily. Includes medications of 
interest: background therapy, 
supportive care, sedating/ paralytic
drugs, and VTE prophylaxis .
Adverse events (AEs) X X X X X X X X XAssess daily .AE collection begins 
whenICF is signed . For i nfections and 
VTEs, additional data are collected
(Section 8.3.6 ).
COVID -19 clinical symptoms X X X X X X X X XAssess daily while hospitalized and on 
day of visits after discharge .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
14Study day 1 4 7 10 14 28Follow -up 
(28 Days 
after Last 
Dose)Follow -up 
Day 60ETVUnsched
uledComments
Interval tolerance (days) ≤3 — — — — — ±4 +7 — —If patient is discharged from hospital, the 
study  visit may include a visit interval 
tolerance (window) of ±2 at Study Day 4, 
Day 7,Day10, Day 14,and Day 28.
Site Visit X X X X XSite visit is preferred after discharge, but 
telephone visit is acceptable after discharge 
and should include collection of 
concomitant medications, adverse events, 
COVID -19 clinical symptoms, and Clinical 
Status Assessment. Failure to conduct 
activities that cannot be reasonably 
performed over the telephone will not be 
considered a protocol deviation.
Telephone Visit X X
Clinical Assessments
Height X May be as measured or reported.
Weight X
Vital signs X X X X X X XAssess and document daily while 
hospitalized .Includes: respiratory rate 
and oxygen saturation, blood pressure, 
body temperature, heart ( pulse ) rate. 
See Section 8.2.1 .
Physical examination XThe complete physical exam is 
performed if feasible ( exclude spelvic, 
rectal, and breast exams ). An
assessment of risk factors for 
tuberculosis (TB) is included (Section 
8.2.2).
Symptom -directed physical 
examination X X X X X X See Section 8.2.2 .
Chest imaging (CT scan or 
x-ray) (local)X X X XAssessed by radiologist or 
pulmo nologist (Section 8.2.4).
Documentation of hospital -
based 
imaging prior to study entry, obtained 
up to 24 hours prior to study entry is 
acceptable .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
15Study day 1 4 7 10 14 28Follow -up 
(28 Days 
after Last 
Dose)Follow -up 
Day 60ETVUnsched
uledComments
Interval tolerance (days) ≤3 — — — — — ±4 +7 — —If patient is discharged from hospital, the 
study  visit may include a visit interval 
tolerance (window) of ±2 at Study Day 4, 
Day 7,Day10, Day 14,and Day 28.
Site Visit X X X X XSite visit is preferred after discharge, but 
telephone visit is acceptable after discharge 
and should include collection of 
concomitant medications, adverse events, 
COVID -19 clinical symptoms, and Clinical 
Status Assessment. Failure to conduct 
activities that cannot be reasonably 
performed over the telephone will not be 
considered a protocol deviation.
Telephone Visit X X
12-lead ECG (local) XPerformed and assessed locally. 
Documentation of hospital -based ECG 
prior to study entry, up to 24 hours 
prior to study entry is acceptable 
(Section 8.2.3).
Clinician-Administered 
Assessments Paper
Clinical Status Assessment X X X X X X X XDocument daily through Day 29. 
Includes status of oxygen/life support 
procedures and proning.
Assessment for the NEWS X X X X X X X Document daily.
Laboratory Tests and Sample 
CollectionsFor laboratory tests and sample 
collections, the timing can be +1 day or 
-1 day from the designated day, unless 
otherwise specified.
Hematology X X X X X X X XPerformed locally. Tests performed in 
the 24 hours prio r to study  entry  will be 
accepted for determination of 
eligibility . Unscheduled collection, if 
clinically warranted, will be entered 
into the eCRF.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
16Study day 1 4 7 10 14 28Follow -up 
(28 Days 
after Last 
Dose)Follow -up 
Day 60ETVUnsched
uledComments
Interval tolerance (days) ≤3 — — — — — ±4 +7 — —If patient is discharged from hospital, the 
study  visit may include a visit interval 
tolerance (window) of ±2 at Study Day 4, 
Day 7,Day10, Day 14,and Day 28.
Site Visit X X X X XSite visit is preferred after discharge, but 
telephone visit is acceptable after discharge 
and should include collection of 
concomitant medications, adverse events, 
COVID -19 clinical symptoms, and Clinical 
Status Assessment. Failure to conduct 
activities that cannot be reasonably 
performed over the telephone will not be 
considered a protocol deviation.
Telephone Visit X X
Laboratory Tests and Sample 
Collections (continued)For laboratory tests and sample 
collections, the timing can be +1 day or 
-1 day from the designated day, unless 
otherwise specified.
Clinical chemistry , including 
creatine kinase (CK)X X X X X X X XPerformed locally. Tests performed in 
the 24 hours prio r to study  entry  will be 
accepted for determination of 
eligibility . Unscheduled collection, if 
clinically warranted, will be entered 
into the eCRF.
Lactate dehydrogenase (LDH) X X X X X X X XPerformed locally. Test performed 
within 2days prior to study  entry  will 
be accepted for determination of 
eligibility . Unscheduled collection, if 
clinically warranted, will be entered 
into the eCRF.
Cardiac t roponin X X X X X X X XPerformed locally. Tests performed in 
the 24 hours prio r to study  entry  will be 
accepted . Unscheduled collection, if 
clinically warranted, will be entered 
into the eCRF.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
17Study day 1 4 7 10 14 28Follow -up 
(28 Days 
after Last 
Dose)Follow -up 
Day 60ETVUnsched
uledComments
Interval tolerance (days) ≤3 — — — — — ±4 +7 — —If patient is discharged from hospital, the 
study  visit may include a visit interval 
tolerance (window) of ±2 at Study Day 4, 
Day 7,Day10, Day 14,and Day 28.
Site Visit X X X X XSite visit is preferred after discharge, but 
telephone visit is acceptable after discharge 
and should include collection of 
concomitant medications, adverse events, 
COVID -19 clinical symptoms, and Clinical 
Status Assessment. Failure to conduct 
activities that cannot be reasonably 
performed over the telephone will not be 
considered a protocol deviation.
Telephone Visit X X
Laboratory Tests and Sample 
Collections (continued)For laboratory tests and sample collections, 
the timing can be +1 day or -1 day  from the 
designated day, unless otherwise specified.
eGFR (MDRD) X X X X X X X XPerformed locally. Test performed in 
the 24 hours prio r to study  entry  will be 
accepted for determination of 
eligibility . Unscheduled collection, if 
clinically warranted, will be entered 
into the eCRF. If eGFR ≥30 to <60 
mL/min/1.73 m2at screening , patient 
will receive blinded 2- mg dose 
(baricitinib or placebo) for the duration 
of the treatment period. See Sections 
6.1and 6.6fordose modification if 
eGFR decreases to <60 mL/min/1.73 
m2after study entry. See Section 7.1.2
for temporary interruption criteria.
Serum pregnancy XRequired prior to randomization. 
Performed locally. Test performed in 
the 24 hours prior to study entry will be 
accepted for determination of 
eligibility . Only for WOCBP (Section 
8.2.5.1 , Appendix 10.4).
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
18Study day 1 4 7 10 14 28Follow -up 
(28 Days 
after Last 
Dose)Follow -up 
Day 60ETVUnsched
uledComments
Interval tolerance (days) ≤3 — — — — — ±4 +7 — —If patient is discharged from hospital, the 
study  visit may include a visit interval 
tolerance (window) of ±2 at Study Day 4, 
Day 7,Day10, Day 14,and Day 28.
Site Visit X X X X XSite visit is preferred after discharge, but 
telephone visit is acceptable after discharge 
and should include collection of 
concomitant medications, adverse events, 
COVID -19 clinical symptoms, and Clinical 
Status Assessment. Failure to conduct 
activities that cannot be reasonably 
performed over the telephone will not be 
considered a protocol deviation.
Telephone Visit X X
Laboratory Tests and Sample 
Collections (continued)For laboratory tests and sample collections, 
the timing can be +1 day or -1 day  from the 
designated day, unless otherwise specified.
Pharmacokinetic (PK) samples XSamples should be collected on all 
intubated patients in ICU if lab kits 
available . Timing starts on the first day 
of invasive mechanical ventilation.
Samples on first day of intubation :
15minutes, 1 hour, and any time 
between 2-4 h ours (all post -dose).
Samples on third day of intubation: 
pre-dose; then 30 min utes, and any 
time between 6-10 hours post-dose .
If collection on the third day of 
intubation is not possible, PK 
sample collection can be done on a 
later day .
Central laboratory.
Erythrocy te sedimentation rate 
(ESR)X X X X X X X XPerformed locally. Test performed in 
the 24 hours prio r to study  entry  will be 
accepted . Unscheduled collection, if 
clinically warranted, will be entered 
into the eCRF.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
19Study day 1 4 7 10 14 28Follow -up 
(28 Days 
after Last 
Dose)Follow -up 
Day 60ETVUnsched
uledComments
Interval tolerance (days) ≤3 — — — — — ±4 +7 — —If patient is discharged from hospital, the 
study  visit may include a visit interval 
tolerance (window) of ±2 at Study Day 4, 
Day 7,Day10, Day 14,and Day 28.
Site Visit X X X X XSite visit is preferred after discharge, but 
telephone visit is acceptable after discharge 
and should include collection of 
concomitant medications, adverse events, 
COVID -19 clinical symptoms, and Clinical 
Status Assessment. Failure to conduct 
activities that cannot be reasonably 
performed over the telephone will not be 
considered a protocol deviation.
Telephone Visit X X
Laboratory Tests and Sample 
Collections (continued)For laboratory tests and sample collections, 
the timing can be +1 day or -1 day  from the 
designated day, unless otherwise specified.
C-reactive protein (CRP) X X X X X X X XPerformed locally. If available, 
high-sensitivity (hs-CRP) is preferred. 
Test performed within 2 days prior to 
study entry will be accepted for 
determination of eligibility . 
Unscheduled collection, if clinically 
warranted, will be entered into the 
eCRF.
Ferritin X X X X X X X XPerformed locally. Test performed 
within 2 days prior to study  entry  will 
be accepted for determination of 
eligibility . Unscheduled collection, if 
clinically warranted, will be entered 
into the eCRF.
D-dime r X X X X X X X XPerformed locally. Test performed 
within 2 days prior to study  entry  will 
be accepted for determination of 
eligibility . Unscheduled collection, if 
clinically warranted, will be entered 
into the eCRF.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
20Study day 1 4 7 10 14 28Follow -up 
(28 Days 
after Last 
Dose)Follow -up 
Day 60ETVUnsched
uledComments
Interval tolerance (days) ≤3 — — — — — ±4 +7 — —If patient is discharged from hospital, the 
study  visit may include a visit interval 
tolerance (window) of ±2 at Study Day 4, 
Day 7,Day10, Day 14,and Day 28.
Site Visit X X X X XSite visit is preferred after discharge, but 
telephone visit is acceptable after discharge 
and should include collection of 
concomitant medications, adverse events, 
COVID -19 clinical symptoms, and Clinical 
Status Assessment. Failure to conduct 
activities that cannot be reasonably 
performed over the telephone will not be 
considered a protocol deviation.
Telephone Visit X X
Laboratory Tests and Sample 
Collections (continued)For laboratory tests and sample collections, 
the timing can be +1 day or -1 day  from the 
designated day, unless otherwise specified.
Procalcitonin X X X X X X X XPerformed locally. Test performed in 
the 24 hours prio r to study  entry  will be 
accepted for determination of 
eligibility . Unscheduled collection, if 
clinically warranted, will be entered 
into the eCRF.
SARS -CoV-2 viral infection 
confirmatio n via NP swabX X X X X X XPerformed locally. Test performed 
during current hospitalization ( prior to 
study entry )will be accepted for 
determination of eligibility per 
inclusion criteria requirements .
Collection of NP swab is at 
investigator’s discretion at other 
timepoints and will not be considered 
protocol deviation if not done.
Explo ratory biomarker 
sample s: serum, whole bloodX X X X XObtained and sent to the Lilly -
designated laboratory. Refer to Section 
8.8for additional information.
Explo ratory biomarker sample : 
nasophary ngeal swabX X X X X XObtained and sent to the Lilly -
designated laboratory. Refer to Section 
8.8 for additional information.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
21Study day 1 4 7 10 14 28Follow -up 
(28 Days 
after Last 
Dose)Follow -up 
Day 60ETVUnsched
uledComments
Interval tolerance (days) ≤3 — — — — — ±4 +7 — —If patient is discharged from hospital, the 
study  visit may include a visit interval 
tolerance (window) of ±2 at Study Day 4, 
Day 7,Day10, Day 14,and Day 28.
Site Visit X X X X XSite visit is preferred after discharge, but 
telephone visit is acceptable after discharge 
and should include collection of 
concomitant medications, adverse events, 
COVID -19 clinical symptoms, and Clinical 
Status Assessment. Failure to conduct 
activities that cannot be reasonably 
performed over the telephone will not be 
considered a protocol deviation.
Telephone Visit X X
Randomization XDosing daily from randomization 
through Day 14, or until patient is 
discharged from hospital, whichever 
comes first .
Abbreviations :CT= computerized tomography ;eCRF = electronic case report form; ECG = electrocardiogram ; eGFR = estimated glomerular filtration rate; 
ETV = early termination (discontinuation) visit;ICU = intensive care unit; ICF = informed consent form; MDRD = Modification of Diet in Renal Disease ; 
NEWS = National Early Warning Score ; NP=nasophary ngeal; NSAIDs = nonsteroidal anti -inflammatory drug s; VTE = venous thromboembolism; WOCBP 
= women of childbearing potential .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
222. Introduction
2.1. Study Rationale
Baricitinib, an approved therapy  for the treatm ent of m oderately to severely act ive rheumatoi d 
arthri tis(RA) in adults ,is being proposed as apotent ial therapy for patients wi th COVID -19
infect ion. The proposed m echanism of action in COVID- 19 infect ion include sreducti on of  
cytokine -mediated inflammat ion and thepotenti alforantiviral act ivity.
There are currently no approved therapies for the treatment of COVID -19 infect ion.
Management of COVID -19 is supportive, and respiratory  failure fro m acute respi ratory  distress 
syndro me (ARDS) is the leading cause of mortalit y.The cause of ARDS i sa hyperinflammatory  
state characterized by upregulat ion of mult iple cy tokines . For example, COVID -19 infected 
patients admitted to the intensive care unit (ICU) in Wuhan ,China, exhibited increased p lasma 
concentrations of IL -2, IL -7, IL -10, G -CSF, IP -10, MCP -1, MIP 1A, and TNFα, compared to the 
non
-ICU pati ents (Huang et al . 2020) . Elevated IL -6 and hyperferrit inemia were predictors of 
death in COVID -19 pati ents in China (Chen X et al. 2020 ; Chen T et al. 2020; Mehta et al. 2020; 
Ruan et al . 2020 ). 
Baricitinib, an oral ly administered inhibitor of JAK1 and JAK2, could be a therapeuti c opti on for 
this condi tion because of the potential to inhibit signaling fro m mult iple cy tokines that are 
impli cated in COVID -19 ARDS (McInnes et al. 2019) . In pati ents wi th RA, there was a dose -
dependent reduction in plasma IL-6 at Week 12 in a Phase 2, rando mized, placebo -controlled, 
study  of baricitinib(Stebbing, et al .
2020). In ex vivo studi es, there was a similar dose -dependent 
effect on inhibit ion of mult iple cy tokines implicated in COVID -19 infect ion. 
The potent 
anti-inflammatory  effects of baricit inib have also been demo nstrated by  the reducti on of  serum  
levels o f IFN-γ, IP-10, GM -CSF and MCP -1 in pedi atric pati ents wi th steroi d-dependent chronic 
inflammat ion, result ing in control of disease activit y and the abilit y to wean or taper steroids
(Sanchez et al. 2018 )
.
In addit ionto the anti -cytokine effect , baricit inib has recent ly been hypothesized (Richardson 
etal. 2020) and shown ( Stebbin get al. 2020) to be a potent inhibitor of numb -associ ated kinases 
(NAKs ), which include AAK1, GAK, and BIKE . These proteins play a crit ical role in the host 
epithelial cell  to facilitate propagation of viruses , including SARS -CoV -
2,that rely on the 
scaffo ld protein known as activator protein 2 (AP2) .Inhibit ing the NAK proteins that activate 
the AP2 scaffo lding protein vital to viral entry  and propagati on coul d be one therapeuti c 
approach to managing COVID -19 infect ion.
The rati
onale for study  treatm ent for up to 14 day s is based on the known onset of efficacy  in the 
RA popul ation, which is as early as 1 week ( Olumiant Summary  of Product Characteri stics),and
onthe expected duration of treatment needed for an acute infect ion such as COVID -19. 
Recent ly,data were published on a case series describing a 14-day treatm ent course of baricitinib 
in patients with mild to moderate COVID -19 infection (Cant ini et al. 2020
).
Baricitinib is administered orally once a day .It has a short half -life (approximately  12hours in 
RA pat ients), so treatment can be interrupted or stopped if necessary. It has few drug -drug 
interact ions (due to low CYP inhibitory  activit y) so i t can be given conco mitantly wit h 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
23background therapi es. Bari citinib has a well -established safety  profile , based on clinical trial data 
and postm arket ing data in patients with RA (Olumiant United States package insert, 2020; 
Olumiant Summary of Product Characteris tics)
.
This profile, together with the observat ion that baricit inib is a potent AAK1/BIKE/GAK 
inhibitor and the known anti-cytokine profile ,provide the rati onale to study  baricitinib in the 
context of a randomized , controlled clinical tri alin pati ents wi th COVID -19 infect ion.
2.2. Background
In December 2019 ,a life -threatening infect ious di sease first observed in Wuhan, China , and later 
ident ified as COVID -19 has rapidly spread, causing a global pandemic. According to the World 
Health Organizat ion(WHO) ,as of 20April 2020 ,2,314,621 confirmed cases have been reported 
worldwide wi th 157,847 deaths (WHO COVID -19 Si tuation Report 91) .
COVID -19 belo ngs to the coronavirus family o f single- stranded RNA viruses that can cross 
species barriers and can cause illness ranging fro m the commo n cold to more severe diseases 
such as SARS and MERS. Transmissio n of C OVID -19 is believed to occur through respiratory  
dropl ets fro m coughing and sneezing. The pathogenesis is unclear, but the virus seems capable of 
producing an excessive immune reaction, which results in extensive t issue damage (Rothan and 
Byrareddy 2020).
The m ajority of individuals infected with C OVID -19 experience a mild respiratory  disease 
generally affect ing the l ower ai rways; symptom s usually app ear after an incubation period of 
approximately  5 days. The m ost comm on symptoms at onset include fever, fatigue, and dry  
cough . Other si gns and symptom s incl ude myalgia, headache, diarrhea, nausea, dy spnea, 
lymphopenia, prolonged thrombin t ime, elevated l actate dehy drogenase, el evated al anine 
transaminase ,and creat ine kinase, and bilateral infiltrates on chest imaging. Patients can 
deteri orate rapi dly. The m edian time fro m first symptoms to hospitalization is 7 days ( Wang D et 
al.
2020).
Huang etal.(2020) reported that 
27% of hospitalized patients diagnosed with C OVID - 19
infect ionin China devel opedARDS after 9 days from onset of symptom srequi ring oxy gen 
therapy  and intensive care. Some pat ients have laboratory  evidence of a severe inflammatory  
response, similar to the cy tokine release syndrome, with persistent fever, elevated inflammatory  
markers (hs -CRP, D -dimer, ferrit in), and m ultiple organ dysfunction (Guan et al . 2020; Chen T 
et al. 2020 ). The major complicat ions during hospitalizat ion include ARDS, arrhy thmia ,and 
shock. Di sease severit y and m ortali ty appears to be associated with those over the age of 70 and 
individuals wit h underlying comorbidit ies such as diabetes, hypertensio n, cardi ovascular di sease, 
chronic renal disease , and chronic lun g disease (Chen N et al. 2020; Guan et al . 2020; Rothan 
and Byrareddy  2020 ; Wang W et al. 2020 ).
There is no approved or standard- of-care treatm ent for COVID -19 infection ; medical 
management is based on supporti ve care. As stated in the guidelines of the United State s
Institutes of Health (NIH) and the World Healt h Organizat ion (WHO), no drug to date has been 
proven safe and effect ive for treating COVID -19infect ion. Furtherm ore, t here are insufficient 
data to recommend eit her for or against the use of any antiviral or immunomodulatory therapy in 
patients wi th COVID -19 infection . As a result of the RECOVERY trial (NCT 04381936; Horby  
et al.
2020 ), the WHO and NIH guidelines recommend use of corticosteroids inpatients with
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
24severe COVID -19 infection, specific ally for patients who require oxygen supplementation or 
who are on invasive mechanical vent ilation. (WHO 2020 b; NIH 202 0b). The use of NSAIDs has 
been questioned since patients who were treated wit h NSAIDs early in their course of infect ion 
have progressed.
2.3. Benefit/Risk Assessment
Baricitinib, which is an approved therapy  for the treatm ent of  moderately  to severely act ive RA 
in adults, is being proposed as a potential therapy for COVID -19. The proposed mechanism o f 
action includes reduced cy tokine -mediated inflammat ion and the potential for ant iviral act ivity.
Patients di agnosed wi th COVID -19 infect ion who are candidates for entry  into Study  KHAA 
will be at an elevated risk f orexcess morbidit y and m ortali ty due to the underlying SARS-CoV -2 
infect ionand subsequent cy tokine activat ion. Of hospitalized p atients wi th COVID -19 infect ion 
in Wuhan ,China ,26% were transferred to the intensive care unit (ICU) , and o f those patients in 
the ICU, complicat ions included acute respiratory  distress syndrome (61.1%), arrhy thmia 
(44.4%) ,and shock (30.6%) (Wang D et al. 2020) . In addition,these pat ients will inherent ly be 
at higher risk for venous thromboembo lism (VTE ) due to immo bilizat ionand the 
hyperinflammatory  state (Klok et al . 2020 ; Chen N et al. 2020; Huang et al . 2020) . 
As stated in the study  rationale, the cy tokine storm that may be responsible for the significant 
complicat ionswill potenti ally be am eliorated by  immuno modulators such as the use of
baricit inib. The potenti al benefi t of baricitinib in the treatment of COVID -19 infect ion is 
described further in the study  rationale (Secti on 2.1).
Baricitinib is a Janus kinase (JAK) inhibitor approved for the treatm ent of RA. In the US, 
baricit inib2-mgis indicated for the treatment of adult patients with moderately  to severely  active 
RAwho have had an inadequate response to one or more tumor necrosi s factor ( TNF)antagonist 
therapi es. In Europe , baricit inib 4-mg is indicated for the treatment of moderate to severe active 
RAin adult pati ents who have responded inadequately  to, or who are i ntolerant to one or m ore 
disease -modifying ant i-rheumat ic drugs . Bari citinib is current ly under development in other 
autoimmune condit ionsincluding atopic dermat itis, alopecia areata, sy stemic lupus 
erythematosus ,and juvenile idiopathic arthritis.
The United States product labeling indicates a boxed warning for the ri sk of seri ous infect ions, 
malignancies ,and thrombosis ,while w arning sand precauti ons incl ude seri ous infect ions, 
thrombosis, gastrointest inal perforations, abnormal laboratory assessments (potential changes in 
lymphocy tes, neutrophils, hemoglobin, liver enzymes, and lipids) ,and avo idance wit h the use of 
live vaccines.
TheSummary  of Product Characterist ics indicates as special warning and precautions for 
infect ions, including tuberculosis (TB), hem atological abnormalit ies, viral react ivation, use of 
live vaccines, increase in blood lipid parameters, increase in hepat ic tra nsaminase, malignancy, 
VTE , hypersensit ivity, and use of baricit inib with potent immunosuppressive medicat ions.
Baricitinib has an established safet y profile wi th a positivebenefit /risk profile in RA. An 
integrated analysis o f patients wi th active RA expo sed to baricit inib with 3770 pati ents and 
10,127 patient -years for a maximum exposure of 7 years (as of February 2018) was recent ly 
published (Genovese et al. 2019). No significant differences were seen for baricit inib4-mg 
versus placebo in adverse events leading to permanent drug discont inuat ion, death, malignancy, 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
25serious infect ion, or m ajor adverse cardi ovascular events. Malignancy (excluding non -melano ma 
skin cancer) incidence rates (IRs) per 100 patient -years were 0.8 (2 -mg) and 1.0 (4 -mg; as-
rando mized analysis). Fewer than 1% of patients discontinued due to abnormal laboratory 
resul ts.
Specifically  regarding VTE, during the 16- week placebo -controlled period of  RA studi es, the IRs
per 100 patient -years for deep vein thrombosis (DVT)/pulmo nary embo lism (PE) were 
numerically  higher in barici tinib 4 -mg (IR=1.7) versus both baricit inib 2 -mg and pl acebo (IR=0). 
With long-term exposures, the exposure -adjusted IRof VTE f or bari citinib-treated pati ents wi th 
RA was similar to the background rates published in the literature for the target population. 
Cases observed with baricit inib were confounded by  1 or m ore recogni zed ri sk factors for VTE 
and the time to onset of an event ranged from 37 to 1658 days.
VTE has been classified as an important potential risk for baricit inib and is also an adverse drug 
reacti on. Mitigation of the risk of venous throm boembo lism will be managed through the 
appropriate exclusio n and discont inuat ion criteria which limit participat ion of pat ients who are at 
an increased risk of VTE (Section 5.2, Secti on 7.1.1 ). The addit ion ofVTE prophylaxis to all 
patients enrolled in this study  unless there is a contraindicat ion will also reduce the potential risk
(Secti on 6.5.2 ).
During the 16- week treatment period of RA studi es, overall infections were numerically  
increased with IRs per 100 patient- years of 100.1 events, 99.1 events and 82.1 events in 
baricit inib 4-mg, baricit inib 2 -mg,and placebo respectively. However, serious infect ions for the 
16-week treatment period were similar between baricit inib 4 -mg, baricit inib 2-mg,and placebo 
(IRs per 100 patient -years 3.7, 3.6 and 4.2 respectively). The frequency o f Herpes zoster was 
higher for baricit inib 4 -mg versus placebo (1.4 vs 0.4) andfor baricit inib 4 -mg versus
baricit inib2-mg (1.4 vs1.0).  
There are provisions in the protocol to mit igate ri sk fro m potenti al concurrent infect ions,
including allowance of appropriate use of standard -of-care for treatment of infect ions and criteria 
for perm anent discont inuat ion of study  drug if the patient is diagnosed with act ive tuberculosis, 
hepat itis B, orhepat itis C(Secti on 6.5.2 , Section 7.1.1 ). Permanent discont inuat ionof study  drug
will also occur if aparticipant develops a serious adverse event which, in the opinio n of the 
investigator or sponsor, would preclude the participant from continuing to receive study  drug
(Secti on 7.1.1 ).
It is difficult to extrapolate the potential risks of baricit inib in a disease state very  different than a 
chronic autoimmune disease such as RA. However, bari citinib has an established safet y profile 
for RA ,with approximately 10,034 pati ents having received baricit inibin all clinical trials and 
150,000 patients estimated to have been treated with baricit inib (based on postm arket ing 
sources )worldwide. In RA ,baricitinib was approved for long -term chronic use whereas the 
durati on of  baricit inib treatment in this COVID -19 study  will be short (up to 14days).Thehalf-
life of the m olecule is approximately 12 hours ,which will lead to a very  short washout period 
once di scont inued andhas few drug -drug i nteractions (due to low CYP inhibitory  activity) so it 
can be given concomitant ly with background therapies .
More detailed informat ion about t he known risks and reasonably expected adverse events of 
baricit inibmay be found in the Investi gator’s Brochure (IB) .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
26In summary, in the context of the cumulative knowledge for baricit inib with respect to the 
established safet y profile, the potential to mit igate the hyperinflammatory  state and cytokine 
storm  associated with SARS-CoV -2,and the high unmet need for a treatment to slow the 
progression of COVID -
19infect ion, the benefit/risk balance for this study is assessed to be 
favorable.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
273. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the effect of baricitinib 4 -mgonce 
daily  (QD) compared to placebo on disease 
progression in patients with COVID -19 infectionProportio n of patients who die or requir enon-invasive 
ventilatio n/high-flow oxygen or invasive mechanical ventilation 
(including extracorporeal membrane oxygenation [ECMO] ) by 
Day 28in these 2 populations
Population 1 -all randomized patients 
Population 2 –patients who,at baseline, requir eoxygen 
supplementation and are not receiv ingdexamethasone or 
other systemic corticosteroids for the primary study 
conditio n.
Key Secondary
To evaluate the effect of baricitinib 4 -mg QD 
compared to placebo on clinical outcomes in 
patients with COVID -19infectionProportio n of patients with at least 1 -point improvement on NIAID -
OS or live discharge from hospital at Day 4, Day 7, Day 10, Day 1 4
Number of ventilator -free days (Day  1 to Day  28)
Time to recover y (NIAID -OS) (Day  1 to Day  28)
Overall improvement on the NIAID -OSevaluated at Day 4 , Day 7, 
Day 10, Day 14
Duration of hospitalization (Day  1 to Day  28)
Proportio n of patients with a change in oxygen saturation from 
<94% to ≥94% from baseline to Day 4, Day 7, Day 10, Day 1 4
All-cause mortality (Day  1 to Day  28)
Other Secondary
To evaluate the effect of baricitinib 4 -mg QD 
compared to placebo on other clinical outcomes 
inpatients with COVID -19 infectionTreatment Period – (Day 1 to Day 28, unless otherwise specified )
Time to recover y (NIAID -OS) by disease duration of < 7 days 
or ≥7days
Duration of stay in the intensive care unit (ICU) in days
Time to clinical deterioration (one -category increase on the 
NIAID -OS)
Time to clinical improvement in one category  of theNIAID -
OS
Time to resolution of fever ,in patients with fever at baseline
Overall improvement on the NIAID -OS evaluated at Day 21, 
Day 28
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
28Objectives Endpoints
Mean change in National Early Warning Score (NEWS)
Time to definitive extubation
Time to independence from non -invasive mechanic al 
ventilatio n
Time to independence from oxygen therapy in days
Time to oxygen saturation of ≥94% o n room air in day s
Number of days with supplemental oxygen use 
Number of days of resting respiratory rate <24 breaths per 
minute 
Landmark analysis –Day 4, Day  7, Day 10, Day  14, Day 28
Proportio nof patients in each severity categor yon the NIAID -
OS
Proportio n of patients with at least 2 -point improvement on the 
NIAID -OS or live discharge from the hospital
Proportio n of patients with at least 1 -point improvement on 
NIAID -OS or live discharge from hospital
Explo ratory
Explo ratory  objectives and endpoints may include the following:
C-reactive protein ( CRP), D- dimer, lactate dehydrogenase (LDH), ferritin
Virologic measures
Characteriz ation ofthe pharmacokinetics of baricitinib in intubated patients with COVID -19infection
Long -term (at least Day 60) clinical outcomes .
Notes: 
   The Day 28 Clinical Status Assessment is entered for midnight to midnight for the previous day. Therefore, the 
Day 28 Clinical Status Assessment is entered on Day 29.
   Recover y is defined as the first day or time from study start on which the participant satisfies 1 of the following 3 
categories from the ordinal scale: Hospitalized, not requiring supplemental oxygen –no longer requires ongoing 
medical care; Not hospitalized, limitation on activities and/or requiring home oxygen; Not hospitalized, no 
limitations on activities (applies to live discharge from hospital to home as well).
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
294. Study Design
4.1. Overall Design
Study  I4V-MC-KHAA (KHAA ) is Phase 3, m ulticenter, randomized, doubl e-blind, 
placebo -controlled, parallel- group study  designed to evaluate the efficacy and safet y of
baricit inib4-mg given once daily (QD ).The primary  endpo int is the proporti on of  patients who 
die or requir e
non-invasive ventilat ion/high-flow oxygen or invasive mechanical vent ilation 
(including ECMO) by Day 28.  Two populations will be evaluated, all rando mized patients and a 
subset of patientswho, at baseline, requi reoxygen supplementati on and are not receiving 
dexamethasone or other systemic corticosteroids for the primary study  condi tion.
The study  durati on will be up to approximately  60 days over 3 study  periods:
Screening: on Day  1 pri or to dosing
Treatment period: treatment is administered for up to 14 days, or up to the day of hospital 
discharge, whichever comes first, followed by treatment evaluat ionsup to Day  28
Follow-up: Period starting after treatment period , with a follow-up visit approximately 
28 da ys after last dose of study  drug and another follow -up visit at approximately  
Study  Day  60.
Patients will  be enrolled if they are hospitalized with coronavirus (SARS -CoV -
2)infect ionand 
meet other study  entry  criteria, incl uding requi ring oxy gen supplemen tation. Patient srequiring
invasive mechanical vent ilation (including ECMO) at the time of study  entry  are not eligible.
While hospi talized , enrolled patients will receive eit her baricit inib or placebo until Day  14or 
until the day of hospi tal discharge, whichever co mes first.
Parti cipants may remain on stable background therapy per local guidelines , including 
antimalarials (hydroxychloroquine) ,and/or antivirals ,and/or azithromycin . Hydroxy chloroquine 
and chloroquine are not approved to treat COVID -19 in fection. Recent ly published data suggest 
that chloroquine and hydroxychloroquine may be associated with increased risk in pat ients with 
COVID -19 infect ion(Mehra et al . 2020; Tang et al. 2020) . Hydroxychl oroquine and chloroquine 
are only permitted as conco mitant m edicat ion if these are recommended or required by local 
COVID -19 treatment guidelines. Conco mitant bi ologics (including interferon, tocilizumab, 
sarilumab, TNFi ) or Janus kinase (JAK) inhibitor s[except for study  drug] ) are not permitted (see 
Secti on 6.5).
Afollow-up visit approximately 28 days after l ast dose is required for all rando mized pat ients, 
including those discharged fro m hospi tal before Day  14. Another follow -up visit occurs at 
approximately  Study  Day  60. These follow-up visits can be conducted as telephone visit s.
Discharge from  the hospi tal prior to Day  14 is not considered early  discontinuat ion from the 
study  drug or from the study .All rando mized patients, including p atients meeting criteria for 
early  discontinuat ion of study  drug , as specified in Secti on 7.1,should be encouraged to remain 
in the study  forthe scheduled study  assessments specified in the Schedule of Activit ies(SoA)
(Secti on1.3).Patients who prematurely discont inue fro m the study  shoul d have an ETV and 
follow-up visit s, if possible, as shown in the SoA .
The study  schema is presented in Sect ion 1.2.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
304.2. Scientific Rationale for Study Design
The double -blind, pl acebo -controlled design o f this study  limits potenti al bias in investigator 
assessments and enables a clear er interpretati on of  the effects of act ive drug compared to placebo 
(background therapy ).
The primary endpo int of this study  isthe proporti on of  patients who die or requir e non- invasive 
ventilation/high-flow oxy gen or invasive m echanical  ventilation (including ECMO) by Day 28.
Progression to requiring non -invasive or invasive mechanical vent ilation is an indicator of 
critical disease and can occur at any  timepo int after hospitalization. 
Time on ventilat ion increases the patient’s risk of complicat ions,including pneumothorax, 
airway injury , alveol ar damage, ventilator -associated pneumo nia, and ventilator -associated 
tracheobronchit is,which are associated with higher death rates and longer hospital stay s (Craven 
et al. 2009 ; Hess 2011 ; Patel 2020). An effective treatm ent shoul d be able to halt progression of 
patients to ventilat ion at any  time. A primary  endpoint capturing progression to death or non-
invasive vent ilation/high-flow oxy gen or invasive vent ilation (including ECMO) byDay 28 
(rather than atDay 28) is clinically meaningful because it utilizes all available data about the 
course of disease progression or resolut ion in response to treatment .
The addition of  the sub popul ationofpatients requiring oxy gen supplementation at baseline to the 
primary  analysis is based on the National  Institute of Allergy  and Infecti ous Diseases ( NIAID )
Adapt ive COVID -19 Treatm ent Tri al 2 ( ACTT -2).Patientrecovery  and mortalit yin ACTT 2 
indicated treatm ent effect was the largest in this sub set ofpatients. The use of dexamethasone is 
recommended for pati ents requi ring oxy gen supplementation or invasive mechanical vent ilation
per the NIH and WHO guidelines and is allowed in this study per the protocol .Theimpact of 
dexamethason e on the efficacy  of baricit inib is unknown andfurther evaluat ions inthetwo 
subpopulati onswillprovi de additional resul tsrelevant to the treatment of COVID -19.
In addit ion, an observat ion of treatment effect for baricit inib to 28 day s is based on US 
regulatory  and WHO recommendations, and allows comparisons across different therapeutic 
agents in COVID -19 studi es.Based on regulatory  feedback, a n additional evaluat ion of patient s’ 
clinical status and safet yassessments will be conducted at Day 60 to evaluate safet y and 
effect iveness for this pat ient population.
The rati onale for study  treatm ent for up to 14 day sis based on the known onset of efficacy in the 
RA popul ation, which is as early as 1 week ( Olumiant Summary  of Product Characteri stics),and 
on the expected duration of treatment needed for an acute infect ion such as COVID- 19. 
Recent ly,data were published on a case series describing a 14-day course of baricit inib in 
patients wi th mild to m oderate COVID -19 infect ion(Cantini et al. 2020)
.
A key  secondary  objective i s improvement on an ordinal scale. The ordinal scale used in this 
study (NIAID -OS) has been used in the NIAID ACTT study  and is similar to the WHO ordinal 
scale recommended for use in the assessment of therapeutics for the treatm ent of  COVID -19 
infect ion (WHO R&D) .Clinical improvement as described by a similar ordinal scale was used in 
a study  com paring the effect iveness of co mbined favipiravir and osel tamivi r therapy  versus 
oseltamivir m onotherapy  in critically  ill patients wi th influenza virus infect ion (Wang Y et al. 
2019) , and was an endpo int recommended by the WHO R&D Blueprint expert group ( WHO 
R&D).
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
31To ensure that sufficient patients enr olled are in the hyperinflammatory  state which correlates
withprogressi on to severe di sease and vent ilation requirements, p atients are requi red to have at 
least one inflammatory marker (CRP, D -dimer, LDH, ferrit in) that is greater than the upper limit 
of norm al (ULN) . 
In thi s study , collecti on of  dem ographic informati on incl udes race and ethnicit y. The scient ific 
rationale is based on the possible need to assess variable response in safety  and/or efficacy based 
on race or ethnicit y. Such a need can be addressed only if all the rel evant data are collected.
The post -treatm ent follow-up peri od allow sfor cont inued safet y and efficacy  monitoring after 
the last dose.
4.3. Justification for Dose
The 4 -mg QD dose of baricit inib selected for this study  in a patient populat ion with COVID -19 
infect ion is based on clinical data showing an effect of baricit inib on inhibit ionof cytokine 
signaling . Upregul ation of mult iple proinflammatory  cytokines has b een shown in pat ients with 
COVID -19 infect ion admitted to ICU units in Wuhan,China, and elevated IL -6 was a predictor 
of mortalit yin COVID -19 pati ents in another China -based study . 
In pati ents wi th RA, there was a dose -dependent reduction in plasma IL-6levels, assessed after 
12 weeks of treatment. In ex vivo studies, there was a similar dose -dependent effect on inhibit ion 
of multiple cy tokines implicated in COVID -19 infection. In a compassi onate use program in 
pediatric patients with chronic aty pical ne utrophilic dermatosis wit h lipody strophy  and el evated 
temperature (CANDLE) syndrome , patients on a mean dose of baricit inib 6 -mg QD show ed a 
striking reducti on in cy tokine signaling (Sanchez et al. 2018) . In healthy vo lunteers,exposures 
observed at the baricitinib 4-mg (or higher)doses are associ ated wi threduct ion of IL -6 induced 
ex vivo pSTAT3 activat ion (Shi et al . 2014) .
In term s of risk considerat ions, the proposed duration of treatment with baricit inib 4 -mg in the 
setting of COVID -19 infect ion is brief (up to 14 days) ; to date, baricit inib has been studied and 
approved for long -term use in the setting of chronic autoimmune condit ions.In a vaccine 
response study , individuals treated with baricit inib 4-mg can mount an appropriate immune 
response to a pneumococcal vaccine ,suggest ingthat transient exposure to baricit inib will not 
resul t in clinically  meaningful changes to adaptive immunit y(Wint hrop et al. 2019) .
In addit ion, the cho ice of the 4 -mg dose is supported by efficacy and safet y data for ba ricitinib in 
Phase 2 and Phase 3 RA studies. In the RA populatio n, there was a dose -dependent reduction in
plasma IL-6 levels, assessed after 12 weeks of treatment (Stebbing et al .
2020). In ex vivo 
studi es, there was a similar dose -dependent effect on inh ibition of mult iple cy tokines. The 
baricit inib 4-mg dose is approved in mult iple regio ns glo bally  for the treatment of RA and is 
currently being studied in large ongoing global Phase 3 studies of RA, systemic lupus 
erythematosus, atopi c derm atit
is,and al opecia areata .
In summary, the potential benefit of the 4 -mg dose in reducing the hyperinflammatory state 
caused by  COVID -19 infect ion, and the short duration of treatment with this dose with a 
well-established safet y profile ,provi des the rati onalefor the assessment of the benefit/risk 
profile of the baricitinib 4-mg dose in the setting of a rando mized, controlled clinical trial in a 
hospi tal setting.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
32Dose Adjustment for Renal Impairment
As detailed in the IB, baricit inib exposure increases with de creased renal funct ion (Study I4V-
MC-JADL [JADL]). Based on PK simulat ions, dose adjustment is not required for patients with 
estimated glo merular filtrat ion rate (eGFR) ≥60 mL/min/1.73 m2. Patients with eGFR
≥30mL/min/1.73 m 2to <60mL/min/1.73 m2at scr eening who are randomized to the 4 -mg 
QD dose will receive a 2 -mg QD dose, to avoid exposures that exceed those of the 4- mg QD 
dose in patients with eGFR ≥60 mL/min/1.73 m2.Patients will remain on t he 2-mg dose
during treatment .
4.4. End-of-Study Definition
A participant i s considered to have co mpleted the study  if heor she has co mpleted the last 
scheduled procedure shown in the SoA (Section
 1.3).
The “end of the study ”is defined as the date of the last visit or last scheduled procedure shown 
in the SoA for the l ast parti cipant in the study globally .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
335. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, als o known as 
protocol  waivers or exempt ions, is not permitted.
All screening evaluat ions must be conducted and reviewed to confirm that potential part icipants 
meet all eligibilit y criteria.
The invest igator will maintain a screening log to record details o f all part icipants screened and to 
confirm eligibilit y or record reasons for screening failure, as applicable .
Due to the crit icality of part icipant health and the setting of this research study , verbal  interview 
of the potenti al participant, or his or her legal representati ve or family  member ,may be the 
source for pre -exist ing condit ions and prespecified medical history ,unless otherwise specified 
within the eligibilit y criteria.
For screen failures and rescreening activit ies wi thin the screening period, s ee Section 5.4.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if they  meet all of the following cri teria 
during the screening period, unless otherwise specified below :
Informed consent
[1]  Patient (or legally authorized representative) who give sinformed consent as described in 
Appendix 10.1,which includes co mpliance wit h the requirements and restrict ions listed in 
the informed consent form (ICF) and in this protocol .
Participant characteristics
[
2] Aremale or female pat ients from 18 years of age (inclusive ), at the time o f enrollment .
Note:   Contraceptive use by women shoul d be consistent with local regulat ions regarding the 
methods of contraception for those participat ing in clinical studies . There are no 
contraceptive requi rements for m en. See Appendix 10.4 for contraception requi rements .
COVID -19pulmonary infection -related inclusion criteria
[3]  Hospitalized with coronavi rus (SARS -CoV -2) infect ion,confirmed by po lymerase chain 
reacti on (PCR) test or other commercial or public healt h assay in any  specimen, as 
docum ented by  either of the f ollowing:
●  PCR positive in sample co llected <72 hours prior to randomi zation; OR
●  PCR positive in sample co llected ≥72 hours prior to randomization (but no m ore than 14 
days pri or to randomizat ion), docum ented inabilit y to obtain a repeat sample ( for 
example, due to l ack of  testing supplies, limited testing capacit y, resul ts taking >24 
hours, etc.) AND progressive disease suggestive of ongoing SARS -CoV -2 infect ion
[4]  Requi re supplemental  oxygenat the time of study  entry  and at randomizat ion.
[5]  Have indicators of risk of progression: at least 1inflammator y markers >ULN (CRP, 
D-dimer, LDH, ferrit in) with at least 1instance o f elevation >ULN wi thin 2 days before
study  entry .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
345.2. Exclusion Criteria
Parti cipants will be excluded fro m study  enrollment if they meet any  of the f ollowing criteria 
within the screening period , unless otherwise specified :
Prior or concomitant therapy
[6]Are receiving cytotoxi c orbiologic treatm ents (such as TNF inhibitors , anti-interleukin -1
[IL-1], anti-IL-6 [tocilizumab or sarilumab], T -cell or B -cell targeted therapies (rituximab) , 
interferon,or Janus kinase (JAK ) inhibi torsfor any  indicati onat study  entry .
Note: A washout period 4 weeks (or 5 half -lives, whichever i s longer) is required prior to 
screening ,with the fo llowing except ions:
●  B-cell targeted therapies: a washout period of 24weeks or 5 half -lives (whichever is 
longer)
●  TNF inhibitors: a washout period of 2 week sor 5 half -lives (whichever i s longer), and
●  JAK inhibitor: a washout period of 1 week or 5 half -lives (whichever is longer ).
SeeSecti on 6.5.1 for require ments .
[7]Have ever r eceived convalescent plasma or intravenous immunoglobulin [IVIg]) for 
COVID -
19.
[
8] Have received high dose corticosteroi ds at doses > 20mg per day (or prednisone equivalent)
administered for 
>14 consecut ive days in the mo nth prior to study entry .
Note: Use of dexamethasone and/or other systemic corticosteroids that do not exceed the
above specified dose and duration in the month prior to study  entry  isacceptable.
[9] Strong inhibitors of OAT3 (such as probenecid) that cannot be discontinued at study  entry .
[
27] Have r eceived neutralizing ant ibodies ,such as b amlanivimab ,casirivimab and imdevimab
for COVID -
19.
Current or historical infections
Note: Documentation from verbal interview or available medical records is acceptable .
[
10] Have diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for less 
than 4 weeks with appropriate ant i
-tubercul osis therapy  per l ocal guidelines (by history  
only, no screening tests requi red).
[11] Suspected serious, active bacterial, fungal, viral, or other infect ion (besides COVID -19)
that in the opinio n of the invest igator could const itute a ri sk when taking investigat ional 
product . Note : Immunocompromised patients, patients with a chronic medical condition, or 
those taking a medication that cannot be discontinued at enrollment, who, in the j udgment of the 
investigator, are at increased risk for serious infections or other safety concerns given the study 
products should be excluded.
Vaccines
[12] Have received any live vaccine within 4 weeks before screening, or intend to receive a live 
vaccine during the study . 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
35Note: Use of nonlive (inact ivated) vaccinat ions is allowed for all part icipants .
Other medical conditions or history
[13]Requi re invasive mechanical vent ilation ,including ECMO at study  entry .
[14] Current diagnosis of act ive malignancy that, in the opinio n of the investigator, could 
constitute a risk when taking invest igational product .
[
15] Have a history  of VTE ( deep vein thrombosis [ DVT ]and/orpulmo nary embolism [PE]) 
within 12 weeks pri or to randomizat ionor have a history  of recurrent (>1) VTE (DVT/PE) .
[16] Anticipated di scharge from  the hospi tal,or transfer to another hospital (or another unit),
which is not a study  site wi thin 72 hours after study entry .
Diagnost ic assessments
[
17]  Have neutropeni a (absol ute neutrophil count < 1000 cells/L) (< 1.00 x 10 3/L or 
<
1.00 GI/L)
[
18] Have lymphopenia (abso lute lymphocy te count <200 cells/ L) (<0. 20 x 10 3/L or 
<0.20GI/L)
[
19] Have alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5 times ULN
[
20] eGFR (Modificat ion of Diet in Renal Disease [MDRD] ) <30 m L/min/1.73 m 2.
Note: For each aforement ioned diagnosti c assessment (criteria 17,
18, 19, 20 ), 1 repeat testing is 
allowed during the screening period, and values result ing from repeat testing may  be accepted 
for a parti cipant’s enrollment eligibilit y if the other eligibilit y criteria are m et.In addit ion, these
tests performed in the 24hours prior to study entry will be accepted for determinat ion of
eligibilit y.
Prior or c oncurrent clinical study experience
[21] Have a known hypersensit ivity to bari citinib or any  of its excipients.
[
22]  Are currently enrolled in any  other clinical study  involving an invest igation product or any  
other ty pe of medical research judged not to be scient ifically or medically co mpat ible with 
this study .
Note: Theparticipant should not be enro lled(start ed)in another clinical trial for the 
treatm ent of COVID- 19 or SARS -CoV -2 through Day 2 8.
Other exclusions
[
23]  Are pregnant, or intend to become pregnant or breastfeed during the study .
[
24]  Are, in the opinio n of the investigator or sponsor, unsuitable for inclusio n in the study .
[25] Are using or will use extracorporeal blood purificat ion(EBP) devi ce to rem ove pro -
inflammatory  cytokines from  the bl ood such as a cytokine absor ption or filtering device , 
for example, CytoSorb®.
[26]  Are, i n the opinio n of the investigator, unlikely to survive for at least48 hours after 
screening.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
365.3. Lifestyle Considerations
Not applicable .
5.4. Screen Failures
Screen failure sare defined as part icipants who consent to participate in the clinical study but are 
not subsequently rando mly assigned to study intervent ion. A minimal set of screen failure 
inform ation is required to ensure transparent reporting of screen failure participant s to m eet the 
Conso lidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  author ities. Minimal information includes demography , 
screen failure details, eligibilit y criteria, and any  serious adverse event .
5.4.1. Allowed Retesting of Screening Investigations
Repeat ing the screening labs associated with criteria [ 17], [ 18], [19], and [ 20] during the 
screening period does not constitute rescreening.
5.4.2. Rescreening of Individual sWho Failed Screening
Individuals who do not meet the COVID -
19 pulmo nary infect ion-related criteria and other
diagnosti c assessments for parti cipat ion in this study (screen failure s) may be rescreened.
Rescreening 1time for any  eligibilit y parameter that was not init ially metis allo wed if pat ient is 
expected to m eet study  requi rements per invest igator assessment. It is not necessary to repeat all 
screening requirements. Patient will not be required to reconsent due to rescreening.
Rescreened participants should be assigned a new participant number.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
376. Study Intervention
Study  intervent ion is defined as an y invest igational intervent ion, marketed product, placebo ,or 
medical device intended to be administered to a study  parti cipant according to the study  protocol .
6.1. Study Interventions Administered
Study  intervent ions
This study  involves baricit iniband placebo, as shown below.
Treatment Name baricitinib placebo
Dosage Formulation tablet tablet
Dosage Levels 4 mg as two 2 -mg tablets * 2 placebo tablets
Routes of Administration Oral** Oral**
Dosing Instructions daily daily
*Patients with eGFR >30 mL/min/1.73 m 2to<60 mL/min/1.73 m 2at screening who 
are randomized to the baricitinib 4 -mg dose will receive a 2 -mg QD dose , to avoid 
exposures that exceed those of the 4- mg QD dose in patients with eGFR ≥60 
mL/min/1.73 m2.Patients on the baricitinib 
2-mgQDdose will r eceive a single 2 -mg 
tablet and will remain on this dose during the study if eGFR >30 mL/min/1.73 m 2 to 
<60 mL/min/1.73 m 2at screening .Patients will remain on 2-mg dose during 
treatment .
Patients wi th eGFR <60 m L/min/1.73 m2at screening who are randomized to placebo 
will receive one placebo tablet.
**Baricitinib will be administered as a 4 -mgdose orally  (po )(two 2- mg tablets) or 
crushed for NG tube, given daily ,for the duration of the hospitalizat ion up to a 14 -day 
total course.   A placebo will  be given as 2tablets po or crushed for NG tube, daily ,for 
the duration of the hospitalizat ion up to a 14 -day total  course .
Invest igational product will be administered to the patient at the study  site.No invest igational 
product will be provi ded to pati entsonce discharg ed from the hospi tal.
Packaging and labeling
Study  intervent ions (baricitinib and placebo) will be supplied by  the sponsor or i ts desi gnee in 
accordance with current Good Manufacturing Practice (cGMP). Clinical trial materials will be 
labeled according to the coun try’s regulatory  requirem ents. All IPs will be stored, inventoried, 
reconciled, and destroy ed according to applicable regulat ions.
6.2. Preparation/H andling/Storage/Accountability
The Pharmacy Manual provides instructions for the preparation, handling , and storage of 
baricit inibdrug product and placebo, and describes site responsibilit y and accountabilit y forthe 
administered products.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
38Invest igators should consult the informat ion provided in the Pharmacy  Manual  or the l abel for 
specific administration informat ion, including warnings, precautions, contraindicat ions, adverse 
reacti ons, and dose m odificat ions.
Handling and storage
Followthestorage and handling instructions on the IP packaging.
Site responsibilit ies and accountabilit y
The fo llowing are responsibilit ies of the invest igator or his or her designee:
●  The invest igator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study  intervent ion received and that any discrepancies are 
reported and resolved before use of the study  intervent ion.
●  Only participants enrolled in the study may receive study intervent ion,and only  
authori zed si te staff may supply  or administer study  intervent ion. All study  intervent ion 
must be stored in a secure, environmentally controlled, and mo nitored (m anual  or 
autom ated) area in accordance wit h the l abeled storage conditions with access limited to 
the invest igator a nd authorized site staff.
●  The invest igator, inst itution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance 
(that is, receipt, reconciliat ion, and final disposi tion records).
Further gui dance and information for the final disposit ion of unused study  interventi ons are 
provi ded in the Pharmacy Manual .
The invest igator or designee is also responsible for
  ex plaining the correct use of the study  intervent ions
  verifying that instructions are fo llowed properly
  ma intaining accurate records of IP dispensing and collect ion, and
  returning all unused medication to Lilly or its designee at the end of the study .
Note:   In some cases, sites may des troy the m aterial if, during the invest igative site 
select ion, the evaluator has verified and documented that the site has appropriate 
facilit ies and written procedures to dispose of clinical materials .
6.3. Measures to Minimize Bias: Randomization and Blinding
Blinding will be maintained in the Phase 3 study .
Method of treatment assignment
Patients who m eet all cri teria for enrollment will be randomized in a 1:1 ratio (baricit inib 4 -mg: 
placebo) at Day 1 .
Randomization will be stratified by these factors:
●  disease severit y:
○  hospi talized not requiring supplemental oxy gen, requi ring ongoing medical care
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
39○  hospi talized requi ring supplemental  oxygenby prongs or m ask
○  hospi talized requi ring non- invasive ventilation or high -flow oxygen
●  age (<65 years; ≥65 y ears)
●  region (United States, Europe, rest of world) , and 
●  dexamethasone and/or other systemic corticosteroid use dat baseline for primary study  
condi tion (Yes/No) .
Assignment to treatment groups will be determined by a co mputer -generated random sequence 
using an interactive web -response system (IWRS).
Emergency  unblinding
Emergency unblinding for adverse events may be perform ed through the IWRS .This opti on m ay 
be used ONLY if the participant’s well -being requires knowledge of the participant’s t reatm ent 
assignment. All actions result ing in an unblinding event are recorded and reported by  the IWRS .
If a participant’s study  treatment assi gnment is unblinded to the invest igator , to site personnel 
performing assessments, or to the participant , the participant must be discont inued fro m the 
study , unless the invest igator obtains specific approval fro m the sponsor’s medical mo nitor for 
the participant to continue in the study  (Secti on 7.1.1 ).
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a parti cipants’ intervent ion assignment is warranted. Participant safety must always be the first 
consideration in making such a determinat ion. Where feasible and when t iming o f the em ergent 
situation permit s, the invest igator should attempt to contact the Lilly medical mo nitor before 
unblinding a participant’s treatment assignment.
In cases where there are ethical reasons to have the participant remain in the study , the 
investigator must obtain specific approval fro m the sponsor for the participant to conti nue in the 
study .
6.4. Study Intervention Compliance
Parti cipants will receive stud y intervent ion directly fro m the invest igator and/or appropriate
designee at the study  site. The date and time of each dose administered will be recorded in the 
source documents and recorded in the case report form ( eCRF).Deviat ions from  the prescribed 
dosage regimen should be recorded in the eCRF.
6.5. Concomitant Therapy
Any medicat ion or vaccine (including over -the-counter or prescript ion medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or receives 
during the study  must be recorded along wit h
●
reason for use
● dat es of administration including start and end dates , and
●  dosage informat ion, incl uding dose for concomitant therap iesof special interest .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
40Parti cipants will be instructed to consult the invest igator or other appropriate study site personnel 
before taking any  new m edicat ions or suppl ements during the study .
Thesponsor’s medical monitor shoul d be contacted if there are any  questi ons.
6.5.1. Prior Med ications
Participants must have been discontinued fro m following medicat ionsbefore enrolling in the 
study , as stated i n Section 5.2:
●  Biologic the rapy (such as anti-IL-1, anti-IL-6 [tocilizumab or sarilumab] , T-cell targeted 
therapi es, interferon )must be discontinued 4weeks or 5 half -lives, whichever is lo nger,
prior to screening
●  B-cell targeted therapies (rituximab) : a washout peri od of  24 weeks or 5 half -lives 
(whichever is longer) 
●  TNF inhibitors: a washout period of 2 weeks or 5 half -lives (whichever is lo nger) , and
●JAK inhibitor: a washout period of 1 week or 5 half -lives (whichever is longer) .
In addit ion,strong inhibitors of OAT3 (such as probenecid) must be d iscontinued at study  entry .
6.5.2. Required and Permitted Concomitant Therapy
Prophylaxis for VTE is required for all pat ients unless there is a major contraindication such as 
active bleeding events or history  of heparin -induced thrombosis.
The fo llowing will be permitted as conco mitant therapy  during the study :
●  Concomitant antibiot ic, ant iviral, antifungal, and/or antimalarial ( background therapy in 
keeping wit h local clinical  pract ice for management of COVID -
19).Hydroxychloroquine 
and chloroquine are only permitted as concomitant medicat ion if these are recommended 
or requi red by l ocal COVID -19 treatm ent gui delines.
●  Corticosteroid use should be limited unless indicated per standard of care for a concurrent 
condi tion such as, but not limit ed to, asthma, chronic obstructive pulmo nary disease , 
adrenal insufficiency .
6.5.3. Prohibited Concomitant Therapy
The fo llowing will be prohibited as concomitant therapy  during the study :
●  Any biologic therapy  (such a
s TNF inhibitor s, anti-IL-1, anti-IL-6 [tocilizumab or 
sarilumab], T -cell or B -cell targeted therapies (rituximab) , interferon, JAK inhibitors 
(other than baricit inibas study  treatm ent), or immunogl obulin (IgG) for any  indicat ion.
●  Live vaccines, including herpes zoster vaccinat ion. Nonlive seasonal vaccinat ions and/or 
emergency vaccinat ion, such as rabies or tetanus vaccinations, are allowed.
●  Strong inhibitors of OAT3 (such as probenecid) that cannot be discont inued at study entry .
●  Extracorporeal blood purification device to remove pro -inflammatory cytokines fro m the 
blood such as a c ytokine absor ption or filtering device, f or exam ple, CytoSorb®.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
416.6. Dose Modification
Patients wi theGFR ≥30mL/min/1.73 m 2to<60mL/min/1.73 m2at scree ning who are 
rando mized to the baricit inib 4 -mg dose will receive a 2-mg QD dose , to avoid exposures that
exceed those of the 4
-mg QD dose in patients with eGFR ≥60 mL/min/1.73 m 2. Patientswill 
remain on this dose during the study if eGFR ≥30mL/min/1.73 m2to <60 mL/min/1.73 m 2at 
screening .
If after rando mizat ion eGFR decreases to less than 60 mL/min/1.73 m2butequal  to or more than 
30mL/min/1.73 m2, pati ents will  receive a 2 -mg QDdose (one tablet) until eG FR returns to 
eGFR ≥60 mL/min/1.73 m2.
Baricitinib is not recommended for use in patients with est imated GFR of <30 mL/min/1.73 m2.
6.7. Intervention after the End of the Study
Baricitinibwill not be provided to parti cipants following co mpletion o f the study .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
427. Discontinuation of Study Intervention a nd Participant 
Discontinuation/Withdrawal
In rare instances, it may be necessary  for a parti cipant to perm anent ly discont inue study  drug.
These sections describe reasons for a participant’s
  permanent or temporary discont inuat ion of study drug, or
  discontinuat ion (wi thdrawal) from  the study .
Discontinuati on of  specific sites or of the trial as a whol earehandled as part of regulatory , 
ethical, and trial oversight considerat ions in Appendix 10.1, Section
 10.1.9 .
Note: In this study , discharge fro m the hospi tal prior to Day  14 is not considered early  
discontinuat ion from the study  drug or from  the study .
7.1. Discontinuation of Study Intervention
Study drug m ay be perm anently discont inued or temporarily wit hheld during the study .
7.1.1. Criteria for Permanent Discontinuation of Study Drug
Data collect ion and safet yfollow-up when study  drug i s permanent ly discont inued
If a patient permanent ly discont inues stu dy drug early  (that i s, pri or to hospi tal discharge or 
Day 14, whichever com es first), the patient should remain in the study  and have the scheduled 
study  assessments specified in the SoA (Section 1.3). Every  effort shoul d be made to encourage 
participants to rem ain in the study  for the durati on of  their planned outcom e assessments. 
Parti cipants shoul d be educated on the continued scient ific importanc e of their data, even if they 
discontinue study  drug.
Unless the participant withdraws consent or meets other cri teria listed in Section 7.2, those who 
discontinue study  drug early  will remain in the study . The reason for participant discont inuation 
of study  drug shoul d be docum ented in the CRF .
If a patient who is not receiving st udy drug is unwilling or unable to conti nue the scheduled 
study  assessments , the si te personnel shoul d attempt to collect as m uch fo llow-up inform ation as 
possible , including, at minimum, informat ion specified for an early  terminat ion visit (ETV) and
infor mation for the follow -up visi ts, including the Study  Day  60 visi t.
Criteria for perm anent discont inuat ion of study  drug
Possible reasons leading to permanent discontinuatio n of study  drug incl ude, but are not limit ed 
to,the following:
Participant decision
●  The participant requests to discont inue the study drug .
Prohibited concomitant medication use
●  The participant requires treatment with a prohibited medicat ion (Section 6.5.3 ).
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
43Pregnancy
●  The participant beco mes pregnant during the study .
Safety considerations
●  The participant shoul d be discontinued if the parti cipant develops any o f the following 
condi tions during the study :
  new malignancy 
  human immunodeficiency virus (HIV)/acqui red immune deficiency  syndrom e (AIDS) 
infect ion
  active TB infection or evi dence of l atent TB (posit ive Quant iFERON -TB Gol d assay  or 
T-SPOT.TB or greater than 1 “ indeterminate ”result for QuantiFERON -TB Gol d assay  
or a “borderline ”resul t T-SPOT.TB assay )
  active hepati tis B (HBV DNA) or hepatit is C (HCV RNA )
VTE (DVT/PE)
●  The invest igator, after consultation with the sponsor’s designated medical mo nitor, 
determines that a systemic hypersensit ivity react ion has occurred and is related to study  
drug administration.
●  The participant experience sany 1 of the fo llowing events on 2 consecutive samples taken 
at least 48 hours , but no more than 1 week, apart .
  
Total white blood cells (WBC )<1000 cells/ L
  Abso lute neutrophil count (ANC) <500 cells/ L
  Abso lute lymphocy te count ( ALC ) <200 cells/ L
●  The participant has an adverse event or serious adverse event or a clinically  significant 
change in a labor atory value that, in the opinion o f the invest igator or sponsor, would 
precl ude the parti cipant from  continuing to receive study  drug .
Hepatic event or liver test abnormality
●  Discont inuat ion of study  drug because o f abnormal liver tests should be considered by the 
investigator when a participant meets one of the following condit ions after consultation 
with the m edical m onitor (see Secti on 8.2.6 )
  ALT or AST >8 times ULN or
  ALT or AST >3times ULN and (total bilirubin >2times ULN or PT-INR >1.5)
Other reasons
●  Unblinding : If an invest igator, site personnel performing assessments, or participant is 
unblinded, the participant must be discontinued from the study drug and cont inue to 
post-treatm ent follow-up. In cases where there are ethical reasons to have the participant 
continue on study  drug, the investigator must obtain specific approval from the sponsor or 
designee for the participant to con tinue.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
447.1.2. Criteria for Temporary Interruption (Withholding) of Study Drug
Study  drug shoul d be interrupted for :
  Abso lute neutrophil count (ANC) < 500cells/L
  Abso lute lymphocy te count (A LC) <200cells/L
  
ALT or AST > 5times ULN 
  estimated GFR of <30 mL/min/1.73 m2
Study  drug may be restarted when these criteria are no longer applicable, at the discret ion of the 
investigator. Retest timing and frequency is at the investigator’s discret ion.
Baricitinib is not recommended for use in patients with est imated GFR of <30 mL/min/1.73 m2.
7.2. Participant Discontinuation/ Withdrawal from the Study
Parti cipant di scontinuati on (wi thdrawal from  the study ) is expected to be unco mmo n.
A participant may withdraw from  the study in the following circumstances :
●  at any  time at his or her own request, or at the request of his or her designee (for example, 
parents or legal guardian)
●  at the discretion o f the invest igator for safet y, behavioral, co mpliance, or administrative 
reasons
●  if the participant enrolls in any other clinical study  involving an invest igational medicinal 
product or enrollment in any other ty pe of m edical  research j udged not to be scient ifically 
or medically com patible with this study
●  if the participant, for any reason, needs to be transferred to another hospital or another 
hospi tal unit
●  if the partici pant, f or any  reason, requi res treatment wi th another therapeutic agent that has 
been demo nstrated to be effective for treatment of the study  indicati on. In this case, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent.
Data collection and fo llow-up for participants who discontinue the study
At the time of discont inuing from the study , an ETV and final fo llow-up visit sshoul d be 
conducted, if possible, as shown in the SoA. See the SoA for data to be collected at the time of 
study  discont inuat ion and fo llow-up and for any  further eval uations that need to be completed .
The parti cipant will be permanently discont inued both from the study  intervent ion and from the 
study .
Withdrawal o f consent for disclosure
If the participant withdraws consent for disclos ure of  future inform ation, the s ponsor m ay retain 
and cont inue to use any data collected before such a withdrawal o f consen t.If a participant
withdraws fro m the study , heor she may request destruction of any  samples taken and not tested ,
and the invest igator must document this in the site study records .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
457.2.1. Discontinuation of Inadvertently Enrolled Participants
If the sponsor or invest igator ident ifiesa parti cipant who did not meet enrollment criteria and 
was inadvertently enrolled, then the participant shoul d be di scontinued from study  treatm ent 
unless there are extenuat ing circumstances that make it medically necessary for the participant to 
continue on study  treatm ent. If the investigator and the sponsor’s clinical research physician 
agree that it is medically appropriate to con tinue, the invest igator must obtain documented 
approval  from the sponsor to allow the inadvertently  enrolled participant to con tinue in the study  
with or wi thout treatm ent wi th invest igational medicinal product. Safetyfollow-up is as outlined 
in the SoA (Secti on 1.3), Secti on 8.2(“Safet y Assessments ”), and Secti on 8.3(“Adverse Events 
and Serious Adverse Events”) .
7.3. Lost to Follow -up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site.Site personnel are expected to 
make diligent attempts to contact participants who fail to return for a scheduled visit or were 
otherwi se unable to be fo llowed up by the site.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
468. Study Assessments and Procedures
Study procedures and their timing are summarized in the SoA (Secti on 1.3). Protocol waiver s or 
exempt ions are not allowed. Adherence to the study design requirements, including those 
specified in the SoA, is essent ial and requi red f or study conduct.
8.1. Efficacy Assessments
8.1.1. COVID -19 Clinical Status Assessment
The COVID -19 Clinical Status Assessment will be used to collect components needed to derive 
scores for the ordinal scales used in this study . This assessment will also collect the use of 
proning and reason for discont inuat ion of invasive mechanical vent ilation. 
The assessment will be co mpleted on each day  of the study  by enteri ng the assessment for the 
previous day  (that is, midni ght to midnight; 00:00 –23:59 [24 hour clock]). 
On Day  1, the pati ent’s status at randomization will be reported. 
On Day  2 the status will  be reported for the period fro m randomization to midnight on Day 1.
The patient’s clinical status will be captured daily through Day  29. 
The hospitalizat ion porti on of  the patient’s clinical status will be co mpleted daily, regardless of 
patient’s discharge status or patient contact.
The patient’s clinical status reflecting data for Day 28 (midnight to midnight) will be recorded in 
the Day  29 eCRF .
A clinical status assessment will be conducted via telephone visit for Day  60.
Primary Endpoint Assessments
The primary  endpoint will assess the proporti on of pati ents who die or requi re non- invasive 
ventilation/high-flow oxy gen or invasive m echanical  ventilation (including extracorporeal  
membrane oxy genati on[ECMO] ) by Day  28. Non -invasive vent ilation/high -flow oxy gen 
includes administr ation of  ventilatory  support wi thout using an invasive artificial airway 
(endotracheal tube or tracheostomy  tube) . High-flow oxy genconsists of breathing support 
administered through a face mask, nasal mask, or a helmet (includ ingBiPAP, CPAP) . 
Patients on non -invasive vent ilation/high -flow oxygen at baseline will be counted toward the 
primary  endpo int if they progress to invasive mechanical vent ilation.
8.1.2. Ordinal Scale
Using data fro m the COVID -19 Clinical Status Assessment , resul ts will be calculated for ordinal 
scales currently being used in other studies , and in thi s study ,to measure clinical outcomes in 
patients treated for COVID -19, in particular the NIAID -OS.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
47The NIAID -OSis as fo llows:
Patient State Descriptor
Not hospitalized, no limitations on activities
Not hospitalized, limitation on activities and/or requiring home oxygen
Hospitalized, not requiring supplemental oxygen –no lo nger requires ongoing medical care :
     (This would include those kept in hospital for quarantine/infection
     control, awaiting bed in rehabilitation facility or homecare, etc ).
Hospitalized, not requiring supplemental oxygen –requiring ongoing medical care (COVID -19 related
     or otherwise)
Hospitalized, requiring supplemental oxygen
Hospitalized, on non-invasive ventilation or high -flow oxygen devices
Hospitalized, on invasive mechanical ventilation or ECMO
Death
Source: Adaptive COVID -19 Treatment Trial (ACTT) [[STUDY_ID_REMOVED] ].
In thi s study , because scores for theordinal scales will be derived fro mdata al ready  entered into 
the eCRF, no addit ional data entry  related to the ordinal scales will be required.
8.1.3. Other Efficacy Assessments
Several secondary efficacy endpo intsof this study  are based on clinical assessments and 
procedures conducted in hospit alized patients with COVID -19infect ion.The fo llowing table 
shows these endpo ints,their definit ionsfor this study ,and measurement method.
Endpoint Defined as Measured by
Ventilator -free days Patient breathing without mechanical 
ventilatio n assistance, if the period of 
unassisted breathing lasts at least 24 
consecutive hours and the patient does not 
die—
Recover y Participant satisfies one of the following 
three categories from the NIAID -OS:
●Hospitalized, not requiring supplemental 
oxygen –no longer requires ongoing 
medical care; 
●Not hospitalized, limitation on activities 
and/o r requiring home oxygen; 
●Not hospitalized, no limitations on 
activities (applies to live discharge from 
hospita l to home as well)score on NIAID -OS
Duration of 
hospitalizationPeriod of time thepatient is hospitalized date of admission to date of 
discharge
Oxygen saturation Measure ofthe oxy gen level of the blood. pulse oximetry
All-ca use mortality 28-day all-cause mortality score on NIAID -OS
Duration of stay in the 
intensive care unit (ICU)Date of admission to ICU to date of 
discharge from ICU —
Clinical deterioration One-category increase on the ordinal scale
(worsening in patient clinical status)score on NIAID -OS
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
48Endpoint Defined as Measured by
Clinical improvement One-category decrease on the ordinal scale
(improvement of patient clinical status)score on NIAID -OS
Time to resolution of 
feverTime to patients being free of fever for the 
first time for patients who had fever at 
baseline.
If temperature is assessed multiple times in 
a day , the maximum temperature will be 
used.
Fever resolution is defined by: 
≤36.6°C (axilla)
≤37.2°C (o ral), or
≤37.8°C (rectal or tympanic)This includes oral, rectal, 
tympanic (ear),axilla, forehead, 
temporal artery temperature 
measurements .
Definitive extubation When patient is removed from mechanical 
ventilatio nscore on NIAID -OS
Non-invasive ventilation / 
high-flow oxygenAdministration of ventilatory support 
without using aninvasive artificial airway 
(endotracheal tube or tracheostomy tube). 
Patients requiring high -flow 
oxygen breathing support administered 
through a face mask, nasal mask, or a 
helmet (includes BiPAP, CPAP)score on NIAID -OS
Supplemental oxygen use Patien ts requiring oxygen by mask or nasal 
prongs (cannula)score on NIAID -OS
Respiratory  rate Measure of resting respiratory rate per 
minute—
Mechanical ventilation 
andintubationPatient requires mechanical ventilation and 
is intubated during the studyscore on NIAID -OS
Abbreviations: BiPAP = bilevel positive airway pressure; CPAP = continuous positive airway pressure.
8.1.3.1. Alert Voice Pain Unresponsive ( AVPU )and National Early Warning Score 
(NEWS)
Alert Voice Pain Unresponsive (AVPU)
Level o f consciousness is an important parameter in assessing the severit y of acute illness. The 
AVPU scale is used to measure and record a patient’s level o f consciousness. The AVPU scale 
used in this study  is the one recommended for use in the calculat ion of NEWS (Roy al College of 
Physicians 2012).
The invest igator and/or appropriate designee assesses the patient’s current condit ion in the 
following sequence, recording only one of these four possible outcomes:
Alert: The patient is fully awake , with spontaneous opening of the eyes, responsiveness 
to voi ce,and motor funct ion.The patient may, or may not be, confused or 
disorientated .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
49Voice:The pat ient makes so me kind of response when spoken to. The patient’s response 
can be a response of eyes, v oice, or m otor f unction, for example, opening eyes 
when spoken to, or making a grunt or moan or moving a limb when spoken to.
Pain: The patient responds to a pain st imulus . The response m ay be wi thdrawal  from pain 
or invo luntary flexio n or extensio n of lim bs. 
Unresponsive: Commo nly called “unconscious .”This outcom e is recorded if the patient 
gives no ey e, vo ice, or motor response to voice or pain .
National Early  Warning Score (NEWS)
In thi s study , because the scores for the NEWS parameters will be derived from data already 
entered into the eCRF, no additional NEWS -specific data entry  will be requi red.
The National Early Warning Score (NEWS) is used to detect and report changes in illness 
severit yin patients with acute illness . The score is determined from six physio logical parameters 
readily  measured over time in hospitalized patients :
●  respirat ion rate
●  oxy gen saturati on
●  tem perature
●  systolic blood pressure
●  heart ( pulse )rate, and
●  level of consciousness , as m easured by AVPU .
A score is assigned to each parameter, with the magnitude of the score representing the extremit y 
of variat ion from the nor m. A weight ing score is added for pati ents needing supplemental  
oxygen (oxy gen delivery  by mask or nasal  cannula) . Theaggregate score is reflect ive of the 
patient’sstatus (Royal Co llege of Physicians 2012).
8.1.3.2. Laboratory Assessments
Laboratory  assessments will be collected at the times shown in the SoA (Section 1.3).
8.2. Safety Assessments
Order of safet y assessments
Ifmultiple safety assessments are scheduled to occur during the sam e visi t, the preferred order of 
completion is
1)  vi tal signs fi rst
2)  other safet y assessments, including physical examinat ions and nonleading (spontaneous)
adverse event collection, and finally
3) sample co llection for clinical laborator y, pharmacodynamic (PD), andbiomarker testing.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
50Data collect ion and reporti ng
The adverse event data collect ion and reporti ng requi rements are described in Sect ion 8.3and 
Appendix 10.3.
Any clinically  significant findings that result in a diagnosis and that occur after the participant 
receives the first dose of study  drug shoul d be reported to Lilly  or its designee as an adverse
event via eCRF.
Safety monitoring
The principle invest igator will monitor safet y and laboratory  data throughout the study and 
shoul d discuss immediate s afety concerns with the sponsor immediately  upon occurrence or 
awareness to determine whether the parti cipant shoul d continue or discontinue the study  
intervent ion.
The sponsor will monitor the safet y data, including adverse events and serious adverse events 
(SAE s), discontinuations, medical history , concomi tant m edicati ons, vital signs, and clinical 
labora tory resul tsby means of periodic blinded reviews and other appropriate methods. These 
methods include reviews by  afunctionally independent safet y physician and/or clinical research 
scientist who regularly reviews SAE reports in real time and across studi es,andwho revi ews 
applicable clinical safet y and epi demi ological publicat ions from the literature . If this safet y 
monitoring uncovers an issue that needs to be addressed by  unblinding at the individual or group 
level, addit ional analyses of the safet y data can be performed (Secti on 9.5and Section 9.6).
8.2.1. Vital Signs
Vitalssigns ( body  temperature, bl ood pressure, heart [pulse ]rate, respi ration rate , oxy gen 
saturation ) will be assessed and docum ented daily , and as clinical  indicated, and entered into the 
eCRF asspecified in the SoA (Section 1.3) and as clinically indicated .
These include the minimum/ maximum vital signs daily  (including tem perature, respi ratory  rate, 
oxygen saturati on).
The m ost recent m easurements pri or to study drug administration will be used to calculate the 
NEWS. Vital signs s hould be perform ed at approximately the same time each day .
Addit ional vital signs may be m easured during thestudy  visitsif warranted, as determined by the 
investigator and/or appropriate designee .
8.2.2. Physical Examinations
A complete physical examinat ionwill be performed at the screening visit iffeasible . This 
examinat ion excludes pelvic, rectal, and breast examinat ionsunless clinically indicated. The 
screening visit should include an asses sment of TB ri sk factors.
A symptom -directed physical  examinat ion will be performed on other day s, as specified in the 
SoA (Section 1.3) and as clinically indicated.
Heightwill be measured or collected as reported ,and weight will also be measured . Both will be 
recorded as specified in the SoA.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
518.2.3. Electrocardiograms
For each participant, a 12- lead standard ECG will be obtained locally and read by a qualified 
physician (the invest igator or qualified designee) at the site on Day 1,as specified in the SoA
(Secti on
 1.3). ECGs obtained up to 24 hours prior to study  entry are acceptable.
8.2.4. Chest Imaging Studies
A chest x -ray or computerized tomography (CT)scan, assessed by a radi ologist pulm onologist, 
or appropri ate physician will be obtained and the resul t shoul d be recorded in the eCRF, as 
specified in the SoA (Secti on 1.3).
A report on imaging (that is, documentation of hospital -based test result) available prior to study  
entry  is acceptable for the Day  1 imaging (up to 24 hours prior to study entry is acceptable) .
Results for i magin g at other tim epoints, if carri ed out, willbe provi dedvia the eCRF .
During screening, all part icipants are to be assessed for risk factors, symptoms, and signs of TB, 
including chest imaging as assessed by a radio logist or pulmo nologist.
8.2.5. Laboratory Tests
Appendix 10.2 liststheclinical laboratory tests to be performed , and the SoA (Section 1.3) 
specifies the study  days at which samples are collected for clinical laboratory  tests .
Laboratory  tests perform ed in the 24hours prior to study  entry will be accepted for 
determinat ion of eligibilit y(except where designated different ly in the So A).
Addit ional tests m ay be perform ed at any  time during the study  as deem ednecessary  by the 
investigator and/or appropriate designee , or as required by local regulat ions.
All protocol -requi red laboratory  assessments, as defined in Appendix 10.2, must be conducted in 
accordance with the laboratory  manual and the SoA.
If laboratory  values fro m non-protocol  specified l aboratory  assessments perform ed at the 
institution’s l ocal laboratory  requi re a change in parti cipant m anagement or are considered 
clinically significant by  the investi gator and/or appropriate designee (forexample, SAE or 
adverse event or dose modificat ion), then the results must be recorded in the eCRF.
Reviewing and recording test results
The invest igator and/or appropriate designee must review the laboratory  report and record any  
clinically relevant chan ges occurring during the study  in the adverse event section of the eCRF.
Docum entati on of  review by the invest igator and/or designee may be co mpleted according to 
institution processes or by  making an entry  in the patient’sprogress notes (medical  record) 
stating that the lab results have been reviewed.
The l aboratory  reports m ust be filed wit h the source documents unless a Source Document 
Agreement or comparable document cites an electronic locat ion that accommodates the expected 
retenti on durati on.
Clinic ally significant abnormal laboratory  findings are those which are not associated with the 
underlying disease, unless judged by the investigator to be more severe than expected for the 
participant ’s condi tion.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
52Repeat testing after clinically significant abn ormal findings
All laboratory  tests wi th values considered clinically  significantly abnorm al during parti cipat ion 
in the study  or wi thin28days after the last dose of study  intervent ion shoul d be repeated until 
the values return to normal or baseline or are no longer considered clinically significant by  the 
investigator or the medical monitorduring study participat ion.If such values do not return to 
norm al/baseline wi thin a period of ti me judged reasonable by the invest igator, the etio logy 
shoul d be i dentified and the sponsor notified.
Blinding of laboratory  test resul ts
Laboratory  resul ts that coul d unblind the study  will not be reported to invest igative sites or other 
blinded personnel (Appendix 10.2).
Sample retenti on
Unless otherwise specified in the subsections of Secti on 8 or in Appendix 10.1, Secti on10.1.12
(“Long -Term  Sample Retent ion”), all samples collected for specified laboratory  tests will  be 
destroy ed wi thin 60 days of receipt of confirmed test results or according to local laboratory  
procedures .Certain samples may be retained for a lo nger period, if necessary , to com ply with 
applicable laws, regulat ions, or l aboratory  certificati on standards .
8.2.5.1. Pregnancy Testing
Pregnancy testing is to be performed on women of childbearing potential (WOCBP) . Parti cipants
who are pregnant will be perm anently discont inued fro m study drug (Section 7.1.1 ).A 
pregnancy test will be performed at screening only .
8.2.6. Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥3times ULN, ALP ≥2 times ULN, or el evated 
TBL ≥2times ULN, liver testing shoul d be repeated within 2 to 3 days including ALT, AST, 
ALP, TBL, direct bilirubin, gamma -glutamyl  transferase, and creat ine kinase to confirm the 
abnorm ality and to determine if it is increasing or decreasing.  If the abnormalit y persists or 
worsens, clinical and laboratory  monitoring shoul d be ini tiated by  the invest igator and in 
consultation with the study  medical mo nitor. M onitori ng of ALT, AST, TBL, and ALP should 
continue until levels normalize or return to appropriate levelsfor the pati ent, per invest igator 
assessment .
Discontinuati on cri teria of investigational products, either temporar y interruption or permanent 
discontinuat ion, due to abnormal ALT, AST, TBL, or ALP, are detailed in Section 7.1.
8.3. Adverse Events and Serious Adverse Events
Adverse events will be reported by  the parti cipant or, when appropriate, by  a caregiver, 
surrogate, or the participant ’s legally authori zed representative.
The invest igator and any qualified designees are responsible for detecting, documenting, and
recording events that meet the definit ion of an adverse event or SAE and remain responsible for 
following up adverse events that are serious, considered related to the study  interventi on or study  
procedures, or that caused the participant to discontinue t he study  interventi onor the study .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
53Pregnancy after maternal or paternal exposure to investigational product does not meet the 
definit ion of an adverse event . However, to fulfill regulatory  requi rements, any  pregnancy shoul d 
be reported using the SAE process described in Appendix 10.3, Section 10.3.4 , to collect data on 
the outcom e for both m other and fetus. See also Section 8.3.5 .
8.3.1. Time Period and Frequency for Collecting A dverse Event and Serious Adverse 
Event Information
All adverse events will be co llected fro m the time ofthe participant ’s signing of the ICF until the 
participant’s last post- treatm ent follow-up visi t.Adverse events will be recorded on the Adverse 
Event eCRF.
Likewise, a ll SAEs will be collected from the signing of the ICF until the last post -treatm ent 
follow-up visit .
Although all adverse events after si gning the ICF are recorded by  the si te in the CRF/electronic 
data entry tool, SAE reporting to the sponsor begins after the participant has signed the ICF and 
has received study  drug . However, if an SAE occurs after signing the ICF but prior to receiving 
study  drug , the SAE needs to be reported ONLY if the SAE is considered reasonably possibly 
related to study  procedures.
SAEs will be recorded and reported to the sponsor or the sponsor’s designee immediately ,and 
under no circumstance should this exceed 24 hours, as indicated in Appendix 10.3. The 
investigator will submit any updated SAE data to the sponsor within 24 hours of i t being 
available. Seriousadverse events, including death, caused by  COVID -19 disease progression
shoul d not be reported onthe SAE formunless the invest igator deems them to be possibly 
related to study  treatm ent(Appendix 10.3 ).
Invest igators are not obligated to actively seek adverse events or SAE safter the concl usion of 
study  participati on, that i s, once the participants have discont inued and/or com pleted the study  
(the Parti cipant Study  Disposi tion eCRF has been completed) . However, if the invest igator learns 
of any SAE, including a death, at any  time after a participant has ended his or her study
participat ion, and the invest igator consid ers the event to be reasonably related to the study  
intervent ion or study  parti cipat ion, the invest igator must prompt ly notify the sponsor.
8.3.2. Method of Detecting A dverse Event s and S erious Adverse Events
The m ethod of recording, evaluat ing, and assessing cau sality of adverse event sand SAE sand the 
procedures for complet ing and transmitting SAE reports are provided in Appendix 10.3.
Care will be taken not to introduce bias when detecting adverse event sand/or SAEs. Open -ended 
and non -leading verbal quest ioning of the participant is the preferred method to inquire about 
adverse event occurrences .
8.3.3. Follow -up of A dverse Event s and S erious Adverse Events
After the init ial adverse event or SAE report, the investigator is required to proactively fo llow 
each parti cipant at subsequent visits/contacts. All SAEs will be fo llowed until reso lution, 
stabilization, the event is otherwise explained (including death) , or the parti cipant is l ost to 
follow-up ( Sectio n7.3). Further informat ion on fo llow-up procedures i s provi dedin 
Appendix 10.3, Secti on10.3.3 .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
548.3.4. Regulatory Reporting Requirements for S erious Adverse Events
Prom pt notificat ion by the invest igator to the sponsor of a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et.
The sp onsor has a l egal responsibilit y to notify both the l ocal regulatory  authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion under clinical investigation. The 
sponsor will co mply wi th country -specific regulatory  requi rements relati ng to safet y reporti ng to 
the regulatory  authori ty, Inst itutional Review Boards (IRB s)/Independent Ethics Co mmittees 
(IEC s), and invest igators.
An invest igator who receives an invest igator safety report describing a SAE or other specific 
safet y informat ion (for example , summary or list ing of SAEs) fro m the sponsor will review and 
then file it along with the IB and will notify the IRB/IEC, if appropriate according to local 
requi rements.
8.3.5. Pregnancy
Details about pregnancy  will be collected for pregnancies occu rring in female study  participants 
andinfemale partners of male study participants .
If a pregnancy  is reported as having occurred during the study or within 1 week after the l ast 
dose of study  intervent ion, the invest igator should inform the sponsor within 24 hours of learning 
of the pregnancy  and shoul d follow the procedures outlined in Appendix 10.4, Secti on 10.4.3 .
Abnorm al pregnancy outcom es (for example , spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, ectopi c pregnancy) are considered SAEs.
8.3.6. Special Assessments of Infections and Venous Thromboembolic Events
Venous Thromboembo licEvent s
Com pletion of the VTE Endpoint eCRF page is required for each VTE reported as an adverse 
event or SAE. All suspected VTE events will be independently adjudicated by a blinded Clinical 
Event Committee.
Infections
Com pletion of the Infect ion Follow-up eCRF page is required for each infect ion reported as an 
adverse event or SAE with site of infect ion and source of culture provided, if a vailable . The 
sponsor will ident ify infect ions considered to be opportunist ic based on Wint hrop et al . (2015).
8.3.7. Complai nt Handling
A product complaint is any written, electronic, or oral communicat ion that alleges deficiencies 
related to the identit y, qualit y, durabilit y, reliabilit y, safety, effect iveness or performance o f a 
trial intervent ion. The sponsor collects produc t complaints on investigational products and drug 
delivery  systems used in clinical studies in order to ensure the safety  of study  participants, 
monitor qualit y, and to facilitate process and product improvements .
Parti cipants will be instructed to contact the invest igator as soon as possible if they have a 
complaint or probl em wi th the invest igational product so that the situation can be assessed.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
55Any adverse events /SAEs that are associated with a product complaint will also fo llow the 
processes outlined in Sect ion 8.3.3 and Appendix 10.3.
Time period for detecting product complaints
Product complaints that result in an adverse event will be detected, documented, and reported to 
the sponsor during all periods of the study  in which the drug/device is used. If the invest igator 
learns o f any product complaint at any  time after a parti cipant has ended his or her study  
participat ion, and s uch inci dent i s considered reasonably related to a drug/device provided for the 
study , the invest igator will prompt ly notify  the sponsor .
Prom pt reporting of product complaints to sponsor
Product complaints will be reported to the sponsor within 24 hours after the invest igator beco mes 
aware of the complaint. The Product Complaint Form will be sent to the sponsor by  a method 
designated by  the sponsor.
Follow-up of  product complaint s
Follow-up applies to all participants, including those who discont inue stud y intervent ion. The 
investigator is responsible for ensuring that fo llow-up includes any supplemental invest igations 
as indicated to elucidate the nature and/or causalit y of the product complaint. New or updated 
inform ation will be recorded on the originally co mpleted form with all changes signed and dated 
by the investigator and submitted to the sponsor.
8.4. Treatment of Overdose
For thi s study , an overdose of baricit inib is considered any dose higher than the dose assigned 
through randomizat ion. In case of an overdose, the patient should be monitored for signs and 
symptoms of adverse reactions. Patients who develop adverse react ions should receive 
appropriate treatment .In the event of an overdose, the invest igator should contact the sponsor’s 
medical mo nitor immediately .
Decisio ns regarding dose interruptions or modifications will be made by the invest igator in 
consultation wit h the sponsor’s medical mo nitor based on clinical evaluat ion of the participant.
8.5. Pharmacokinetics
For patients who progress to intubat ionin ICU , venous blood sam pleswill be drawn on the days 
and times indicated in the SoA (Section 1.3).
These blood samples will be used to determine the plasma concentrations of baricit inib. 
Concentrations of baricit inib in human plasma will be determined by  a validated liquid 
chromatography tandem mass spectrom etry (LC/MS/MS) method. 
Theactual  date and exact timing (24 -hour clock) of sample collection and the date and time o f 
study  drug dosing should be recorded. 
Thesampling schedule should be fo llowed as cl osely as possible; however, fa ilure to take PK 
samples at thespecified times will not be considered a protocol vio lation.
Only samples from pat ients receiving baricit inib will be assayed; samples from pat ients receiving 
placebo will  not be assayed. PK samples will be kept in storage a t a laboratory  facility 
designated by  the sponsor. PK results will not be provided to invest igative sites .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
56Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor. 
Samples will  be analyzed at a l aboratory  approved by  the sponsor .
Sample retenti on
Thepurpose of retention, the maximum duration of retent ion, and facilit y for long-term storage
of samples is described in Appendix 10.1, Section 10.1.12 .
8.6. Pharmacodynamics
This sect ion is not applicable.
8.7. Genetics
This sect ion is not applicable.
8.8. Biomarkers
Nasopharyngeal swab (to assess viral load and other characterizat ions), s erum , and w hole b lood 
for RNA , epigeneti c analysis and cellular phenotyping for exploratory  nonpharmacogenetic 
biomark er research will be collected on days specified in the SoA (Section 1.3),where local 
regul ations allow.
The baseline exploratory  sample is essential to determining progressive viral load changes in the 
exploratory  analysis during participat ion in the study . If,due to central lab kit supply, the first 
(Study  Day 1) sam ples are not collected , it is not necessary  to collect future exploratory  
biomarker central samples (NP swabs or blood samples) ; this will not be considered a protocol  
deviat ion. If the central lab kits are available, NP swabs and whole blood samples should be 
collected on study  visit days per the SOA unless a phone visit is conducted and therefore the 
samples cannot be obtained ; this woul d not be consi dered a protocol deviat ion.
Sample use
Exploratory  biomarker research is performed to address quest ions of relevance to drug 
disposi tion, target engagem ent, PD, mechanism o f action, variabilit y of parti cipant response 
(including safet y), and/or clinical outcome. Sample collect ion is incorporate d into clinical studies 
to enable examinat ion of these quest ions through measurement of viral load, biomolecules ,
RNA, proteins, lipids, and other cellular elements .
Samples may be used for research on the drug target, disease process, variable response 
tobaricit inib,pathways associated with the studi ed disease , mechanism  of action of  baricitinib, 
and/or research method sor in validat ing diagnostic tools or assays related to the disease orto 
baricit inib.
Confident iality
All samples will be coded with the participant number. These samples and any data generated 
can be linked back to the participant only by the investigative site personnel.
Sample retenti on
Thepurpose of retention, the maximum duration of retent ion, and facilit y for long-term storage
of samples is described in Appendix 10.1, Section 10.1.12 .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
578.9. Immunogenicity Assessments
Immunogenicit y is not assessed in this study .
8.10. Medical Resource Utilization and Health Economic s
This sect ion is not applicable.
C O N FI D E N TI A L Pr ot oc ol  I 4 V -M C -K H A A( e) 
5 8 9. St atistic al C o nsi der ati o ns 
9. 1. St atistic al H y p ot heses 
Pri mar y O bject i ve 
T he pri mar y  o bject i ve of t his st u d y  i s t o test t he h y p ot hesis t hat baricit i ni b 4 -m g Q D +
bac k gr o u n d t hera p y is s u peri or t o place b o +bac k gr o u n d t hera p y i n t he treat me nt of h os pi talize d 
pati e nts wi t h C O VI D - 1 9 i nfecti o n ,as assesse d b y  t h e pr o p orti o n of  patie nts w h o die or re q uir e
n o n -i n vasi ve ve nt ilat i o n/ hi g h -fl o w o x y ge n or i n vasi ve m ec ha nical  v e nt ilat i o n (i ncl u di n g E C M O) 
b y D a y  2 8 .
T he pri mar y  o bject i ve will be assesse d i n t h ef o ll o wi n g p o p ulati o ns 
P o p ul at i o n 1- all ra n d o mize d patie nts , a n d 
P o p ul at i o n 2 –pati e nts w h o, at baseli ne, re q ui reo x y ge n s u p ple me ntati o n a n d are n ot 
recei v i n g de xa met has o ne or s y ste mic c ortic oster oi ds f o r t he pri mar y st u d y  c o n di ti o n 
Testi n g Sc he me f o rt h e Pri mar y Anal yses 
T he 1 -si de d p -val ues a n d ass oci ate d test stati st ics are defi ne d as 
  is t he 1- si de d p- val ue f o r P o p ulat i o n 1 ;   is t he ass ociate d test statistic 
  is t he 1- si de d p- val ue f o r P o p ul at i o n 2 ;   is t he ass ociate d test statistic 
T he h y p ot heses are 
H0 1 is t he n ull h y p ot hesis c orres p o n di n g t o P o p ulati o n 1 
H0 2 is t he n ull h y p ot hesis c orres p o n di n g t o P o p ulati o n 2 
H0 1 will be rejecte d if :
  <α1O R (   < 0. 0 2 5 A N D   <α2)
H0 2 will be rejecte d if :
  < α 2O R (   < 0. 0 2 5 A N D   <α1)
α1a n d α2are cri ti cal t hres h ol ds preser v i n g t h e o verall 1 -si d e d t y pe 1 st u d y  err or at 0. 0 2 5.   
If eit her of t he t w o tests is si g nifica nt, t he n the st u d y will be declare d s uccessf ul .  
T he testi n g sc he me will pr o vi de a str o n g c o ntr ol  of T y pe -I err or f or t he st u d y  at a 1 -si de d 0. 0 2 5 
le vel a n d is base d o n t he cl ose d testi n g pri nci ple ( Marc us et al. 1 9 7 6).  T he testi n g sc he me is 
para m etri c, w here t he k n o w n c orrelat i o n is acc o u nte d f or bet wee n t he 2 test statist ic s   a n d   .  
T he α1 f o r P o p ul at i o n 1 will be pre -s pecif ie d i n t he Stati st ical A nal ysis Pla n ( S A P ). T he α2f o r 
P o p ul at i o n 2will be calc ulate d t o c o ntr ol t he st u d y T y pe I err or rate at 0. 0 2 5 , acc o u n ti n g f or t he 
pres pe cifie d val ue of α1a n d t he c orrel at i o n bet wee n t he t w o test stati st ics . If  t he P o p ul at i o n 1 test 
is rejecte d a n d t he P o p ul ati o n 2 test is n ot, or vice versa, t he re mai ni n g α will be rec ycle d a n d 
use d f or s u bse q ue nt testi n g of t he p o p ulat i o n t hat was n ot si g nifica nt ( Mille n a n d D mitrie n k o 
2 0 1 1). T he fi nal α le vels will be base d o n t he perce nta ge of  P o p ul at i o n 2wi t hi n P o p ul at i o n 1
o bser ve d i n t he fi nal a nal ysis data set .  A d dit i o nal details will be descri be d i n t he S A P .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
599.2. Sample Size Determination
In the protocol amendment C, it was assumed that the proporti on of  patients progressing to death 
or no n-invasive vent ilation/high-flow oxy gen or invasive m echanical  ventilation (including 
ECMO) by  Day 28 was28% and 18.5% for placebo and baricit inib, respect ively. Accordingly, 
the sam ple size wasincreased to 600 to yield approximately 80% power to detect an absolute 
difference of 9.5% between the baricit inib treatment group and the placebo treatment group 
using a two -sided al phaof 0.05 with the provi sion that sam ple size may  be updated in a blinded 
manner during the study  from 600 up to approximately 1000 , ifwarranted based on newly  
available external study  data. Thi s woul d include the various differing factors amongst the 
studi es, including, for example, the ACTT -2 results.
In protocol amendment D, the sample size is updated based on newly  available data from the 
ACTT -2 study  (ACTT-2 press release 2020). Based on the em erging data and evolving 
therapeuti c opti ons f or standard of care , the assumpti on for the proporti on of patients in the 
placebo group progressing to death or non-invasive vent ilation/high -flow oxy gen or invasive 
mechanical vent ilation (including ECMO) by Day 28 isrevised to approximately 25 %.The
sample size of 1000 pati ents will yield approximately 47% power to detect an abso lute difference 
of 5% and 83% power to detect an abso lute difference o f 7.5%between the baricit inib treatment 
group and the placebo treatment group using a two -sided alpha of 0.05.
In protocol amendment E, the sample size is updated to approximately 1400 pat ients based on
blinded review o f the proporti on of  patients requiring oxy gen supplementati on wi thout the use of 
dexamethasone or s ystemic corticosteroids a t baseline andthe potenti al that concomi tant use of 
systemic corticosteroids may reduce the magnitude of  thetreatm enteffect . 
The table below describes the p ower calculations for various scenari os wi th a total 
sample size of 
1400.  Thi s assumes , for illustrati on, that α1 for Population 1 is 75% of the total alpha and that
60% of the patients were taking dexamethasone or other corticosteroi d
sat baseline .
Treatment effect size in patients who are at OS 5 or 
OS 6 at baseline Combined Effect Size Power for at least one of 
the two primaries to 
succeed
Patients using 
dexamethasone or a 
systemic corticosteroidPatients not using 
dexamethasone or a 
systemic corticosteroid
0.075 0.075 0.075 81%
0.040 0.075 0.054 54%
Abbreviations: NIAID = National Institute of allergy and Infectious Diseases; OS 5 = #5 on the 8 -point NIAID 
ordinal scale -Hospitalized , requiring supplemental oxygen; OS 6 = #6 on the 8 -point NIAID ordinal scale –
Hospitalize d, on noninvasive ventilation or high - flow oxygen devices.
Note: Power estimates were obtained from a custom simulation program .
There is still significant uncertaint y with these assum ptions given the limited available data.
Therefore, t he sample size may be increased using an unblinded sample size re- estimat ion during 
aninterim analysis (Gao et al. 2008).
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
609.3. Populations for Analyses
The following popul ations are defined for this study :
Population Description
Entered All participants who sign the informed consent form
Intent -to-Treat (ITT) All participants randomly  assigned to study  interventio n. Participants will be 
analy zed according to the intervention to which they were assigned.
Per Protocol Set (PPS) ThePPS of the ITT population analysis set will include those participants who do 
not have any identif ied important protocol violations considered to impact efficacy 
analy ses. Qualifications for ,and identification of ,significant or important protocol 
violations will be determined w hile the study remains blinded, prior to database 
lock.
Safety All partic ipants randomly assigned to study intervention and who receive at least 1 
dose of study intervention and who did not discontinue from the study for the reason 
‘Lost to Follow -up’ at the first postbaseline visit. Participants will be analyzed 
according to t he intervention they actually received.
Follow -up All randomized participants who received at least 1 dose of investigational product 
and have entered the post -treatment follow -up period. Participants will be analyzed 
according to the intervention which they received in the treatment period.
A sensit ivity analysis excluding pat ients who die within 24 hours of rando mizat ion and have Do 
Not Resuscitate (DNR) or Do Not Intubate (DNI) in ITT/PP analyses populat ions will be 
conducted.
9.4. Statistical Analys es
The s tatistical analysis o f this study  will be the responsibilit y ofthe sponsor or its designee.
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a principal feature of the protocol. Any  other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the SAP and clinical study  report. Addi tional expl oratory  analyse s of the data will be 
conducted as deemed appropriate.
The SAP will be finalized prior to unblinding. It will include a more technical and detailed 
descript ion of the statist ical analyses described in this section. This section is a summary o f the 
planned statisti cal analyses of the m ost important endpo ints,including primary and key 
secondary  endpoints.
9.4.1. General Considerations
Efficacy analyses will be conducted on the Intent -to-Treat (ITT) Populat ion. Selected efficacy  
analysis may  also be conducted using the Per Protocol  Set. Safet y analyses will be conducted on 
the Safet y Populati on.
All tests of treatment effects will be conducted at a 2 -sided al pha level of 0.05, unless otherwise 
stated.
Treatment comparisons of di chotom ous efficacy  variables between baricitinib 4 -mg QD + 
background therapy  andplacebo + background therapy will be m ade using a l ogisti c regressio n 
analysis with baseline stratificat ion factors and treatment group in the model . The percentages, 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
61difference in percentages, and 95% confidence interval  (CI) of  the difference in percentages will 
be reported. When logist ic regressio n sample size requirements are not m et (<5 responders in 
any category  for any  factor), the p -value fro m Fisher ’sexact test is produced instead of the odds 
ratio and C I.
Treatment comparisons for ordi nal efficacy  variables between baricit inib 4 -mg QD + 
background therapy  and placebo + background therapy  will be m ade using proporti onal odds 
model with baseline stratificat ion factors and treatment group in the model .
Treatment comparisons of continuous efficacy and healt h outcome variables will be made using 
analysis of covariance (ANCOVA) with baseline rando mizat ion factors and treatm ent group in 
the model, if the m ethod is appropri ate. Type III tests for least square s (LS)means will be used 
for statistical co mpar isonsbetween treatment groups. The LS mean difference, standard error, 
p-value, and 95% CI may also be reported. The method used to handle missing data is described 
briefly in Sect ion
 9.4.1.3 and will be described in more detail in the SAP.
Treatment comparisons of ventilation-free days will be made using Wilcoxon rank sum test and 
will be described in more detail in the SAP .
When evaluat ing cont inuous measures over time, a restricted maximum likelihood -based mixed 
model for repeated m easures ( MMRM) may also be used. The model will include treatment, 
baseline rando mizat ion factors , visit, and treatment -by-visit-interacti on as fixed categorical 
effects ,and baseline score and baseline score -by-visit-interact ionscore (for endpo ints other than 
baseline disease severit y) as fixed cont inuous effects for endpoints other than baseline disease 
severit y. An unstr uctured (co)variance structure will be used to model the between -and 
within-patient errors. If this analysis fails to converge, other structures will be tested. The 
Kenward -Roger m ethod will be used to estimate the degrees of freedo m. Type III sum s of 
squares for the LS means will be used for the statistical co mpar ison; the 95% CI will also be 
reported. Contrasts will be set up within the model to test treatment groups at specific t ime points 
of interest. Further details on the use of MMRM will be describe d in the SAP.
Log-rank test will be used as the primary analysis method for evaluating treatment effect in 
time-to-event endpo ints.Kaplan -Meier curves and median survival w ill beestimated for each 
treatm ent group. Hazard ratio with 95% CIwill be cal culated using a Cox proporti onal hazards 
model with treatm entas covariate and adjusted for baseline values of stratificat ion factors. 
Diagnostic tests for checking the validit y of the proporti onal hazards assumpt ion maybe 
perform ed. If the as sumpti on of  proporti onal hazards i s not j ustified, a statistical model capable 
of handl ingnonproportional hazard will be explored to assess treatment effect , such as a max -
Combo test (Lee 1996) , restricted mean survival t ime model(Roy ston and Parm ar et a l 2013) , 
and win rat io analysis (Pocock et al . 2012) .An addit ional analysis may be perform ed to treat 
death as a competing event. The compet ing risk survival model, such as Fine -Gray  model (Fine 
and Gray  1999) and cause -specific hazard model ,will be considered. Further details onthese 
methods will be described in the SAP.
Subgroup analyses for the primary  and selected key  secondary outcom es will  evaluate the 
treatm ent effect across the fo llowing subgroups: baseline OS ( OS 4 vs. OS 5 and OS 6
combined) ,
baseline usage of remdesivir (Y/N), baseline usage of corticosteroi ds (Y/N), 
geographi c regi on, durati on of  symptom s prior to enrollment , age ,sex, dexamethasone and/or 
other sy stemic corti costeroi d used at baseline for primary  study  condi tion,and com orbidi ties (if 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
62applicable) . Interacti on tests will be conducted to determine whether the effect of treatment 
varies by  subgroup.
Fisher’s exact test will be used for TEAEs, discontinuat ions, and other categorical safet y data for
between -treatm ent g roup comparisons. Continuous vital signs, body  weight, and other
continuous safet y variables ,including laboratory  variables ,will be analyzed by  an analysis o f 
covari ance (ANCOVA )withtreatm ent and baseline value in the model. Shift tables for 
categori cal safet y analyses (for example, ‘high’ or ‘low’ laboratory  resul ts) will also be 
produced.
Adjustment for Multiple Comparisons
Multiplicity controlled analyses will be performed on the primary  and keysecondary  endpoints 
to con trol the overall fa mily-wise Ty pe I error rate at a 2 -sided α level o f 0.05. The graphical 
multiple testi ng procedure described in Bretz et al. (2011) will be used. The graphical approach 
is a closed testing procedure ;hence it strongly controls the family -wise error rate (F WER) across 
all endpo ints (Alosh et al. 2014). Details o f the specific graphical testing scheme (including 
testing order, interrelat ionships, Ty pe I error allo cation, and the associated propagation) will be 
prespecified in the SAP.
The primary  and key  seco ndary  endpoints to be tested are listed in Section 9.4.2 and 
Secti on9.4.3 , respectively.
9.4.1.1. Participant Disposition
A descript ion of participant disposi tion will be provided, including a summary of the number and 
percentage of participants entered into the study , enrolled in the study , and treated, as well as the 
number and percentage of participants complet ing the study ( participants who receive at least 
1dose of study  drug and have at l east 1 postbaseline assessment), or discont inuing (ov erall and 
by reason for discont inuat ion). All patients who discontinue from the study  or from the study  
treatm ent will be listed and alo ng with their reason for discont inuat ion.Patients who stop taking 
study  drug because they  are discharged from  hospital  are not consi dered as having discontinued 
study  treatm ent (s ee Section 4.1and Section 7).Reasons for discont inuat ion from the study  will 
be summarized by treatment group and compared between groups with Fisher’s exact test.
A summary  of important protocol deviat ions will be pro vided .
9.4.1.2. Participant Characteristics
Baseline demographic data and disease characteristics, historical diagnoses, pre -exist ing 
condi tions, and prior therapies will be summarized descript ively by treatm ent group. Descript ive 
statist ics including number of pat ients, mean, standard deviation, median, minimum, and 
maximum will be provided for continuous measures, and frequency counts and percentages will 
be tabulated for categorical measures. No formal statist ical com parisons will be made amo ng 
treatm ent groups u nless otherwise stated in the SAP .Other participant baseline characterist ics 
will be summarized by  group as deem ed appropri ate.
9.4.1.3. Missing Data Imputation
Multiple imputation will be performed as appropriate for the primary and key secondary 
analyses. Addit ional sensitivityanalyses for the primary  and key secondary  endpoints, such as 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
63tipping point analyses and reference -based mult iple im putati on method ,may be perform ed.Full 
details o f these analyses will be included in the SAP for this study .
9.4.2. Primary Endpoint
The primary  com parison of interest is the proportion of pat ients who die or requir e non-invasive 
ventilation/high-flow oxy gen or invasive m echanical  ventilation (including ECMO )by Day 28 .
Patients on non -invasive vent ilation/high -flow oxygen at baseline will be counted toward this 
endpo int if they  progressed to invasive mechanical ventilat ion.Treatm ent com parisons between 
baricit inib 4 -mg QD + background therapy and placebo + background therapy will be m ade 
using logistic regressio nwith baseline stratificat ion factors and treatment group in the model .  
The primary  object ivewill be assessed in two popul ations. The primary  endpoint will be met if 
either of the two tests described in Se ction 9.1is statistically significant .
If the sample size is increased as a result of the interim analysis, the Cui, Hung, and Wang 
(CHW) procedure (Cui et al. 1999) will be applied to the endpo ints to control the ty pe I error at a 
one si ded α=0.025 significance level. The CHW method ensures strong control of type Ierror 
when the sample size is increased in a data dependent manner.
If the sample size is increased as a result of the interim analysis, a n unadjusted point estimate for 
the primary  efficacy analysis will be calculated and reported. A median unbiased point estimate 
and a stage -wise adjusted confidence interval for the primary  efficacy analysis will be calculated 
and reported based on the app roach described by  Brannath and colleagues (Brannath et al. 2009) 
to assess sensit ivity of the point estimate.
9.4.3. Secondary Endpoints
Secondary  com parisons of interest (key secondaries) are:
●  proportion of pat ients with at least 1 -point improvement on the N IAID -OS or live 
discharge from  the hospi tal at Day  4, Day  7, Day 10, Day 1 4
●  number of vent ilator -free days (Day 1 to Day  28)
●  time to recovery  (NIAID -OS) ( Day 1 to Day 28 )
●  overall improvement on the NIAID -OS evaluated at Day  4, Day  7,Day 10,Day 14 
●  duration of hospitalizat ion (Day 1 to Day  28)
●  proportion of pat ients with a change in oxygen saturation from <94% to ≥94% from 
baseline to Day  4, Day  7, Day 10, Day  14, and 
●  all-cause m ortali ty (Day 1 to Day  28).
Analys es for these endpoints are described in Sect ion 9.4.1 .
9.4.4. Safety Analyse s
Safety analyses will include adverse events (AEs) , serious adverse events ( SAEs ),adverse events 
of special interest (AESIs ), vital signs, and laboratory  analy tes, using the Safet y Popul ation. 
Continuous safety  measures will be summarized as mean change by visit and analyzed using
ANCOVA with treatment and baseline value in the model . For binary safet y measures ,Fisher’s 
exact test will be used to perform co mpar isons between the baricit inib 4- mg QD+ background 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
64therapy group and the placebo + background therapy group. Further analyses may be performed ,
and details of the analyses willbe included in the SAP.
Exposure to study  intervent ion will be calculated for each participant and summarized by 
treatm ent group.
Adverse events will be coded according to the Medical Dict ionary for Regul atory  Activit ies 
(MedDRA) and summarized by system organ class, preferred term, and severi ty. A treatm ent-
emergent adverse event (TEAE) is defined as an event that either first occurred or worsened in 
severit y after the first dose of study  treatm ent and on or prior to the last visit date during the 
analysi s peri od. Safet y analyses will be conducted separately  for the double -blind treatment 
period and the post-treatm ent follow-up peri od.For events that are gender -specific, the 
deno minator and computation of the percentage will include only part icipants from the given 
gender.
Adverse events of special interest will be ident ified by a standardized MedDRA query (SMQ) or 
a Lilly-defined MedDRA preferred term list. The number and percentage of participant s who 
experienced TEAEs, TEAEs by  maximum severit y, deaths, SAEs, permanent discontinuations 
from the treatm ent due to an adverse event, incidence of abnorm al values, and AESIs will be 
summarized. TEAEs (all, by  maximum  severi ty), SAEs including deaths, an d adverse events that 
lead to treatment discont inuat ion will be summarized and analyzed by MedDRA system  organ 
classand preferred term.
All clinical laboratory  resul ts will  be descri ptively summarized by treatment group. Individual 
resul ts that are outsid e of norm al reference ranges will be flagged in data list ings. Shift tables 
will be presented for selected laboratory measures.
Post-Treatment Follow -up
Safety analyses for the post -treatm ent follow-up peri od will be conducted on the fo llow-up 
popul ation. Follow-up em ergent adverse events , SAEs including deaths, and adverse events that 
lead to study  discontinuat ion will be summarized . All adverse events , including pre- exist ing 
condi tions, will be listed by participant, visit, preferred term, treatment group , severit y, and 
relationship to the treatment.
9.4.5. Pharmacokinetic Analysis
If available, t he concentration -time data for bari citinib will be evaluated via graphical 
comparison to known PK profiles at 4- mg QD dosing that have been characterized for other 
popul ations such as healt hy subjects ,patients wi th RA, etc. The PK data may also be analyzed 
using a population modeling approach via a nonlinear mixed -effects m odeling (NONMEM) 
program , if deemed necessary . The SAP will describe the planned PKanalyses in gre ater detail.
9.5. Interim Analyses
The a nalysis for the primary  database l ock will  be conducted when all part icipants have either
completed the double- blind treatment period or have discont inued .
Interim analyses at other time po ints, including time points prior to the primary  database l ock,
willbe conducted using safet y and/or efficacy  data . The seinterim analyses will be used for 
safet y monitoring, potenti allystopping for excess mortalit yorfutilit y, sample size re -estimat ion,
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
65or to implement unexpected recommendat ions from the DMC andtosupport planning activit ies 
associ ated wi th the development program.
Unblinding details will be specified in the unblinding plan sect ion of the SAP ,theDMC charter 
and/or in a separate unblinding plan document.
Assessments of unblinded interim data will be conducted by an external  data m onitor commi ttee 
(DMC) . The DMC will be authorized to evaluate unblinded interim efficacy and safet y analyses , 
including evalua tion of excess m ortali ty. SeealsoSecti on9.6.
The SAP will describe the planned interim analyses in greater detail. To minimize bias, the SAP 
will be finalized and approved before any unblinding. Inform ation that m ay unblind the study  
during the analyses will not be reported to study  sites or the blinded study  team  until  the study  
has been unblinded.
Study  sites will receive informat ion about interim analysis results only if the invest igators need 
to know for the safet y of their parti cipants.
9.6. Data Monitoring Committee (DMC)
An independent, external data m onitoring commi ttee (DMC) will oversee this study . The DMC 
will consist of members external to Lilly .This DMC will fo llow the rules defined in th e DMC 
charter, focusing on potential and ident ified risks for this mo lecule and for this class of 
compounds. The DMC may reco mmend stopping the study for fut ilityand sample size re -
estimat ion.DMC membership will include, at a minimum, a specialist with experti se in statistics 
and other appropriate specialt ies. Details o f the DMC will be documented in a DMC charter. See 
also Appendix 10.1, Section 10.1.5 .
Access to the unblinded data will be limited to the DMC and the external Statist ical Analysis 
Center statisticians who are providing the analysis of the data. These statisticians will be 
independent fro m the study  team . The study  team  will not have ac cess to the unblinded data. 
Only the DMC isauthori zed to eval uate unblinded interim analyses. 
The study  sites will receive informat ion about i nterim results ONLY if they  needto know for the 
safet y of their pati ents. The DMC m ay request to review efficacy  data to evaluate the benefit/risk 
relationship in the context of safet y observations for ongoing patients in the study . In addi tion to 
the DMC m embers, a limit ed number of pre -ident ified individuals may gain access to the limited 
unblinded data, as specified in the unblinding plan, prior to the final database lock .Inform ation 
that may  unblind the study  during the analyses will not be reported to study  sites or blinded study  
team until the study  has been unblinded.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
6610. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the pro tocol  and wi th the f ollowing:
●  Consensus ethical principles derived fro m internat ional guidelines ,including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
(CIOMS) International Ethical Guidelines
●  Applicable Internati onal Council for Harm onisati on (ICH) Good Clinical Practice (GCP) 
Guidelines , and
●  Applicable laws and regulat ions.
The protocol, protocol amendments and addenda , ICF, I B, and other relevant documents ( for 
example , advertisements) mus t be submitted to an IRB/IEC by  the invest igator and reviewed and 
approved by  the IRB/IEC before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for chan ges necessary  to eliminate an immediate 
hazard to study  parti cipants.
The invest igator will be responsible for the fo llowing:
●  Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or m ore 
frequently in accordance with the requir ements, policies, and procedures established by  
the IRB/IEC
●  Notifying the IRB/IEC of SAEs or other significant safet y findings as required by 
IRB/IEC procedures , and
●  Provi ding oversight of the conduct of the study  at the site and adherence to require ments 
of 21 United States Code of Federal Regulat ions (CFR), ICH gui delines, the IRB/IEC, 
European regulat ion 536/2014 for clinical studies (if applicable), and all other applicable 
local regulati ons.
After reading the protocol, each principal invest igator will sign the separate protocol signature 
page and send a copy  of the si gned page to a Lilly  representative.
Invest igator sites are compensated for participat ion in the study  as detailed in the clinical trial 
agreem ent.
10.1.2. Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authori ties.Investigators are 
responsible for providing informat ion on financial interests during the course of the study  and for 
1year after complet ion of the study .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
6710.1.3. Informed Consent Process
The invest igator or his or her representative will explain the nature of the s tudy, incl uding the 
risks and benefits, to the parti cipant or his or her legally authorized representative and answer all
questions regarding the study .
Participants m ust be inform ed that thei r parti cipat ion is vo luntary.
Participants or their legally auth orized representative swill be required to sign a statement of 
inform ed consent that meets the requirements of 21 CFR 50, local regulat ions, ICH guidelines, 
Health Insurance Portabilit y and Accountabilit y Act (HIPAA) requi rements, where applicable, 
and the IRB/IEC or study  center. The sponsor or its representatives must approve the ICFs, 
including any  changes made by the ERBs, before the ICFs are used at the invest igative sites.
Due to strict respiratory  isolation policies, limited access to COVID -19 patien t rooms ,and 
SARS -CoV -2 transmissibilit y via droplet -contaminated paper, verbal consent and alternat ive 
methods of obtaining consent ( for example , by phone) will be allowed if approved by  the IRB. In 
addition, if a signed paper copy  of the ICF is all owed by hospi tal policy , how i t will  be obtained 
and stored will need to be determined. Any  variation fro m the standard the consent process due 
to iso lation and infection control should be sent to the IRB for approval prior to enrollment. The 
site shoul d docum ent the process in their regulatory files and demo nstrate that the process has 
IRB concurrence or approval.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained before 
the participant was entered in the study . The statement must include the date on which the 
written consent was ob tained. The authorized person obtaining the informed consent and, if 
applicable, the individual designated to witness a verbal consent, must also sign the ICF s.
Parti cipants m ust be re -consented to the most current versio n of the ICF during th eir 
participat ion in the study.
A copy  of the ICFs must be provided to the participant or the participant’s legally  authori zed 
representati veand must be kept on file .
10.1.4. Data Protection
Parti cipants will be assign ed a unique identifier by the sponsor. Any part icipant records ,datasets
or tissue samples that are transferred to the sponsor will contain the identifier only; participant 
names or any  information which would make the participant ident ifiable will not be transferred.
The parti cipant must be inform ed that hi sor her personal study -related data will be used by  the 
sponsor in accordance wit h local data protecti on law. The l evel of disclosure m ust also b e 
explained to the participant who will be required to give consent for his or her data to be used as 
described in the informed consent .
The parti cipant must be inform ed that hi sor her medical records may be examined by Clinical 
Qualit y Assurance auditors or other authorized personnel appo inted by  the sponsor, by  
appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
The sponsor has processes in place to ensure data protection, informat ion securit y,and data 
integrity. These processes include appropriate contingenc y plans for appropriate and timely 
response in the event of a data securit y breach.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
6810.1.5. Committee Structure
Data Monitoring Committee (DMC)
The DMC is described in Sect ion 9.6.Details about theDMC membershi p, purpose, 
responsibilit ies, and operation will be described in a DMC charter, which will be approved prior 
to the first unblinding .
Clinical Event Committee
A blinded Clinical Event Committee will adjudicate VTEs and deaths .
10.1.6. Dissemination of Clinical Study Data
Reports
The sponsor will disclose a summary o f study  information, including tabular study results, on 
publicly available websites where required by  local law or regul ation.
Data
The sponsor provi des access to all individual part icipant data collected during the trial, after 
anonymizat ion, wi th the excepti on of  pharmacokinetic (PK) or genet ic data. Data are available to 
request 6 months after the indicat ion studied has been approved in the United States and the 
European Unio n and after primary  publicat ion acceptance, whichever is later. No expiration date 
of data requests is current ly set once data are made available.  
Access i s provi ded af ter a proposal  has been approved by  an independent revie w committee 
ident ified for this purpose and after receipt of a signed data sharing agreement. Data and 
docum ents, including the study  protocol , statistical analysis plan, clinical study  report, bl ank or 
annotated case report forms, will be provided in a se cure data sharing environment for up to 
2years per proposal.  
For details on submitting a request, see the instructio ns provided at www. vivli.org.
10.1.7. Data Quality Assurance
Invest igator responsibilit ies
All participant data relat ing to the study  will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically ( for example , laboratory  data).
The invest igator is responsible for verifying that data entries are accurate and correct by 
physically or electronically sign ing the CRF.
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF. This docum entation might include laboratory  and diagnostic 
test reports, medical records, and clinical notes.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  
agency  inspect ions and provide direct a ccess to source data documents.
Data monitoring and management
Moni toring details describing strategy  (for example , risk-based init iatives in operati ons and 
qualit y,such as risk management and mit igation strategi es and analy tical risk-based monitorin g), 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
69methods, responsibilit ies and requirements, including handling o f nonco mpliance issues and 
monitoring techniques are provided in the Monit oring Pl an.
The sponsor or designee is responsible for the data management of this study ,includin g quali ty 
checking o f the data. The sponsor assumes accountabilit y for acti ons del egated to other 
individuals ( for example , contract research organizations ).
Study  monitors will perform  ongoing source data verification to confirm that data entered into 
the CRF/e CRF by authori zed si te personnel are accurate, complete, and verifiable from source 
docum ents; that the safet y and ri ghts of  parti cipants are being prot ected; and that the study is 
being conducted in accordance with the current ly approved protocol and any other study 
agreem ents, ICH GCP, and all applicable regu latory requirements.
In the event that on -site monitoring activit ies cannot occur, alternat ive measures (for example, 
use of technology  for off -site monitoring, providing or showing pseudonymized copies of source 
docum ents to the m onitor el ectroni cally , etc.) will  be used, as allowed by local regulat ions. The 
remote source data verification will be focused on crit ical efficacy data and important safety 
data.
Records retention and audits
Records and documents, including signed ICFs, pertaining to the conduct of this study  must b e 
retained by the invest igator for the time period outlined in the Clinical Trial Agreement (CTA)
unless local regulat ions or inst itutional policies requi re a l onger retenti on peri od. No records m ay 
be destroy ed during the retention period without the writ ten approval  of the sponsor. No records 
may be transferred to another location or party  without wri tten notificat ion to the sponsor .
In addit ion, the sponsor or its representatives will periodically  check a sample of the parti cipant 
data recorded against s ource documents at the study site. The study  may be audi ted by  the 
sponsor or its representatives, and/or regulatory  agencies at any  time. Invest igators will be given 
notice before an audit occurs.
Data Capture System
The invest igator is responsible for ensuring the accuracy , com pleteness, l egibili ty, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of CRF 
data. The invest igator maintains a separate source for the dat a entered by  the invest igator or 
designee into the sponsor -provided EDC system. The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the eCRF .
Addit ionally , clinical  outcom e assessment (COA) data will be collected by  the invest igativesite 
personnel , via a paper source document and will be transcribed by the invest igative site 
personnel into the EDC sy stem .
Data collected via the sponsor-pr ovided data capture sy stem swill be stored at third parties. The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem s.Prior to decommissio ning, the invest igator will receive an archiva l 
copy  of pertinent data for retention.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
70Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system and reports will be provided to the investigator for review 
and retention. Data wi ll subsequent ly be transferred fro m the central  vendor to the sponsor ’sdata 
warehouse.
Data from co mplaint forms submitted to the sponsor will be encoded and stored in the global 
product complaint management sy stem .
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the invest igator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed fro m source documents 
must be consistent with the source documents ,or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on the 
study . Also, current m edical records must be available.
The d efinit ion of what constitutes source data can be found in Section 10.1.7 .
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  isopen for recruit ment of participants .
The sponsor or designee reserves the right to close the study  site or to terminate the study  at any  
time for any  reason at the sole discret ion of the sponsor.
Site Cl osure
Study  sites will be cl osed upon study  com pletion.A study  site is considered cl osed when all 
requi red docum ents and study  supplies have been collected and a study -site closure visit has 
been performed.
The invest igator may init iate study -site closure at any  time, provi ded a reasonable cause exists 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include ,but are 
not limited to , these :
●  Failure of the investigator to comply with the protocol , the requi rements of the IRB/IEC or 
local heal th authori ties, the sponsor ’s procedures, or GCP guidelines
●  Inadequate recruitment of participants by the investigator, and
●  Discont inuat ion of further study  intervent ion development .
Premature Terminat ionor Suspension o f the Study 
Pending the evaluat ion by the Data Moni toring Committe eand discussio n with the sponsor , 
enrollment and/or further dosing may be stopped, or the dose and/or other study parameters may 
be modified (Section 9.5and Section 10.1.5 ).
If the study  is prematurely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research organizat ions 
used in the study  of the reason for terminat ion or suspensio n, as specified by the ap plicable 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
71regul atory  requi rements. The investigator shall prompt ly inform  the participant and assure 
appropriate participant therapy  and/or foll ow-up.
10.1.10. Publication Policy
In accordance with the sponsor’s publication po licy,the resul ts of this study  will be submitted 
for publicat ion by a peer -reviewed journal.
10.1.11. Investigator Information
Physicians with expert ise in the care of patients with COVID -19 infect ion may parti cipate as 
investigators .
This includes physicians with a special ty ininfect ious disease, acute or critical 
care, pulmo nary disease , immuno logy,or other appropriate specialt ies when just ified.
10.1.12. Long -Term Sample Retention
Sample retenti on enables use of new techno logies, response to regul atory  quest ions, and 
inves tigation of variable response sthat may not be observed unt il later in the development of  
baricit inibor after it becom es co mmercially available for the studied indicat ion.
The fo llowing tabl e lists the m aximum retenti on peri od for sam ple ty pes. 
The retenti on peri od begins after the last participant visit for the study .
The m aximum  retent ion times may  be shorter , if specified in local regul ations and/or if
ERBs/IRB s impose shorter time limits , or by  decisi on by the sponsor .
Any samples remaining after the specified retent ion peri odwill be destroy ed.
The sample retention facility will be selected by the sponsor or its desi gnee .
Sample Type Custodian Retention Period after Last Participant Visit
Pharmacokinetics (PK) Sponsor or designee 1year
Long -term storage samples Sponsor or designee up to 15 years
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
7210.2. Appendix 2: Clinical Laboratory Tests
10.2.1. Clinical Laboratory Tests
The clinical laboratory  tests listed in the tabl e bel owwill be performed by acentral  laboratory or 
by a local laboratory as specified in the table.
Addit ional tests may be performed at any  time during the study  as determined necessary  by the 
investigator or as required by local regulat ions.
Protocol -specific requirements for the inclusio n or exclusio n of participants are specified in 
Secti on 5 of the protocol.
Pregnancy testing is described in the SoA, in Section 8.2.5.1 , and in the table below.
Invest igators must document their review of the laboratory  safety report as described in Sect ion 
8.2.5 .
Laboratory  test resul ts that coul d unblind the study will not be reported to invest igative sites or 
other blinded personnel.
Notes
Hematology Performed locally
Hemoglobin
Hematocrit
Erythrocy te count ( red blood cells [RBC])
Mean cell volume
Mean cell hemoglobin
Mean cell hemoglobin concentration
Leukocytes ( white blood cells [WBC])
Absolute count of:
   Neutrophils, segmented (absolute )
    Neutrophils, juvenile (bands)
    Lymphocytes (absolute )
    Monocytes
    Eosinophils
    Basophils
Platelets
Cell morphology (RBC and WBC) Performed if applicable and/or needed
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
73Notes
Clinical Chemistry Performed locally
Sodium
Potassium
Chloride
Bicarbonate
Total bilirubin (TBL)
Direct bilirubin
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Gamma -glutamyl transferase (GGT)
Blood urea nitrogen (BUN)
Creatinine
Total protein
Albumin
Calcium
Phospho rus
Glucose
Creatine kinase (CK)
Lactate dehydrogenase (LDH)
Notes
Hormones (females) Performed locally
Serum p regnancy  To be performed only on women of childbearing potential
Notes
Biomarkers Performed locally
Erythrocy te sedimentation rate (ESR)
C-reactive protein (CRP) High-sensitivity (hs -CRP) is preferred if available
Ferritin
D-dime r
Procalcitonin
Cardiac troponin
Notes
Viral Testing Performed locally .See Section 1.3,Schedule of 
Activities, Comment scolumn ,for additional information.
SARS -CoV-2 viral infection confirmation Utilizing nasopharyngeal s wabs
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
74Notes
Pharmacokinetics (PK)Assay ed by Lilly -designated laboratory.
Results will not be provided to the investigative sites.
Baricitinib
Notes
Long -Term Stored Samples:
Exploratory Biomarker SamplesAssay ed by Lilly -designated laboratory.
Results will not be provided to the investigative sites.
Explo ratory  biomarker samples:See Section 8.8for instructions relating to central lab kit 
supply and tests.
     N asopharyngeal swab
     Serum
     Whole blood RNA
     Whole blood EDTA (epigenetics)
    Whole blood for cellular phenotyping (EDTA
      plus smart reagent )To be collected by sites with the logistic or technical 
ability
10.2.2. Clinical Laboratory Calculations
eGFR (Modificat ion of Diet in Renal Disease [MDRD] )
●  For creatinine resul ts reported in conventional units (m g/dL):
GFR (mL/min/1.73 m²) = 175 × (S cr)-1.154× (Age)-0.203× (0.742 if female) × (1.212 if 
African American) 
●  For creatinine resul ts reported in SI uni ts (pm ol/L):
GFR (mL/min/1.73 m²) = 175 × (S cr/88.4)-1.154× (Age)-0.203× (0.742 if female) × (1.212 if 
African American) 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
7510.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a patient or clinical study  parti cipant, 
temporally  associ ated wi th the use of study  intervent ion, whether or not considered related to 
the study  intervent ion.
NOTE:  An AE can ,therefore ,be any unfavorable and unintended sign (including an 
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associ ated wi th the use of study  intervent ion.
Events Meeting the AE D efinition
–  Any abnormal laboratory test results (hematology, clinical chemistry , or uri nalysis) or other 
safet y assessments ( for example , ECG, radi ological scans, vi tal signs m easurements), 
including those that worsen fro m baseline, considered clinically significant in the medical 
and scient ific judgment of the invest igator (that is, not rel ated to progressi on of  underlying 
disease).
–  Exacerbat ion of a chronic or intermittent pre -existing condit ion ,including eit her an increase 
in frequency and/or in int ensity of the condi tion.
–  New condit ion sdetected or di agnosed after study intervent ion administration even though 
theymay have been present before the start of the study .
–  Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
–  Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming intent ; 
report such overdoses regardless of sequelae.
–  “Lack of ef ficacy ”or “failure of expected pharmaco logical act ion ”per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments.
However, the signs, symptoms, and/or clinical sequelae result ing fro m lack of efficacy will 
bereported as an AE or SAE if they fulfil lthe definit ion of an AE or SAE.
Events NOT Meeting the AE D efinition
–  Any clinically significant abnormal laboratory findings or other abnormal safet y 
assessments which are associated with the underlying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condit ion.
–  The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than exp ected for the participant’s 
condi tionor resul ts in death .
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
76–  Medi cal or surgical  procedure ( for example , endoscopy , appendectomy): the condit ion that 
leads to the procedure is the AE.
–  Situations in which an untoward medical occurrence did not occur (so ci al and/or 
convenience admissio n to a hospital).
–  Ant icipated day -to-day fluctuations of pre -exist ing diseases or condit ions present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definit ion above, then it cannot be an SAE even if serious condit ions 
are met ( for example , hospi talizat ion for signs/symptom s of the disease under study ).
AnSAE is defined as any untoward medical occurrence that, at any dose:
a.  Results in death
b.  Is life-threatening
The term  ‘life-threatening’ in the definit ion of ‘serious ’refers to an event in which the 
participant was at ri sk of death at the time o f the event. The term does not refer to an event 
which hypothetically  might have caused death if the e vent were more severe.
c.  Prolongation of existing hospitalization or readmission after discharge but before 
discontinuation from study
–  In general, hospitalizat ion signifies that the participant has been admi tted to hospi tal for 
observat ion and/or tre atment that woul d not have been appropriate in the physician’s office 
or outpatient setting. Complicat ions that occur during hospitalizat ion are AEs. If a 
complicat ion prol ongs hospi talizati on or f ulfills any  other seri ous cri teria, the event i s 
serious. W hen in doubt as to whether 
‘hospi talizat ion’occurred or was necessary , the AE 
shoul d be considered serious.
–  Hospitalization for elect ive treatment of a pre -exist ing condit ion that di d not worsen from  
baseline is not considered an AE.
d.  Results in persistent disability/incapacity
–  The term ‘disabilit y ’means a substant ial disrupti on of a person’s abilit y to conduct normal 
life funct ions.
–  This definit ion is not intended to include experiences of relat ively minor medical 
significance ,such as unco mplicated headache, nausea, vo miting, diarrhea, influenza, and 
accidental  traum a (for example , sprained ankle) which may  interfere wi th or prevent 
everyday life functions but do not constitute a substantial disrupt ion.
e.  Is a congenital anomaly/birth defect
f.  Other situations:
–  Medi cal or sci entific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may  not be immediately 
life-threatening or resul t in d eath or hospi talizat ion but m ay jeopardi ze the parti cipant or m ay 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
77requi re medical or surgi cal intervent ion to prevent one of the other outcomes listed in the 
above definit ion. These events should usually  be consi dered seri ous.
–  Examples of such events in clude invasive or malignant cancers, intensive treatment in an 
emergency room  or at hom e for allergic bronchospasm, blood dy scrasias or convulsio ns that 
do not result in hospitalizat ion, or development of drug dependency or drug abuse.
10.3.3. Recording and Follo w-Up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
docum entati on (for example , hospi tal progress notes, l aboratory  reports, and di agnostics 
reports) related to the event.
The invest igator will then record all relevant AE/SAE informat ion in the CRF /eCRF .
It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records to the sponsor or designee in lieu of completion of the AE/SAE CRF page.
There may be instances when copies of medical records for certain cases are requested by  the 
sponsor or desi gnee .In thi s case, all participant ident ifiers, wi th the except ion of the 
participant number, will be redacted on the copies of the medical records befo re submissio n to 
the sponsor or designee .
The invest igator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical informat ion. Whenever possible, the diagnosis (not the individual 
signs/symptom s) will be document ed as the AE/SAE.
Assessment of Intensity
The invest igator will make an assessment of intensit y for each AE and SAE reported during 
the study  and assign it to oneof the fo llowing categori es:
Mild: An event that is easily tolerated by the participant, causing minimal disco mfort and 
not interfering wit h every day act ivities.
Moderate: An event that causes sufficient disco mfort and interferes with normal everyday 
activit ies.
Severe: An event that prevents normal everyday activit ies.
Note: An AE that is assessed as severe should not be confused wit h a SAE. Severe is a 
category  utilized for rati ng the intensit y of an event , and both AEs and SAEs can be assessed 
as severe. An event is defined as ‘seri ous’ when i t meets at l east 1 of the predefined outcomes 
as described in the definit ion of an SAE, NOT when it is rated as severe.
Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and each 
occurrence of each AE/SAE.
A “reasonable possibilit y”of a rel ationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relationship, rather than a relat ionship cannot be rul ed out.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
78The invest igator will use clinical judgment t o determine the relat ionship.
Alternat ive causes, such as underlying diseases, conco mitant therapy , and other ri sk factors, as 
well as the temporal relat ionship of the event to study  intervent ion administration will be 
considered and invest igated.
The inve stigator will also consult the IB and/or Product Information, for marketed products, in 
his/her assessment.
For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the invest igator has minimal 
inform ation to include in the init ial report to the sponso r or designee . However, i t is very  
important that the invest igator always make an assessment of causalit y for every  event before 
the init ial transmission o f the SAE data to the sponsor or designee .
The invest igator may change his/her opinio n of causalit y in light of fo llow-up inform ation and 
send a SAE fo llow-up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  reporting 
requi rements.
Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by the sponsor or 
designee to elucidate the nature and/or causalit y of the AE or SAE as fully as poss ible. This 
may include addit ional laboratory  tests or investigations, histopathological examinat ions, or 
consultation wit h other health care professio nals.
If a participant dies during participation in the study or during a recognized fo llow-up period,
the invest igator will provide the sponsor or desi gnee with a copy  of any post -mortem findings,
including histopathology .
New or updated informat ion will be recorded in the originally co mpleted CRF /eCRF .
The invest igator will submit any updated SAE data to the sponsor or designee within 24 hours 
of recei pt of  the information.
10.3.4. Reporting of SAEs
SAE Reporting via Paper CRF
Facsimile transmissio n of the SAE paper CRF is the preferred method to transmit this 
inform ation to the sponsor .
Initial notificati on via telephone does not replace the need for the invest igator to complete and 
sign the SAE CRF pages wit hin the designated reporting t ime frames.
Contacts for SAE reporting can be found in in site training docum ents.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
7910.4. Appendix 4: Contraceptive Guidance an d Collection of Pregnancy 
Information
10.4.1. Definitions
Woman of Childbearing Potential (WOCBP)
A wo man is considered fertile fo llowing menarche and unt il beco ming post -menopausal unless 
perm anent ly sterile (see below) .If fertility is unclear (for example, amenorrhea in ado lescents or 
athletes) and a m enstrual  cycle cannot be confirmed before first dose of study  interventi on, 
consider addit ional evaluat ion.
Woman NOT of Childbearing Potential ( not WOCBP)
Female pat ientsof non‒child -bearing potenti al are defined as
●  Women who are infertile due to surgical sterilization (hysterectomy , bilateral  
oophorectomy , or tubal  ligation)
●  Postmenopausal, defined as a wom an meet ing one of the fo llowing cri teria:
○  womanat least 50 y ears of age wi th an intact uterus, not on horm one therapy , who has 
either
–At least 6 months of spontaneous amenorrhea with fo llicle -stimulat ing hormone 
(FSH)of≥40mIU/mL , or
–  Wo men aged 55 y ears or ol der who are not on hormone therapy , and who have 
had at least 6 months of spontaneous amenorrhea .
○  Women aged 55 y ears or ol der who have a diagnosis of menopause .
10.4.2. Contraception
Females
Women of childbearing potential
Female pat ients of child -bearing potenti al who are abstinent (if this is complete abstinence, as 
their pref erred and usual lifestyle) or in a same- sex rel ationship (as part of their preferred and 
usual lifest yle) must agree to either remain abst inent or stay in a same -sex rel ationship wit hout 
sexual relat ionships with the oppos ite sex.
Total  abstinence is defined as refraining fro m intercourse duri ng the ent irety of the study  and for 
at least 1 week fo llowing the l ast dose of invest igatio nal product. Periodic abst inence such as 
calendar, ovul ation, symptothermal, post -ovulation methods and withdrawal are not acceptable 
methods of contraception.
Otherwi se, female pat ients of childbearing potential must agree to use 1 highly effect ive formof 
contraception for the ent irety of the study  and f or at l east 1 week following the last dos e of 
investigat ional product.
The fo llowing contraception methods are considered acceptable ; the pat ient should choose one
that is highly effect ive, defined as less than 1% failure rate per y ear when used consistently and 
correctly :
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
80Highly effect ive birth control  methods
○ Com bined (estrogen and progestogen containing) hormonal contraception associated 
with inhibit ion of ovulation: oral, intravaginal, or transdermal
○ Progestogen -only containing horm onal contracepti on associated with inhibit ion of 
ovulation: oral , intravaginal, or transdermal
○Intrauterine device (IUD)/intrauterine hormone -releasing system (IUS)
○ Vasectomized male (with appropriate post -vasectomy documentation of the absence of 
sperm  in the ejaculate )
Effect ive birth control methods
○  Male or f emale condom  with spermicide
Diaphragm  with spermicide
Cervical sponge
Cervical cap wit h spermicide
It should be noted that the use of male and female condoms as a double barrier 
method is not considered acceptable due to the high failure rate when these methods 
are combined.
Note: When local guidelines concerning highly effective or effect ive methods of birth control 
differ fro m the above, the local guidelines must be fo llowed.
Women not of childbearing potential (not WOCBP)
Women who are notWOCBP may part icipate in the study  if they  meet all  study  entry  criteria. 
For such women, there are no con tracepti on requi rements.
Males
For men, there are no con tracepti on requi rements .
10.4.3. Collection of Pregnancy Information
Male participants wi th partne rs who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male participant’s female 
partner who becomes pregnant while the male participant is in this study . This applies only to 
male participants who receive study  intervent ion.
After obtaining the necessary  signed informed consent from the pregnant female partner direct ly, 
the invest igator will record pregnancy informat ion on the appropriate form and submit it to the 
sponsor within 24 hours of learning of the partne r’s pregnancy. The female partner will be 
followed to determine the outcome of the pregnancy . Information on the status of the mother and 
child will be forwarded to the sponsor. Generally, the fo llow-up will be no l onger than 
6to8weeks fo llowing the est imated delivery date. Any terminat ion of the pregnancy will be 
reported regardless of fetal status (presence or absence o f anomalies) or indicat ion for the 
procedure.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
81Female participants who become pregnant
The invest igator will co llect pregnancy informati on on any female participant who becomes 
pregnant while part icipating in this study . The init ial informat ion will be recorded on the 
appropriate form and submitted to the sponsor within 24 hours of learning o f a participant ’s
pregnancy.
The parti cipant wil l be followed to determine the outcome of the pregnancy . The invest igator 
will co llect fo llow-up inform ation on the participant and the neonate ,and the information will be 
forwarded to the sponsor. Generally, fo llow-up will not be required for longer than 6 to 8 weeks 
beyo nd the est imated delivery date. Any terminat ion of pregnancy will be reported, regardless o f 
fetal status (presence or absence of ano malies) or indicat ion for the procedure.
While pregnancy  itself is not considered to be an adverse event (AE)or SAE, any  pregnancy  
complicat ion or el ective terminat ion of a pregnancy  for medical  reasons will be reported as an 
AE or SAE.
A spontaneous abortion (occurring at < 20weeks gestational age) or still birth (occurring at 
>
20weeks gestational age) is always considered to be an SAE and will be reported as such.
Any post -study pregnancy -related SAE consi dered reasonably related to the study  interventi on 
by the investigator will be reported to the sponsor as described in Sect ion8.3.4 .While the 
investigator is not obligated to actively seek this informat ion in former study  parti cipants, he or 
she m ay learn of an SAE through spontaneous reporting.
Any female part icipant who becomes pregnant while participat ing in the study  will discont inue 
study  interventi on.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
8210.5. Appendix 5: Abbreviations
Term Definition
ACTT Adaptive COVID -19 Treatment Trial
AESI adverse event of special interest
ALC absolute lymphocy te count
ALP alkaline phosphatase
ALT alanine aminotransferase
ANC absolute neutrophil count
ANCOVA analy sis of covariance
AVPU Alert Voice Pain Unresponsive
ARDS acute respiratory distress syndrome
AST aspartate aminotransferase
BiPAP bilevel positive airway pressure
blinding A double -blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the subjects 
are aware of the treatment received.
CPAP continuous positive airway pressure
CFR United States Code of Federal Regulations
CI
COAconfidence interval
clinical outcome assessment
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug o r drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
COVID -19 coronavirus disease 2019
CRP C reactive protein
CYP cytochrome P 450 (CYP P)
DNA deoxyribonucleic acid
DNI Do Not Intubate
DNR Do Not Resuscitate
DVT deep vein thrombosis
EBP extracorporeal blood purification
eCRF /CRF electronic case report form /case report form
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
83ECMO extracorporeal membrane oxygenation
eGFR estimated glomerular filtration rate
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ERB Ethical Review Board (see IRB)
ETV early  termination (discontinuation) visit
GCP good clinical practice
HBV hepatitis B virus
HCV hepatitis C virus
hs-CRP C reactive protein, high -sensitivity
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
ICU intensive care unit
IEC Independent Ethics Committee (see IRB)
Ig immunoglobulin
IL interleukin
informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to parti cipate. Informed consent is 
documented by means of a written, signed and dated informed consent form.
INR internatio nal no rmalized ratio
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
product (IP)A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IR incidence rate
IRB Institutional Review Board (IRB), also called Independent Ethics Committee (IEC) or 
Ethical Review Board (ERB)
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
84ITT intention to treat: The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a participant (that is, the 
planned treatment regimen) rather than the actual treatment given. It has the 
consequence that participant allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.
IWRS interactive web -response sy stem
JAK Janus kinase
LDH lactate dehydrogenase
MDRD Modification of Diet in Renal Disease
MERS Middle East respiratory syndrome
NAKs numb -associated kinases
NEWS Natio nal Early  Warning Score
NIAID Natio nal Institute of Allergy and Infectious Diseases
NIAID- OS NIAID ordinal scale
NIH Natio nal Institutes of Health
NOAEL no-observed -adverse -effect level
NONMEM nonline ar mixed effects modeling
NP nasophary ngeal
NRI non-responder imputation
NSAID nonsteroidal anti -inflammatory drug
OS ordinal scale
PA posterior –anterio r
participant Equivalent to Clinical Data Interchange Standards Consortium (CDISC) term “subject,” 
meaning an individual who participates in a clinical trial, either as recipient of an 
investigational medicinal product or as a control.
In this protocol, the term “participant ”is used to indicate an individual who participates 
in a clinical trial, either as a recipient of an investigational medicinal product or as a 
control. This usage reflects preferences indicated by patient advocates t o more 
accurately reflect the role of people who take part in clinical trials. The term “patient” is 
also used to indicate an individual who participates in thisclinical trial .
PD pharmacodynamic s
PE pulmo nary embolism
PK pharmacokinetic s
PK pharmacokinetics
QD once daily
RA rheumatoid arthritis
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
85RNA ribonucleic acid
SAE serious adverse event
SAP statistical analysis plan
SARS severe acute respiratory syndrome
SARS -CoV-2 novel SARS coronavirus 2
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SI internatio nalsystem of units 
SoA Schedule of Activities
study drug See “study intervention”
study intervention Any investigatio nal interventio n, marketed product, placebo, or medical device 
intended to be administered to a study participant according to the study protocol
TB tuberculosis
TBL total bilirubin level
TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
TNFi tumor necrosis factor inhibitor
ULN upper limit of normal
VTE venous thromboembolism
WBC white blood cell
WHO World Health Organization
WOCBP women of childbearing potential
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
8610.6. Appendix 6: Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
Amendment D (20 October 2020):
This amendment i s consi dered to be substant ialbased on the cri teria set forth in Art icle 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
The main purpose of this protocol amendment is to modify  the study  inclusio n criteria and 
provi de the opportunit y for the sample size to be increased (sample size re- estimat ion) during an 
interim analysis. These changes are based on newly  available data from the ACTT -2 study  and 
on evo lution in clinical management of the disease. In addit ion, based on regulatory  feedback, a 
follow-up visit is added at Day  60.
Sections # and Name Description of Change Brief Rationale
1.1, Sy nopsis: Overall Design Added a Day 60 assessment in the 
follow -up period and increased the 
total maximum duratio n.To evaluate safety and efficacy at 
Day 60 for this patient population 
based on regulatory feedback.
1.1, Sy nopsis: Number of 
ParticipantsChanged sample size to 1000 
patients. Added text for a sample size 
re-estimation to potentially increase 
the final sample size beyond 1000 
patients.To increase sample size based on 
ACTT- 2 data and modeling 
assessments. Included a sample size 
re-estimation to maintain an 
adequately  powered study.
1.2, Schema Changed figure to include a Day 60 
assessment.To add a Day 60 assessment based 
on regulatory feedback.
1.3, Schedule of Activities Added a column for Day 60 
assessments. 
Added text clarifying the conduct of 
various procedures. 
Added visit windows for patients 
discharged from hospital.To add a Day 60 assessmen t based 
on regulatory feedback. 
To provide clarity on study visit 
procedures.
To provide greater visit window 
flexibility for patients who have 
been discharged from the hospital.
2.2, Background Added citations for NIH and WHO 
guidelines on use of cortic osteroids.To reflect current NIH and WHO 
guidelines.
3,Objectives and Endpoints Added an exploratory objective for 
long-term (at least Day 60) clinical 
outcomes.To reflect addition of Day 60 
assessment based on regulatory 
feedback.
4.1, Overall Design Added a Day 60 assessment in the 
follow -up period and increased the 
total maximum duration; changed 
description of study population.Regulatory feedback, as stated for 
Section 1.1; see also rationale for 
Section 5.1.
4.2, Scientific Rationale for 
Study D esignAdded a statement and a phrase about 
the Day  60 assessment.Regulatory feedback, as stated for 
Section 1.1
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
87Sections # and Name Description of Change Brief Rationale
4.3, Jus tification for Dose Added bold font format and 
clarify ing text about patients who 
have eGFR ≥30 mL/min/1.73 m2to 
<60 mL/min/1.73 m2at screening .To clarify for investigators; these 
patients will remain on blinded 2 -mg 
dose (baricitinib or placebo) during 
treatment.
5.1, Inclusion Criteria Revised protocol inclusion criterion 
#4, stating that patients must require 
oxygen supplementation at entry and 
randomization.Changed study population based on 
ACTT- 2 data availability and 
populatio n that derived greatest 
benefit in recover y and mortality. 
6.1, Study Interventions 
AdministeredAdded bold font format and 
clarify ing tex t about patients who 
have eGFR ≥30 mL/min/1.73 m2to 
<60 mL/min/1.73 m2at screening .
Added clarifying text about 
investigational product after patient’s 
discharge from hospital.To clarify for investigators; these 
patients will remain on blinded 2 -mg 
dose (baricitinib or placebo) during 
treatment.
To clarify for investigators: Patients
who are discharged from hospital 
will not be given investigational 
product for home use.
6.5.3, Prohibited Concomitant 
TherapyAdded a clarification in a 
parenthetical p hrase about prohibited 
concomitant medication.Baricitinib for treatment of 
COVID -19 is required for certain 
participants according to the study 
design. However, JAK inhibitors are 
prohibited as concomitant therapy 
during the study .
6.6, Dose Modification Added words “equal to or”; corrected 
some symbols, replacing > with ≥.To provide consistency between text 
statement and the “greater than or 
equal to” symbol ( ≥) in the 
preceding sentences.
7.1.1, Criteria for Permanent 
Discontinuation of Study 
DrugAdded a phrase about the Day 60 
assessment.Regulatory feedback, as stated for 
Section 1.1
8.1.1, COVID -19 Clinical Status 
AssessmentAdded a statement about a Day 60 
assessment.Regulatory feedback, as stated for 
Section 1.1
8.3.1, Time Period and 
Frequenc y for Collecting 
AEs and SAEs Added a statement that serious 
adverse events, including death, 
caused by COVID -19 disease 
progression should not be reported 
on the SAE form unless the 
investigator deems them to be 
possibly related to study treatment .To clarify the SAE reporting process 
and to align with language already in 
Section 10.3.
9.2, Sample Size Determination Moved the assumptions of the sample 
size as stated in amendment C, and 
provided new assumptions for 
amendment D.To update the assumptions used to 
calculate the new sample size. The 
assumptions use modeling inclusive 
of data available from the ACTT -2 
study.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
88Sections # and Name Description of Change Brief Rationale
9.3, Populations for Analyses Revised removed the phrase “within 
each study period” from the 
statement about analyzing 
participants acc ording to the 
interventio n they  received.To clarify the sentence, given that 
participants receive intervention in 
only one study  period.
9.4.1, General Considerations Added subgroups for subgroup 
analy ses.To assess subgroups of interest .
9.4.2, Primary Endpoint Added statement about statistical 
procedure to be used to control type I
error if the sample size is increased 
as a result of interim analysis.To control type Ierror in the event of 
a sample size increase.
9.4.4, Safety Analyses Rem oved text about the analysis 
period being defined as the treatment 
period plus up to 30 days off -drug
follow -up time.
Rem oved text stating that the
treatment period will be used as the 
postbaseline period for the analysis.
Rem oved text about summary of 
treatment -related TEAEs .To reflect that safety assessments 
will include safety data collected 
within the Treatment period.
To provide clarity.
To remove a nonstandard summary .
9.5, Interim Analyses Added sample size re -estimation 
considerations of interim analyses.
Added that unblinding details may be 
specified in DMC charter or in SAP 
or separate unblinding plan 
document.To reflect that sample size 
re-estimation may be a rationale for 
interim analyses. To provide a more 
comprehensive list of documents 
where unblinding details may be 
described.
9.6, Data Monitoring Committee 
(DMC)Added a phrase about sample size 
re-estimation.To maintain an adequately powered 
study; see rationale for Section 1.1.
10.2.1, Clinical Laboratory Tests Added a note that cell morphology is 
performed “if applicable and/or 
needed.”To clarify conduct of assessment if 
warranted.
10.3.1, Events Not Meeting AE 
Definitio nAdded clarifying text , stating that 
disease being studied or expected 
progression is not reported unless 
more severe than expected “or results 
in death” .To clarify reporting of adverse 
events given death is endpoint being 
measured.
10.3.2, Definition of SAE Clarified definition of SAE if death is 
due to progression of COVID -19
disease.To clarify that SAE due to 
progression of COVID -19disease is 
report edas adverse event.  
11, References Added references and links for 
updated guidance documents from 
NIH and WHO, press release for the 
ACTT- 2 study, Gao et al., Cui et al., 
and B rannath et al.To support statement about 
corticosteroid use in the protocol’s 
background section, and to support 
statements about sample size in the 
protocol’s statistical section.
various sections Changed singular nouns to plural (for 
example, visit to visits ); changed verb 
tense from present to past.Grammatical correctness.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
89Amendment C (12 Aug 2020 ):
This amendment wasconsidered to be substant ial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
The main purpose of this protocol amendment wasto increase the sam ple size to accommodate 
evolving changes in standard -of-care therapy , especi ally concomi tant use of dexamethasone.
Sections # and Name Description of Change Brief Rationale
1.1 Synopsis: Rationale Replaced “data on file” with citations Information has been published, 
citations added.
1.1 Synopsis: Number of 
Participants and Intervention 
GroupsIncreased the total number of patients 
to be randomized from the original 
number to a range of 600 to 1000, 
keeping same randomization ratio
and same number of treatment groupsSample size was increased to 
accommodate evolving changes in 
standard-of-care therapy, especially 
concomitant use of dexamethasone.
1.3 Schedule of Activities Provided introductory text and 
clarify ing text on the row called Site 
VisitProvided clarification for situations 
in which patient is not able to have 
an on-site visit and what procedures 
should be done for telephone visit
1.3 Schedule of Activities Updated Comments column for 
physical examination rowEditorial change , no intended change 
in meaning
1.3 Schedule of Activities Updated Comments column for chest 
imaging row and ECG rowTo clarify the acceptable timing of 
the procedure
1.3 Schedule of Activities Created a separate row for Lactate 
dehy drogenase (LDH, which was 
previously written in the row for 
clinical chemistry; updated Clinical 
Chemistry row, removing LDHTo clarify that LDH is acceptable 
within 2 days of study entry
1.3 Schedule of Activities Clarified text in Comments columns 
on rows for D-dime r, ferritin , 
C-reactive protein (CRP)To make text about lab timing 
consistent with inclusion criteria 
requirements
1.3 Schedule of Activities Clarified and updated text in 
Comments column about 
requirements for SARS -CoV-2 viral 
infection confirmation via 
nasophary ngeal s wabTo clarify text per inclusion criteria 
requirements, if patient has 
confirmed COVID -19 infection; also 
to provide investigator judgement for 
collection of samples at other 
timepoints to reduced number of NP 
swabs, patient burden, and site 
burden
1.3 Schedule of Activities Updated text in Comments column in 
two rows about exploratory 
biomarker samplesTo reference a section describing 
collection based on lab kit 
availability
2.1 Study Rationale Replaced “data on file” with 
citations; updat ed year of United 
States package insert (USPI)Information has been published, 
citations added; UPSI was updated.
4.3 Justification for Dose Replaced “data on file” with citation Information has been published, 
citation added.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
90Sections # and Name Description of Change Brief Rationale
5.2 Exclusion Criteria Added a note to exclusion criterion 
#8To clarify corticosteroid use (dose 
and duration) for dexamethasone 
and/o r other sy stemic corticosteroids
5.2 Exclusion Criteria Added “or” in the phrase about deep 
vein thrombosis and pulmonary 
embolismTo clarify a nd support site 
understanding
5.2 Exclusion Criteria Added a parenthetical reference to 
the aforementioned exclusion criteria 
following exclusion criterion #20To support site understanding
6.1 Study Interventions 
AdministeredClarified dosing instructions for 
patients with eGFR >30 mL/min/1.73 
m2to <60 mL/min/1.73 m 2at 
screeningTo support site understanding
6.3 Measures to Minimize Bias: 
Randomization and BlindingChanged o ne of the factors for 
stratification: removed the symptom 
onset factor, and added a factor about 
use of dexamethasone and/or other 
systemic corticosteroid use at 
baseline for primary study conditionTo accommodate evolving changes 
in standard-of-care therapy
6.6 Dose Modification Clarified dosing instruc tions for 
patients with eGFR >30 mL/min/1.73 
m2to <60 mL/min/1.73 m 2at 
screeningTo support site understanding
8.1.3 Other Efficacy 
AssessmentsClarified text on resolution of fever To clarify the definitions and options 
for assessment of fever
8.2.1 Vital Signs Revised text about body temperature, 
simplifying the textTo avoid redundancy and potential 
inconsistency. Section 8.1.3 provides 
the information about body 
temperature.
8.2.3 Electrocardiograms Revised text about timing of ECGs 
that are accep table, per the SOATo keep text consistent with changes 
in the SOA, as described above
8.2.4 Chest Imaging Studies Revised text about timing of imaging 
that is acceptable, per the SOATo keep text consistent with changes 
in the SOA, as described above
8.8 Biomarkers Added text about sample collection 
based on availability of centrally 
supplied lab kits To clarify collection based on lab kit 
availability
9.2 Sample Size Determination Changed the number of patients to be 
randomized, changed power; changed
assumptions for the power 
calculationTo accommodate evolving changes 
in standard-of-care therapy
9.4.1 General Considerations Changed text about subgroup 
analy sis, including dexamethasone 
and/o r other sy stemic corticosteroid 
used at baseline for primary study  
conditio nTo maintain consistency with other 
changes already described
9.4.1.3 Missing Data Imputation Changed f rom LOCF to multiple 
imputation methodsTomore accurately account for the 
variability of missing data
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
91Sections # and Name Description of Change Brief Rationale
9.5 Interim Analyses Clarified t hat interim analyses may 
be used for safety monitoringTo clarify intended uses of interim 
analy ses
9.6 Data Monitoring Committee Added mention of external statistical 
analy sis; removed mention of 
populatio n PK/PD model 
developmentTo provide clarity and to update with 
correct information, as no PK/PD 
modeling is planned
10.2.1 Clinical Laboratory Tests Added text and cross -references 
about SARS -CoV-2 viral infection 
confirmatio n and exploratory 
biomarker samplesTo provide consistency and 
flexibility of investigator assessment 
for collection, consistent with 
inclusion criteria requirements and at 
other timepoints ; and to clarify 
exploratory biomarker sample 
collection based on central lab kit 
availability
10.4.2 Contraception For males and for women not of 
childbearing potential, c hanged 
verbiage from “there are no 
conception requirements” 
to “there are no con traception 
requirements”To correct a typographical error
10.5 Abbreviations Defined several terms, including but 
not limited to, ACTT, CYP, JAK, 
NP, OS, WHOTo improve ease of reading
10.6 Protocol Amendment 
Histor yInserted amendment B history To maintain the history of the 
protocol
Section 11 References Added Beigel, Horby, Stebbing
publicatio ns; updated date of the 
USPI; updated access date of 
Summary of Product CharacteristicsInformation has been published, 
citations added, USPI updated.
various sections Added punctuation marks that were 
previously missingEditorial consistency
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
92Amendment B (03 Jun2020):
This amendment wasconsidered to be substant ialbased on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
The main purpose of this protocol amendment wastoaddress regulatory  comments regarding the 
primary  endpoint.
Sections # and Name Description of Change Brief Rationale
1.1Synopsis
3.0 Objectives and Endpoints
4.1 Overall Design
4.2 Scientific Rationale
8.1.1 COVID -19 Clinical Status 
Assessment ( Primary  Endpoint 
Assessments )
9.1 Statistical Hypotheses
9.2 Sample Size Determination
9.4.2 Primary EndpointUpdat edprimary  endpoint Response to FDA feedback. The 
updated primary endpoint is proportion 
of patients who die or require non -
invasive ventilation/high -flow oxygen 
or invasive mechanical ventilation 
(including extracorporeal membrane 
oxygenation [ECMO]) by Day 28.
1.3 Schedule of Activities Added clarification for Vital 
Signs to be assessed and 
documented daily.Response to FDA feedback. Added 
clarify ing test that Vital Signs ar e
assessed and documented daily while 
hospitalized in the comment box in 
first position.
4.1 Overall Design
6.5.2 Required and Permitted 
Concomitant Therapy
11.0 ReferencesAdded statement allowing use of 
hydroxy chloroquine and 
chloroquine only if 
recommended or required by 
local COVID -19 treatment 
guidelines.Updated given updates in scientific 
literature.
5.1 Inclusion Criteria Update to Criterion #3 to 
provide duration of time 
between confirmatory testing 
and enrollmentResponse to FDA feedback. The 
updated criteria provide the duration of 
time between confirmatory testing and 
enrollment should not be more than 14 
days for SARS -CoV -2 confirmation 
>72 hou rs.
5.2 Exclusion Criteria Update to Criterion #11 with 
addition of clarifying text for 
patients that may have ongoing 
infectionResponse to FDA feedback. The 
updated criteri onincludes “ Note: 
Immunocompromised patients, 
patients with a chronic medical 
conditio n, or those taking a medication 
that cannot be discontinued at 
enrollment, who, in the judgmen t of 
the investigator, are at increased risk 
for serious infections or other safety 
concerns given the study products 
should be excluded ”.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
93Sections # and Name Description of Change Brief Rationale
5.2 Exclusion Criteria Update to Criterion #22 that 
patients should not be enrolled in 
any other trials for COVID -19.Response to FDA feedback. The 
updated criterion provides the 
participant should not be enrolled 
(start) in anot her clinical trial for the 
treatment of COVID -19 o r SARS 
CoV-2 through Day 28.
5.2 Exclusion Criteria
6.5.3 Pro hibited concomitant 
therapyAddition of Exclusion Criterion
#25 for the use of e xtracorpo real 
blood purification (EBP) device 
to remove pro -inflammatory 
cytokines from the blood.
Added EBP device to remove 
pro-inflammatory cytokines 
from the blood to list of 
prohibited concomitant therapy.The new criterion was added and the 
prohibited concomitant therapy list 
updated given recent input on current 
practices and EUA that is in place and 
use of t his modality  can confound 
assessments in KHAA. The new 
exclusion criterio napplies if “Are 
using o r will use extracorporeal blood 
purificatio n (EBP) device to remove 
pro-inflammatory cytokines from the 
blood such as a cytokine absorption or 
filtering device, for example, CytoSorb 
®.”  
5.2 Exclusion Criteria Addition of Exclusio n Criterion
#26 to exclude patients that are 
unlikely  to survive participation 
in the studyThe new criterion provides exclusion if 
the patient, in the opinion of the 
investigator, unlikely to survive for at 
least 48 hours after screening.
9.3 Populations for Analyses Addition of clarification of 
analy ses population The new language provides that a 
sensitivity analysis excluding patients 
who die within 24 hours of 
randomization and have do not 
resuscitate (DNR) or do not intubate 
(DNI) in ITT/PP analyses populations 
will be conducted.   
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
94Amendment A (27 May 2020) : 
Amendment A occurred before any  study  parti cipant was consented or dosed at any  study  site.
Overall Rationale for Amendment A:
The main purpose of this protocol amendment wastoaddress regulatory  comments regarding the 
primary  endpoint and regarding the role of an internal assessment committee in the review of 
unblinded data. 
Sections # and Name Description of Change Brief Rationale
1.1Synopsis
3 Objectives and Endpoints
4.1 Overall Design
9.1 Statistical Hypotheses
9.4.2 Primary EndpointChanged primary endpoint.
Changed wording of primary 
objective.Response to FDA feedback .
The new primary  endpoint is 
proportion of patients requiring 
non
-invasive ventilation/high -flow 
oxygen or invasive mechanical 
ventilatio n (including extracorporeal 
membrane oxygenation [ECMO]) by 
Day 28. 
A related secondary endpoint 
[“Proportion of patients requiring 
mechanical ventilation (Day 1 to Day 
28)”] has been removed; this 
secondary objecti ve is unnecessary 
given the new primary endpoint.
The primary objective wording was 
changed (from “on clinical 
improvement of patients” to “on 
disease progression in patients”) to 
align with the primary endpoint.
1.1 Synopsis
3 Objectives and Endpoints
9.4.3 Secondary EndpointsAdded a secondary endpoint. Response to FDA feedback .
The new secondary endpoint is overall 
improvement in NIAID ordinal scale 
evaluated at Day 10 . It has been 
incorporated into the existing key 
secondary endpoint of “ Overall 
impro vement on the NIAID -
OS 
evaluated at Day 4, Day 7, Day 10, 
Day 14.”
1.2 Schema Rem oved timepoint indicator for 
the primary endpoint.Changed to maintain consistency with 
changed primary endpoint described 
above.
2.2 Background Replaced “creatinine kinase”
with “creatine kinase.”Changed to fix typographical error.
4.1 Overall Design Rem oved a statement about use 
of oxygen therapy at time of 
study entry.Changed to prevent misreading.
4.2 Scientific Rationale for Study 
DesignProvided rationale for the new 
primary  endpoint.New information is included for 
consistency with the new primary 
endpoint.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
95Sections # and Name Description of Change Brief Rationale
8.1.1 COVID -19 Clinical Status 
AssessmentAdded two paragraphs defining 
terms relevant to the primary 
endpoint.Changed for consistency with other 
listed chan ges and to improve clarity.
8.1.3 Other Efficacy Assessment Added “high -flow oxygen” to 
the endpoint cell for non -
invasive ventilation.Changed for consistency with other 
listed changes and to improve clarity.
8.2.4 Chest Imaging Studies Added “or appropriate 
physician” to the list of 
personnel who may assess the 
chest imaging scans.Changed to provide flexibility to sites.
8.2.5 Laboratory Tests
10.2.1 Clinical Laboratory TestsChanged the requirements for 
documentation of reviews of 
laborato ry reports.Changed to decrease site burden, 
allowing flexibility on how the review 
is documented.
9.2 Sample Size Determination Modified rationale for sample 
size.Changed to align with response to 
FDA feedback, and to use more 
recently available data as part of the 
justification of sample size.
9.4.1 General Considerations Added Wilcoxon rank sum test 
for treatment comparison of 
ventilatio n-free days.Changed for consistency with changes 
in other sections.
9.4.2 Primary Endpoint Revised primary endpoint.  
Added statement about how 
patients on non -invasive 
ventilatio n at baseline will be 
counted in the new endpoint.Changed as a result of response to 
FDA feedback .
9.4.3 Secondary Endpoints Rem oved secondary endpoints, 
as previously described.See above.
9.5Interim Analyses
9.6 Data Monitoring Committee
10.1.5 Committee Structure
10.1.9 Study and Site Start and 
ClosureRem oved all references to 
Internal Assessment Committee 
(IAC ).
Clarified the use of interim 
analy ses.Response to FDA feedback .
Unblinded da ta reviews will be carried 
out by the external Data Monitoring 
Committee (DMC) , not an IAC.
10.5 Appendix 5: Abbreviations Added and removed 
abbreviations.Editorial. Changed for consistency 
with other changed sections.
11 References Added and removed references. Editorial. Changed for consistency 
with other changed sections.
C O N FI D E N TI A L Pr ot oc ol  I 4 V -M C -K H A A( e) 
9 6 1 1. Refere nces 
[A da pt i ve C O VI D -1 9 Treat m e nt Tri al , A C T T ; N C T 0 4 2 8 0 7 0 5 ]A m ult ice nter, a da pti ve, 
ra n d o mize d bli n de d c o ntr olle d trial o f t h e safet y a n d efficac y o f i n vesti gati o nal t hera pe ut ics 
f o r t he treat m e nt of  C O VI D -1 9 i n h os pitalize d a d ults. Cli nical Trials. g o v we bsite . 
ht t ps://cli nicaltrials. g o v/ct 2/s h o w/ N C T 0 4 2 8 0 7 0 5 . U p date d 2 0 A pril 2 0 2 0. Accesse d A pril 2 5, 
2 0 2 0. 
[ A C T T -2 press release] Barici ti ni b has si g nifica nt effect o n rec o ver y ti me, m ost i m p a ctf ul i n 
C O VI D -1 9 pati e nts re q ui ri n g o x y g e n [ ne ws release]. I n dia na p o lis, I N: Eli Lill y a n d C o m pa n y: 
Oct o ber 8, 2 0 2 0. htt ps:// i n vest or.lill y.c o m/ ne ws -r el eases/ ne ws -release -details/ baricit i ni b -has -
si g nifica nt -effect -rec o ver y -ti me -m o st -i m pac tf ul . Accesse d Oct o ber 1 3, 2 0 2 0 .
Al os h M, Bretz F, H u g ue M. A d va nce d m ult i plicit y a dj ust me nt  m et h o ds i n cli nical tri als. St at 
Me d . 2 0 1 4; 3 3( 4): 6 9 3 -7 1 3. htt ps:// d oi. or g/ 1 0. 1 0 0 2/si m. 5 9 7 4. 
Bei g el  J H, T o m as he k K M, D o d d L E, et al. Re m desi vir f o r t he treat m e nt of C o vi d - 1 9 – 
preli mi nar y re p ort [ p u blis he d o nli ne Ma y 2 2, 2 0 2 0]. N E n gl J Me d . htt ps:// d oi. or g/ 
1 0. 1 0 5 6/ N EJ M oa 2 0 0 7 7 6 4 .
Bra n nat h W, Me hta C R, P osc h M. E xact c o nfi de nce b o u n ds f o ll o wi n g a da pt i ve gr o u p se q ue ntial 
tests. Bi o met ri cs. 2 0 0 9 J u n; 6 5( 2): 5 3 9 -4 6. htt ps:// d oi. or g/ 1 0. 1 1 1 1/j. 1 5 4 1 -0 4 2 0. 2 0 0 8. 0 1 1 0 1. x. 
Bretz F, P osc h M, Gli m m E, et al. Gra p hical a p pr oac hes f or m ult i ple c o m paris o n pr oce d ures 
usi n g wei g hte d B o nferr o ni, Si mes, or para metric tests. Bi o m J . 2 0 1 1; 5 3( 6): 8 9 4 -9 1 3. htt ps:// 
d oi . or g/ 1 0. 1 0 0 2/ bi mj. 2 0 1 0 0 0 2 3 9 .
Ca nti ni F, Nicc o li L, Matarrese D, et al. Baricit i ni b t hera p y  i n C O VI D -1 9: A pil ot st u d y  o n 
safet y a n d cli nical i m pact, J o ur n al of I nfecti o n ( 2 0 2 0), 
ht t ps:// d oi . or g/ 1 0. 1 0 1 6/j .j i nf. 2 0 2 0. 0 4. 0 1 7. 
C he n N, Z h o u M, D o n g X, et al. E pi de mi ol o gical a n d cli nical  c haracterist ics of 9 9 cases of 2 0 1 9 
n o vel c or o na vir us p ne u m o nia i n W u ha n, C hi na: a descri pt i ve st u d y . L a ncet . 
2 0 2 0; 3 9 5( 1 0 2 2 3): 5 0 7 -5 1 3. htt ps:// d oi. or g/ 1 0. 1 0 1 6/ S 0 1 4 0 -6 7 3 6( 2 0) 3 0 2 1 1 - 7. 
C he n X, Z ha o B, Q u Y, et al. Detecta ble ser u m S A R S -C o V -2 viral l o a d ( R N Aae mia) is cl osel y 
c orrel ate d wi t h  drast icall y ele vate d i nterle u ki n 6 (I L- 6) l e v el  i n cri ti call y ill C O VI D - 1 9 
pati e nts [ p u blis he d o nli ne a hea d of pri nt A pril 1 7, 2 0 2 0]. Cli n I nfect Dis . htt ps:// d oi: 
1 0. 1 0 9 3/ci d/ciaa 4 4 9 .
C he n T, W u D, C he n H, et al. Cli nical c haracterist ics of 1 1 3 decease d pat ie nt s wi t h  c or o na vir us 
di sease 2 0 1 9: retr os pecti ve st u d y . B M J . 2 0 2 0 Mar 2 6; 3 6 8: m 1 0 9 1. htt ps:// 
d oi . or g/ 1 0. 1 1 3 6/ b mj. m 1 0 9 1. Errat u m i n: B MJ. 2 0 2 0 Mar 3 1; 3 6 8: m 1 2 9 5. 
Cra ve n D, Cr o ne o us A, Zi as N, Hj al mars o n K. Ve nt ilat or -ass ociate d trac he o br o nc hit is:  T he 
i m pact of tar gete d a nti bi otic t hera p y o n patie nt o utc o mes. C hest . 2 0 0 9; 1 3 5( 2): 5 2 1 -5 2 8. htt ps:// 
d oi . or g/ d oi . or g/ 1 0. 1 3 7 8/c hest. 0 8 - 1 6 1 7. 
C ui  L, H u n g H M, Wa n g SJ. M o dificat i o n of sa m ple siz e i n gr o u p se q ue nt ia l cli nical trials. 
Bi o m etri cs. 1 9 9 9 Se p; 5 5( 3): 8 5 3 -7. ht t ps:// d oi. or g/ 1 0. 1 1 1 1/j. 0 0 0 6 -3 4 1 x. 1 9 9 9. 0 0 8 5 3. x. 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
97Fine JP and Gray  RJ. A proporti onal hazards m odel for the subdistribut ion of a compet ing risk. 
Journal of the American Statistical Association . 1999;94(446):496-509. https://
doi.org/10.1080/01621459.1999.10474144.
Genovese MC, Smo len JS, Takeuchi T, et al. THU0078 Safet y profile of baricit inib for the 
treatm ent of rheumatoid arthrit is up to 7 years: an updated integrated safety analy sis [abstract]. 
Ann Rheum Dis . 2019;78(Suppl 2):308- 309. http:// dx.doi.org/10.1136/annrheumdis -2019-
eular.691. 
Gao P, Ware JH, Mehta C. Sample size re -estimat ion for adaptive sequent ia
l design in clinical 
trials. J Bi opharm  Stat. 2008;18(6):1184 -96. https:// doi.org/ 10.1080/10543400802369053.
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China 
[published online February  28, 2020]. N Engl J Med . https://
doi.org/10.1056/NEJMoa2002032 .
Hess D. Approaches to convent ional mechanical vent ilation of the patient with acute respiratory  
distress syndrome. Resp Care. 2011;56(10):1555 -1572. https:// doi.org/ 
10.4187/respcare.01049.
Horby  P, Lim WS, Emberson J, et al. Dexamethasone in hospitalized patients with COVID -19: 
preliminary report [published online July 17, 2020]. N Engl J Med . https:// doi.org/
10.1056/NEJMoa2021436.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus 
in Wuhan, China. Lancet . 2020;395(10223):469 -470. https:// doi.org/10.1016/S0140 -
6736(20)30183-5.
Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complicat ions in 
critically  ill ICU pat ients with COVID -19. Thromb Res . 2020 Apr 10. pii: S0049 -
3848(20)30120- 1. https:// doi.org/ 10.1016/ j.thromres.2020.04.013 .
Lee JW. Some versat ile tests based on the simultaneous use of weighted log -rank statist ics. 
Biometrics . 1996;52(2):721 -725. https:// doi.org/10.2307/2532911.
Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered 
analysis of variance. Biometrika . 1976;63(3):655 -660. 
McInnes, IB, By ers NL, Hi ggs, RE, et al . Com parison of baricit inib, upadacit inib, and tofacit inib 
mediated regulation o f cytokine signaling in human leukocy te subpopul ations. Arthritis Res 
Ther. 2019;21(1):183. https://doi.org/ 10.1186/s13075-019-1964- 1.
Mehra MR, Desai SS, Ruschitzka F, Patel AM. Hydroxy chloroquine or chl oroquine wi th or 
without a m acrolide for treatment of COVID -19: a m ultinational registry  analysis. Lancet . 
2020. https://doi.org/10.1016/S0140 -6736(20)31180 -6.
Mehta P, McAuley  DF, Brown M, et al . COVID -19: consi der cy tokine storm  syndrom es and 
immunosuppressio n. Lancet . 
Volume 395, Issue 10229, 28 March–3 April  2020, Pages 1033 -
1034. https:// doi.org/10.1016/S 0140- 6736(20)30628 - 0.
Millen BA, Dmitrienko A. Chain procedures: a class of flexible closed testing procedures with 
clinical trial applicat ions. Stat Biopharm Res . 2011;3(1):14 -30. 
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
98[NIH] Nati onal Institutes of Health. Coronavirus Disease 2019 (COVID -19) T reatm ent 
Guidelines. Updated April 21, 2020. https:// covid19treatmentguidelines.nih.gov/introduction/ . 
Accessed April 25, 2020.
[NIH] Nati onal Institutes of Health. Coronavirus Disease 2019 (COVID -19) Treatm ent 
Guidelines. Updated August 27, 2020. Available at: 
https://www.covid19treatmentguidelines.nih.gov/immune -based -
therapy /immuno modulators/corti costeroi ds/. Accessed October 8, 2020.
Olumiant [ United States package insert]. Indianapolis, IN: Eli Lilly and Co mpany; 20 20. http s:// 
uspl.lilly.com /olumiant /olumiant.html#pi .pdf. Accessed August 09,2020.
Olumiant [Summary  of Product Characteristics]. https://www.ema.europa.eu/ 
en/documents/product -informat ion/olumiant -epar-product -information_en.pdf. Accessed 
A
ugust 09, 2020 .
Patel  BK. Overview of m echanical vent ilation. In: Crit ical Care Medicine, Merck Manuals 
Professio nal Edi tion. May  2020. Available at https:// 
www.m erckmanuals.co m/professio nal/crit ical-care-medicine/respiratory -failure -and-
mechanical -ventilation/overview -of-mechanical -ventilation. Accessed May  26, 2020.
Pocock SJ, Ariti CA, Co llier TJ, Wang D. The win ratio: a new approach to the analysis o f 
composite endpoi nts in clinical trials based on clinical priorit ies. Eur Heart J . 2012;33(2):176 -
182. https:// doi.org/10.1093/eurheartj/ehr352.
Richardson P, Griffin I, Tucker C, et al. Baricit inib as potenti al treatm ent for 2019 -nCoV acute 
respi ratory  disease [published online February  3, 2020]. Lancet . 2020;395(10223):PE30 -PE31. 
https:// doi.org/10.1016/S0140 -6736(20)30304-4.
Rothan HA , Byrareddy SN. The epi demi ology and pathogenesis of coronavirus disease 
(COVID -19) outbreak [published online February 26, 2020]. J Autoimmun . https://
doi.org/10.1016/j .jaut.2020.102433 .
[Royal  College of Physicians 2012]. National Early Warning Score (NEWS): Standardising the 
assessment of acute -illness severit y in the NHS . Available at: https://
www.rcpl ondon.ac.uk/file/32/download? token=5Nwj EyTq. Published July 2012. Accessed 
March 31, 2020.
Royston P , Parm ar MK B. Restri cted m ean survival t ime: an alternat ive to the hazard ratio for the 
design and analysis o f randomized trials wit h a time -to-event outcome. BMC Med Res 
Methodol . 2013 ;13:152. https:// doi.org/10.1186/1471-2288-13- 152.
Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortalit y due to COVID -19 based on an 
analysis of data of 150 patients from Wuhan, China. Intensive Care Med . 2020 Mar 3. https:// 
doi.org/ 10.1007/s00134-020-05991- x. [Epub ahead of print] . [Erratum in Correction to: 
Clinical predictors of mortalit y due to COVID -19 based on an analysis o f data of 150 patients 
from Wuhan, China. Intensive Care Med. 2020].
Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK 1/2 inhibit ion with baricit inib in the treatment 
of autoinflammatory  interferonopathi es. J Clin Invest . 2018;128(7):3041- 3052. https:// 
doi.org/10.1172/JCI98814.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
99Shi JG, Chen X, Lee F, et al. The pharmacokinet ics, pharmacodynamics, and safet y of 
baricitinib, an oral  JAK 1/2 inhibitor, in healt hy volunteers. J Clin Pharmacol . 
2014;54(12):1354 -1361. https:// doi.org/10.1002/jcph.354.
Stebbing J, Krishnan V, de Bono S , et al .Mechanism of baricit inib supports artificial
intelligence -predicted testing in COVID -19 pati ents. EMBO Mol Med. 2020; 12(8) :e12697. 
https://doi .org/ 10.15252/emmm.202012697 .
Tang W, Cao Z, Han M, et al. Hy droxychl oroquine in pati ents wi th mainly mild to moderate 
coronavirus disease 2019: open label, rando mised controlled trial. BMJ. 2020; 369: m1849. 
https://doi .org/10.1136/bmj.m1849 .
Wang D, Hu B, Hu C, et al. Clinical characterist ics of 138 hospitalized patients with 2019 novel 
Coronavirus -infected pneumonia in Wuhan, China [published online February 7, 2020]. 
JAMA . https:// do i.org/10.1001/j ama.2020.1585.
Wang W , Tang J , Wei F. Updated understanding of the outbreak of 2019 novel coronavirus 
(2019 ‐nCoV) in Wuhan, China . J Med Virol. 2020 ; 92: 441– 447. https:// 
doi.org/10.1002/jmv.25689 .
Wang Y, Fan G, Salam A, et al. Com parat ive effectiveness of co mbined favipiravir and 
oseltamivir therapy  versus osel tamivir m onotherapy  in critically  ill patients with influenza 
virus infect ion [published online December 11, 2019]. J Infect Dis. https://
doi.org/10. 1093/infdis/jiz656.
Wang Y, Zha ng D, Du G, et al. Remdesivir in adults with severe COVID -19: a randomised, 
doubl e
-blind, placebo -controlled, mult icentre trial. Lancet 2020 May 16;395(10236):1569 -
1578. https:// doi.org/ 10.1016/S0140 -6736(20)31022 -9.
[WHOCOVID 19 Si tuation Report 91].Coronavirus disease 2019 (COVID -19), Situation 
Report –
91.  Available at: https://www.who.int/docs/default -source/coronaviruse/ situation-
reports/20200420
-sitrep-91-covid-19.pdf?sfvrsn=fcf0670b_4 . Published 20 April 2020. 
Accessed April 25 , 2020.
[WHO R&D]. Coronavirus disease ( COVID -19) R&D .Available at: https://
www.who.int/blueprint/priority -diseases/key -action/COVID -
19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf .  Accessed on 
March 31, 2020.
[WHO 2020]. World Heal th Organizat ion. 
Clinical management of severe acute respiratory  
infect ion (SARI) when COVID -19 di sease is suspected: Interim guidance V 1.2. Interim 
guidance 13 March 2020. https://www.who.int/publicat ions-detail/ clinical -management -of-
severe -acute -respi ratory -infecti on-when -novel -coronavirus -(ncov) -infect ion-is-suspected.
[WHO 2020 b] World Heal th Organizat ion. Corti costeroids for COVID -19. 2 September 2020. 
Available at: https://www.who.int/publicat ions/i/item/WHO -2019- nCoV -Corti costeroi ds-
2020.1 . Accessed October 8, 2020.
Wint hrop KL, Bingham III CO, Komocsar WJ, et al. Evaluat ion of pneumo coccal  and tetanus 
vaccine responses in patients with rheumatoi darthri tis receiving baricit inib: results fro m a 
long-term extensio n trial substudy . Arthritis Res Ther . 2019 ;21:102. https://
doi.org/10.1186/s13075-019-1883-1.
CONFIDENTIAL Protocol  I4V-MC-KHAA( e)
100Wint hrop KL, Novosad SA, Baddley JW, et al. Opportunist ic infect ions and bio logic therapies in 
immune -mediated inflammatory  diseases: consensus recommendat ions for infecti on reporting 
during clinical trials and postm arket ing surveillance. Ann Rheum Dis . 2015;74(12):2107- 2116. 
https:// doi.org/10.1136/annrheumdis -2015-207841.
Leo Document ID = 259810bc-5072-4c25-81b4-52c64e95262a
Approver: 
Approval Date & Time: 25-Nov-2020 14:19:01 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 25-Nov-2020 15:22:48 GMT
Signature meaning: Approved
PPD
PPD